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1. CRYPTOCOCCOSIS 
1.1 History of Cryptococcus neoformans 
Cryptococcus neoformans is an encapsulated yeast-like fungus, which can cause a 
systemic infection (cryptococcosis), mainly in patients with impaired cell mediated 
immunity. The organism was identified as a human pathogen in 1894 by the 
pathologist Busse, and the surgeon Buschke (1). They independently cultured the 
same fungus from lesions of the tibia and cutaneous lesions, respectively, of a 31-year 
old woman. In the same year, C. neoformans was isolated from peach juice by the 
Italian Sanfelice, who later proved its pathogenicity in laboratory animals (2).  
Until 1950 many case reports were published on clinical infection with C. 
neoformans, including animal experiments with the organism isolated from these 
patients (3). Infection in the brain, lungs, kidneys and many other organs were 
described. Pathologist reported gelatinous masses and chronic granulomatous and 
tumor-like lesions (4) as well as relative absence of polymorphonuclear infiltrates (5). 
These different appearances of the yeast caused an on-going confusion with regard to 
the correct nomenclature. For example, Saccharomyces hominis, Cryptococcus 
hominis, Torula histolytica, Debaryomyces hominis were all early names for the 
pathogen. Around 1950 the name C. neoformans was established and two varieties 
were recognized: var. neoformans and var. gattii. Currently we recognize 3 varieties: 
grubii (serotype A), gattii (serotype B, C) and neoformans (serotype D). Most likely, 
var. gattii will be renamed as a novel species and called C. bacillisporus (6). The 
name of the teleomorphic form of C. neoformans var. neoformans is Filobasidiella 
neoformans (7).  
From 1981 on the incidence of C. neoformans-infected patients has increased 
dramatically as a result of the ongoing AIDS epidemic. An estimated 36 million 
people worldwide are currently living with HIV, and some 20 million people have 
already died, giving a cumulative total number of HIV infections of 56 million (8). 
There were 5.3 million new HIV infections globally in 2000, and there is a clear 
potential for further massive spread. In most western countries 5-10% of HIV infected 
patients will develop cryptococcosis (9). In 1991 over 1200 cases of cryptococcal 
meningitis were diagnosed in New York City (10). Recently a decrease in incidence 
in these countries has been described, probably due to the introduction of HAART 
(Highly Active Antiretroviral Therapy) for treatment of HIV-infection (11). In sub-
Saharan Africa, 10-15% of HIV infected patients will develop cryptococcosis (12). In 
Zimbabwe, however, cryptococcosis constitutes in 88% of HIV-infected patients the 
AIDS-defining illness, where it currently represents the most important cause of 
meningitis in adults (13;14). 
Before 1950 untreated cryptococcal meningitis was, with some sporadic exceptions, 
in 100% of cases fatal (15). With the introduction of Amphotericin B in the late 
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1950’s the first effective therapy against cryptococcosis was discovered (16) and 
death rates dropped to 10-25% of patients during treatment or in the immediate 
follow-up period (17;18). Due to the high prices of currently available antimycotics, 
we have unfortunately been able to observe the natural history of untreated HIV and 
cryptococcal meningitis in sub-Saharan countries. In Zimbabwe, for example median 
survival time from diagnosis to death is 14 days and only 22% of patients survived for 
more then 30 days without treatment (13). In Malawi, a median survival time after 
diagnosis is 4 days (19). 
1.2 Clinical manifestation 
Cryptococcosis, a systemic infection with C. neoformans, is mostly seen in patients 
who have a compromised immune system. Most important predisposing factors for 
cryptococcosis are HIV infection, use of immunosuppressive drugs, organ and bone 
marrow transplantation, chronic leukemias and lymphomas. The severity of clinical 
manifestation depends on the immune status of the host. In patients with AIDS, as 
compared to immunocompetent patients, the fungal burden is usually higher, and 
more extraneural sites of infection are present. In addition, relapse rates are higher. 
Time between first presentation and diagnosis is significantly longer in non-HIV 
infected patients (described in chapter 2). Cryptococcal meningitis (infection of the 
subarachnoid space) and meningoencephalitis (infection of both the subarachnoid 
space and the brain parenchyma) are the most frequently encountered life-threatening 
manifestations of cryptococcosis. Patients usually present with symptoms like 
headache, fever, nausea/vomiting, seizures, altered mentation, vision changes, and/or 
cranial nerve paresis which may have been already existing for 2 to 4 weeks before 
presentation. Physical examination can reveal signs such as papilledema and cranial 
nerve paresis. Nuchal rigidity does occur in 28% of HIV infected patients, and in 14% 
of non-HIV infected patients (chapter 2). 
Pulmonary cryptococcosis is the second most relevant site of infection for C. 
neoformans. Clinical course depends on immune status of the host. C. neoformans can 
cause pneumonia in immunocompetent host. Symptoms include cough (54%), chest 
pain (46%), increased sputum production (32%), weight loss and fever (26%) (20). 
Immunocompromised (either HIV or non-HIV infected) patients with cryptococcal 
pneumonia generally have a more rapid clinical course and a greater tendency to 
disseminate their infection then immunocompetent patients (21;22). 
Radiographically, cryptococcal pneumonia in the normal host may present with well-
defined, non-calcified single or multiple lung nodules (23). Pulmonary cryptococcosis 
is diagnosed through antigen detection and culture of expectorated sputum, BAL 
(broncho alveolar lavage), transbronchial lung biopsy or needle aspiration. Serum and 
cerebrospinal fluid (CSF) analysis for antigen and cryptococcal culture should be 
performed to assess dissemination. 
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C. neoformans involvement of skin, eyes, genitourinary tract, bone and joints, muscle, 
heart, gastrointestinal tract, breast, lymph nodes, thyroid, adrenal gland head and neck 
has been described. Most of these cases should be considered as manifestations of 
disseminated cryptococcosis . It is currently an accepted practice to exclude presence 
of cryptococci in the brain by examination the CSF of all patients in whom the yeast 
has been isolated from another body site and who have defined risk factors for 
dissemination (see before) even if they are asymptomatic. Investigation of 
disseminated cryptococcosis should include CSF and blood culture as well as 
serological tests.  
Microscopically, encapsulated C. neoformans can be detected in specimens of CSF or 
other host fluids dissolved in Indian ink preparations (24). Indian ink examination is a 
rapid test that can often deliver an immediate diagnosis within minutes after lumbar 
puncture. C. neoformans can be cultured from CSF, blood, sputum, urine and other 
specimens. Furthermore, latex agglutination tests for cryptococcal antigen (capsule) in 
body fluids are available (25). These tests are approximately 95% sensitive and 95% 
specific for identification of invasive cryptococcosis (26). Histopathologically, C. 
neoformans can be relatively easy identified in tissue because of its prominent 
capsule. 
1.3 Management of cryptococcal disease 
The choice of treatment for disease caused by C. neoformans depends on both the 
anatomic sites of involvement and the host’s immune status. Recently, guidelines for 
the management of cryptococcal disease were published by M.S. Saag et al. (27). For 
immunocompetent hosts with isolated pulmonary disease, careful observation may be 
warranted; in case of symptomatic infection, the indicated treatment is fluconazole, 
200-400 mg/day for 3-6 months. This treatment is also recommended for individuals 
with non-CNS-isolated cryptococcemia, a positive serum cryptococcal antigen titer 
>1:8, urinary tract or cutaneous disease. For patients with more severe disease, 
treatment with amphotericin B (0.5-1 mg/kg/d) may be necessary for 6-10 weeks. For 
otherwise healthy hosts with CNS disease, standard therapy consists of amphotericin 
B 0.7-1 mg/kg/d, plus flucytosine, 100 mg/kg/d, for 6-10 weeks. Fluconazole 
“consolidation” therapy may be continued for as long as 6-12 months, depending on 
the clinical status of the patient. HIV-negative, immunocompromised hosts should be 
treated in the same fashion as those with CNS disease, regardless of the site of 
involvement.  
For those patients with HIV who present with isolated pulmonary or urinary tract 
disease, fluconazole at 200-400 mg/d is indicated, lifelong (see later). For patients 
with more severe disease, a combination of fluconazole (400 mg/d) plus flucytosine, 
(100-150 mg/kg/d) may be used for 10 weeks, followed by fluconazole maintenance 
therapy. Among patients with HIV infection and cryptococal meningitis, induction 
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therapy with amphotericin B 0.7-1 mg/kg/d, plus flucytosine, 100 mg/kg/d, for 2 
weeks followed by fluconazole (400 mg/d) for a minimum of 10 weeks is the 
treatment of choice. After 10 weeks of therapy, the fluconazole dosage may be 
reduced to 200 mg/d, depending on the patient’s clinical status.  
Secondary prophylaxis against C. neoformans used to be indicated in all HIV infected 
patients with a history of cryptococcal disease. However, the introduction of HAART 
has dramatically changed the course of HIV infection (28). The improvements in 
immunological function, as the result of HAART, made it possible to stop primary 
and secondary prophylaxes against various opportunistic infections (29;30). Very 
recently, two studies suggesting that it is safe to stop secondary prophylaxis against C. 
neoformans in patients responding to HAART (increase in CD4 cell count to >100 
cells/mm3), without relapse of their cryptococcal disease have been published (31;32). 
 
2. C. NEOFORMANS AND HOST RESPONSE 
2.1 Innate host defense in the lung  
C. neoformans is a worldwide occurring free-living organism that can survive in a 
variety of environmental niches. It has been isolated from pigeon and other avian 
excreta, fruits and soils (33). In contrast to bacteria, eukaryotic pathogens are 
generally not passed from person to person, and their evolution has not necessarily 
attained specific abilities to infect or invade the human host. A human fungal 
infection is generally the result of an accidental encounter during the life cycle of the 
fungus. Virulence genes and factors, in nature necessary for the organism to survive 
under various circumstances, are used to overcome the natural defenses of the host. A 
number of genes that allow the organism to grow and survive in the mammalian host 
have been defined.  
Several lines of evidence suggest that human cryptococcosis result from inhalation of 
either desiccated, poorly encapsulated yeast forms, or basidiospores (34-36). These 
poorly encapsulated strains have a diameter of about 2 to 5 µm (37) and can penetrate 
the alveoli if not expelled through respiratory epithelia. In the alveolar spaces C. 
neoformans is initially confronted by alveolar macrophages (38), which play a central 
role in host defense against C. neoformans. Macrophages are able to bind, ingest and, 
with appropriate stimulation, kill yeast cells (39;40). Macrophage phagocytosis of C. 
neoformans can occur through either antibody (41), and complement receptors (42) 
(serum-dependent-phagocytosis) or mannose (39), and β-glucan (43) receptors 
(serum-independent-phagocytosis). In the alveoli primitive opsonins, termed 
collectins, are present which contribute to innate resistance against inhaled 
microorganisms (44-47).  
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Collectins are humoral lectins found in mammals and birds. They belong to the 
animal C-type lectin superfamily characterized by a carbohydrate recognition domain 
(CRD), which binds ligands in a Ca2+-dependent manner, plus a collagen tail involved 
in their biological function (48). They are related structurally and functionally to the 
first component of the classical complement pathway, C1q, and serve important roles 
in innate immunity through opsonization and complement activation. The lectin 
domain binds carbohydrates on microorganisms, while the collagenous regions are 
ligands for the collectin receptor (C1q receptor) on phagocytes and also mediate C1q-
independent activation of the classical complement pathway (49). The pulmonary 
surfactant proteins A (SP-A) and SP-D, as well as the serum collectins mannose-
binding lectin, conglutinen and CL-43 have been identified (50). The serum collectin 
human mannose binding lectin is involved in TNF-α production by human monocytes 
stimulated with mannoprotein, one of the capsule components of C. neoformans (51). 
One of the pulmonary collectins, SP-D, has been described to agglutinate acapsular C. 
neoformans (52). The role of SP-D and SP-A in serum-independent phagocytosis of 
C. neoformans is described in chapter 4. Serum-free phagocytosis of acapsular C. 
neoformans by macrophages induces a range of proinflammatory cytokines, which 
may stimulate an effective cell mediated immune response before the yeasts are able 
to grow and synthesize appreciable quantities of capsule, which is known to 
undermine host defense (see later). Also, human alveolar macrophages containing 
phagocytosed C. neoformans can induce proliferation of autologous T lymphocytes, 
suggesting their role as antigen-presenting cells in cryptococcal infection (53). 
2.2 Cell mediated immunity 
2.2.1 Delayed type hypersensitivity 
Full protection against C. neoformans is dependent on multiple factors, which include 
innate and adaptive immune defenses. The factors that stand out as being crucial are 
the functional CD4+ T helper cells and the ability of the host to mount a cell mediated 
immune response. The importance of cell-mediated immunity (CMI) in protection 
against C. neoformans has been firmly established in both animal experiments and 
patients (54-56). In absence of CD4+ T cells, patients with disseminated 
cryptococcosis are not able to clear the organism completely even with the best 
available antifungal therapy, and must be put on maintenance antifungal therapy for 
life (38) (see before). Evidence that CMI response induced by low dose infection with 
C. neoformans is protective has come from studies with nude mice (54). After 
infection, heterozygous nu/+ mice developed an anticryptococcal delayed type 
hypersensitivity (DTH) response and concomitantly the numbers of cryptococcal 
Colony Forming Units (CFU) in tissues were reduced. T-cell-deficient nude (nu/nu) 
mice did not develop an anticryptococcal CMI response but did make high levels of 
anticryptococcal antibodies and showed no signs of controlling the infection (54). 
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Positive DTH responses not only indicate the presence in the body of activated T 
cells, but also confirm that other components in the CMI cascade such as cytokines, 
chemokines, adhesion molecules, chemokine receptors and leukocyte migration are 
functioning.  
The leukocyte infiltrate after intratracheal inoculation of C. neoformans into 
susceptible mice (like CBA/J mice) consists of macrophages, lymphocytes (CD4+ T 
cells, CD8+ T cells, B cells and NK cells), neutrophils and eosinophils (57;58). 
Activated macrophages appear to be the most important fungicidal effector cell 
(40;59). Thus, the recruitment and activation of phagocytes is an important 
component of CMI during cryptococcal infection. Mechanisms by which the host 
defense cells are attracted to the site of infection are complex. They involve local 
production of chemotactic factors that promote directed migration of phagocytes.  
2.2.2 Chemokines 
Specific substances termed chemotactic factors trigger directed locomotion of 
phagocytes towards the actual site of infection (chemokinesis). The phagocytes carry 
several receptors on their cell surface by which they are able to recognize these 
chemotactic factors. Chemoattractants are either secreted by activated host cells, or 
produced by complement activation or by the invading microorganism itself. They 
form gradients, which determine the direction of phagocyte migration. Well known 
chemoattractants for phagocytes are platelet-activating factor (PAF), arachidonate 
metabolite leukotrine B4 (LTB4), complement fragment C5a, bacterial derived 
formylated peptides like N-formyl-methionyl-leucyl-phenylalanine (fMLP) and 
chemokines like IL-8 and MCP. The two most important chemokine families are 
subdivided based on the position of the first two conserved cysteine residues: C-C 
chemokines (two adjacent cysteine residues) and the C-X-C chemokines (two cysteine 
residues separated by one aminoacid) (60;61). The C-C chemokines include MCP-1, 
MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β, and are predominantly chemotactic 
for mononuclear cells. The C-X-C chemokines include IL-8, MIP2, and PF4, attract 
mainly neutrophils. Binding of chemotactic factors to their specific receptors activates 
multiple intracellular signaling pathways that regulate the intracellular machinery 
necessary to propel the cell in its chosen direction. The C-C chemokine MCP-1 is 
involved in clearance of pulmonary cryptococcal infection, and plays a critical role in 
the T cell-dependent immune response to C. neoformans (62). MIP-1α production is 
required during the efferent phase of pulmonary CMI for the recruitment of 
macrophages and neutrophils to the site of C. neoformans infection (63). Data of 
Huffnagle et al. (62;63) support the hypothesis that MCP-1 plays an important role in 
the initial recruitment of leukocytes (T lymphocytes and a small number of monocytes 
and neutrophils) that produce MIP-1α, which, in turn, mediates the bulk of monocytes 
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and neutrophil recruitment into the lungs. Furthermore, neutralization of MIP-1α 
reduces both TNF-α and IL-6 levels in C. neoformans infected mice (63).  
2.2.3 Cytokines 
Peripheral blood mononuclear cells (PBMC) and neutrophils have been shown to 
produce proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 when stimulated 
with C. neoformans or their cell wall components (51;64;65). The presence of certain 
cytokines during the induction phase of a CMI response also determines whether Th1 
cells or Th2 cells predominate as activated T cells (66). Typically, the presence of IL-
12, IL-18 or IFN-γ ensures that Th1 cells develop, whereas the presence of IL-10 
and/or IL-4 directs the response to a Th2 response. Production of TNF-α is required 
for the development of protective T cell immunity to C. neoformans (67). The 
development of a protective Th1 type CMI and the production of Th1- and 
macrophage-activating cytokines TNF-α, IL1β, IL-12, IFN-γ, and GM-CSF are 
required to eradicate the infection (68), control cryptococcal dissemination from the 
lungs, and eliminate subsequent invasion in the brain (69). Phagocytes like 
macrophages, monocytes, and PBMC stimulated with pro-inflammatory cytokines 
show in general enhanced phagocytosis and fungicidal activity (70). In chapter 5 
cytokines, which are produced by PBMC of healthy donors stimulated with C. 
neoformans and its capsular components, have been studied. 
2.3 Dissemination to the brain compartment 
In cases of dissemination from the lungs, cryptococci are able to escape local 
(impaired) innate and adaptive immunity and gain access to the bloodstream. In the 
vascular compartment, polymorphonuclear cells and monocytes are present. These 
cells have demonstrated effective in vitro killing, especially in the presence of 
opsonins, like complement (71;72). C. neoformans has a unique, partly unexplained, 
predilection for the brain. The yeast produces a unique phenol oxidase that converts a 
variety of hydroxybenzoic substrates, including catecholamines (e.g. norepinephrine 
and dopamine), into melanin, which impart a dark color to colonies (73). Melanin can 
function as an antioxidant, which may protect C. neoformans from oxidative host 
defenses (74). The wide availability of catecholamines in the brain could be a factor 
for the neurotropic features of the yeast.  
In order to produce infection in the brain yeast cells must cross the blood brain 
barrier. Endothelial cells are able to phagocytose acapsular C. neoformans through a 
serum-dependent process (75), however no direct killing activity has been 
demonstrated in vitro (76). These observations suggest that endothelial cells may take 
up poorly encapsulated forms and that this phenomenon may contribute to C. 
neoformans dissemination to the brain compartment (75). After arriving in the brain, 
biosynthesis routes leading to capsule formation are strongly up-regulated. Brain 
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cryptococci are characterized by the presence of huge capsules and high levels of 
capsular products are shed into the vascular compartment.  
In an autopsy series of 27 patients with cryptococcal meningoencephalitis significant 
differences in neuropathologic inflammatory response between AIDS and non-AIDS 
infected patients were found (77). Most non-AIDS patients had granulomas, 
supporting a role for CMI, whereas AIDS patients did not show granulomatous 
inflammation. The principal reactive cells in cryptococcal meningoencephalitis in 
AIDS patients were brain macrophages and microglia. In order to investigate if 
chemokines play a role in the recruitment of these cells, the induction of MIP-1α, 
MIP1-β and RANTES by HIV and non-HIV infected macrophages stimulated by C. 
neoformans was investigated in chapter 6. 
In HIV-infected patients with cryptococcal meningitis cytokine profiles in CSF were 
analyzed and showed high levels of the C-X-C chemokine, interleukin 8 (IL-8) (78). 
C. neoformans products such as GXM (see later) can directly induce IL-8 production 
by isolated microglial cells in culture (79). IL-8 is a chemotactic cytokine, which 
partially mediates the adhesion of neutrophils to the endothelium and their migration 
through the vascular wall. Despite the high levels of IL-8 in CSF of infected patients, 
no leucocytosis was observed (78). Cryptococcal polysaccharides are generally 
considered to mediate inhibition of neutrophil extravasation (80). 
 
3. POLYSACCHARIDE CAPSULE 
3.1 Chemical composition  
A distinctive feature of C. neoformans relative to other medically important yeasts is 
the ability to produce an extracellular polysaccharide capsule. In nature it may protect 
the yeast from desiccation or reduce its ability to be ingested and destroyed by soil 
amoebae (81). In the pathogenesis of cryptococcosis the capsule has been shown to be 
a virulence factor (82;83). Several genes necessary for capsule formation CAP59, 
CAP64, CAP60, and CAP10 have been identified (82;84). In experimental 
cryptococcosis, capsule-free isolates are less virulent than their encapsulated wild-
type cells (85). An encapsulated strain created by complementation of the CAP64 
mutation produced fatal infection of mice within 25 days, while the CAP64 acapsular 
strain was avirulent (82). A number of effects of cryptococcal capsule 
polysaccharides, which may contribute to enhanced virulence, have been described. 
The capsule inhibits phagocytosis of C. neoformans by macrophages, monocytes, and 
neutrophils (86). The capsule does not directly modulate phagocytic function, but 
instead, presents a surface that is not recognized by phagocytes (87). Furthermore, 
interference with antigen presentation by the cryptococcal polysaccharides has been 
described (88).  
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The capsule can vary in size between <1 µm and >50 µm, depending on growing 
conditions. The capsule consists for 88% of glucuronoxylomannan (GXM), for 10% 
of galactoxylomannan (GalXM) and for 2% of mannoproteins (MP) (89). GXM is 
composed of a α-1,3-linked polymannose backbone with β-linked monomeric 
branches of xylose and glucuronic acid. The four described serotypes A, B, C and D 
are discriminated on the base of differences in GXM structure. The different serotypes 
have a common core-repeating unit, but differ in the degree of mannosyl substitution 
and the molar ratios of mannose, xylose, and glucuronic acid (90). GalXM is 
composed of a backbone of α (1→6) linked galactose substituted with small side 
chains consisting of mannose, xylose and galactose (91). For individual strains there 
are differences in sugar composition in the GalXM, indicating that this polysaccharide 
is structurally heterogeneous (92). MP and GalXM often fractionate together in 
polysaccharide preparations. When GalXM-containing material is further fractionated 
on a concanavalin A affinity chromatography column, three peeks containing GalXM, 
MP1/MP2 and MP4 are observed. MP is proposed to be consisting of a protein 
backbone heavily substituted by short oligosaccharides mainly containing mannose 
although significant amounts of galactose and xylose are present (91). MP4 consists 
of 20% protein (predominant amino acids are serine, threonine, and alanine) and sugar 
moieties (xylose-mannose-galactose in a 1 to 7.7 to 0.8 ratio) (91).  
3.2 Interference with neutrophil migration 
The circulatory and migratory properties of leukocytes have evolved to allow efficient 
surveillance of tissues for infectious pathogens and rapid accumulation at sites of 
injury and infection. It is currently believed that leukocytes leave the circulation by 
first adhering to activated endothelial cells, followed by migration through the 
interendothelial junctions (93). Localized inflammation results in dilatation of vessels 
and diminished blood flow, allowing the transient adherence of PMN to endothelial 
cells by selectin-mediated tethering and rolling along the vessel wall (94;95). CD62L-
mediated rolling precedes a further functional up-regulation of PMN following 
exposure to pro-inflammatory cytokines and chemoattractants (96), resulting in 
firmer, integrin-mediated adherence. Up-regulation of integrins is accompanied by 
shedding of CD62L from the cell surface (94;96). Further stimulation of PMN 
phenotypically high in CD11b/CD18 (CR3, Mac-1) initiates transendothelial 
migration via an interaction of Mac-1 with its counterreceptor ICAM-1 (97). Finally, 
chemotactic gradients guide migrating PMN to the site of infection. Patients who are 
genetically deficient in the leukocyte integrins have been described. Neutrophils in 
these leukocyte adhesion deficiency I (LAD-I) patients fail to cross the endothelium 
and accumulate at inflammatory sites and in vitro are deficient in binding to and 
migrating across resting or activated endothelial monolayers (98).  
Chapter 1 
18 
The potency of C. neoformans culture supernatant to inhibit leukocyte migration was 
recognized almost half a century ago (99). Disseminated cryptococcosis is 
characterized by the presence of high levels of capsular antigens GXM and GalXM in 
the CSF and serum of affected patients (100;101). GXM titers in both serum and CSF 
from AIDS patients can reach levels up to 20 mg/ml (102). Despite the elevated IL-8 
CSF/serum ratio and the elevated serum levels of TNF-α and IL-1β, the CSF of 
patients with cryptococcal meningitis typically contains few mononuclear cells and 
virtually no PMN (78). GXM is capable of interfering with leukocyte migration 
towards potent chemoattractants, such as fMLP and C5a (80;103;104). Furthermore, 
GXM can induce the production of IL-8 by human microglia but inhibits neutrophil 
migration towards IL-8 (79). GXM sheds L-selectin from neutrophils (105), and can 
bind to CD18 adhesion molecules thereby blocking interaction of activated 
neutrophils with ligands on the endothelium (106). To investigate if GXM actually 
interferes with leukocyte migration in clinical cryptococcosis, we compared 
retrospectively the GXM titer in serum and CSF with the CSF leukocyte cell counts of 
35 Dutch HIV-infected patients with culture-proven diagnosis of cryptococcal 
meningitis (chapter 7). Furthermore, GXM has been described to delay translocation 
of PMN across the blood-brain barrier in a rabbit bacterial meningitis model (107).  
Therefore, the initial aim to further study was to investigate the molecular mechanism 
by which GXM prevents PMN migration toward chemoattractants. Surprisingly, we 
found that cryptococcal culture filtrate (CneF) from GXM-producing and GXM-
nonproducing (∆CneF) strains, both prevented PMN migration towards IL-8 and 
fMLP. These results seriously question the opinion that GXM is the sole cryptococcal 
component preventing extravasation. The finding that MP-4 was primarily responsible 
for the inhibition of PMN migration is described in chapter 8. 
 
4. OUTLINE OF THIS THESIS 
In chapter 2 a survey of cryptococcosis cases in the Netherlands is described during a 
14-year retrospective analysis of cases (1986-2000). In chapter 3, 4, 5 and 6 we 
follow C. neoformans on its route through the human body.  
Cryptococcosis is likely to occur via inhalation of small, acapsular C. neoformans. 
The inhaled particles are small enough to reach alveolar spaces. One of the initial 
steps in host defense, is the interaction between acapsular cryptococci and alveolar 
macrophages. In a laboratory environment, this interaction (binding and phagocytosis) 
is usually measured in tubes where both target (C. neoformans) and effector cells (for 
example alveolar macrophages) are in suspension. In vitro, however it is more likely 
that alveolar macrophages act as adherent cells. Therefore, in chapter 3 a method is 
described to measure phagocytosis of C. neoformans by adherent effector cells. 
Serum-free phagocytosis of C. neoformans by alveolar macrophages may be an 
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important part of the innate immune response because in the lung high concentration 
of serum opsonins, like complement factors, might be missing. Chapter 4 describes 
the influence of non-serum opsonins, surfactant protein A and D on phagocytosis of 
C. neoformans by a number of effector cells, including human alveolar macrophages. 
A next step in immune response against C. neoformans includes influx of leucocytes 
to the side of infection, including PMN and mononuclear cells. Furthermore, in 
disseminated infection, cryptococci are able to escape to the vascular compartment. 
Chapter 5 describes the cytokine profile of PBMC stimulated with C. neoformans 
and analysis the components responsible. Finally, yeast cells will be able to reach the 
brain compartment. In AIDS related cryptococcal meningoencephalitis brain 
macrophages and microglia were identified as principal inflammatory cells. In 
chapter 6 a study is described which analysis which chemokines are produced by 
HIV-infected macrophages after stimulation with C. neoformans or GXM. CSF of 
patients with AIDS related cryptococcal meningoencephalitis contains few 
neutrophils despite high levels of neutrophil chemoattractant IL-8. As mentioned 
before cryptococcal polysaccharides are thought to play a role in the interference with 
neutrophil migration. In chapter 7 patient data were analyzed for their titers of GXM 
in serum and CSF, and the results were correlated to matching CSF-counts. In 
chapter 8, the role of another cryptococcal polysaccharide, MP4, in interfering with 
leukocyte migration, is investigated. 
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SUMMARY 
To describe prevalence, clinical features, and prognosis of cryptococcosis in the 
Netherlands we performed a retrospective analysis. Data on cryptococcosis were 
collected nationwide from January 1986-December 1999 through a national reference 
laboratory and 5 major microbiology laboratories. Clinical data were obtained by 
reviewing medical records. In 14 years, cryptococcosis was diagnosed in 268 patients. 
The increasing number of cryptococcosis cases from 1987 on initially paralleled the 
growing AIDS epidemic, 203 patients with cryptococcosis (76%) were infected with 
HIV. Introduction of Highly Active Antiretroviral Therapy (HAART) in 1996 was 
associated with a sharp decline in the incidence of cryptococcosis. In non- HIV-
infected patients, there was a significant delay in diagnosis. Favorable clinical 
outcome was associated with initial treatment with amphotericin B plus flucytosine. 
The strongest adverse prognostic factor in multi variate analysis was altered 
consciousness at the time of presentation at the hospital (P<0.05).  
This retrospective analysis of cryptococcosis cases demonstrates changes in the 
occurrence of cryptococcosis that are mainly caused by changes in the epidemiology 
of AIDS in the Netherlands and are temporally associated with the introduction of 
HAART.  
Because untreated cryptococcosis in HIV-, and non-HIV-infected patients has a high 
mortality rate, fast recognition and diagnosis of this infection is important.  
 
INTRODUCTION 
Cryptococcosis is a systemic mycotic infection caused by the encapsulated yeast 
Cryptococcus neoformans, mainly occurring in patients with impaired cell mediated 
immunity (1).  
The incidence of cryptococcosis has increased dramatically worldwide in the last 
decades, paralleling the rising numbers of susceptible immunocompromised patients. 
Most important predisposing factors for infection with C. neoformans are HIV 
infection, use of immunosuppressive drugs, organ and bone marrow transplantation, 
chronic leukemia and lymphomas. In most western countries 5-10% of HIV infected 
patients will develop cryptococcosis (2). In sub-Saharan Africa 10-15 % of HIV 
infected patients become infected with C. neoformans (3;4), in some of these 
countries it is the most important cause of meningitis (5). 
Mortality of cryptococcosis is high. Between 10 and 25% of AIDS patients die during 
initial treatment, and between 30 and 60% of patients succumb within 12 months 
(6;7). In non-AIDS patients mortality rates are even higher, between 25-30% of 
patients die during initial treatment. 
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The aim of this study was to gain insight into prevalence, clinical features and 
prognosis of cryptococcosis in the Netherlands. Prior to 1985, the annual incidence of 
cryptococcosis was 5 cases (8). We retrospectively analyzed data from 268 patients 
with cryptococcosis from January 1986 through December 1999. In July 1996, highly 
active antiretroviral therapy (HAART) for HIV-infected patients was widely 
introduced in the Netherlands. This allowed us to also evaluate the effect of HAART 
on the incidence of cryptococcosis. 
 
PATIENTS AND METHODS 
Study population and source 
From January 1986 through December 1999 data from patients with cryptococcosis 
were retrospectively collected. Patients were identified from the registers of the 
Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in Amsterdam 
and 5 academical microbiology laboratories (University Medical Centre Utrecht, 
Erasmus University Medical Centre Rotterdam, Academical Hospital Nijmegen St. 
Radboud, Academical Medical Centre Amsterdam, University Medical Centre Vrije 
Universiteit Amsterdam. The NRLBM receives isolates and sera of approximately 
90% of all patients with meningitis in the Netherlands (9). 
Case definition  
Cryptococcosis was diagnosed in cases with a positive C. neoformans culture and/or 
positive antigen detection test combined with clinical suspicion of cryptococcosis 
and/or the presence of cryptococci by tissue histology. In 211 of 268 patients (78%) 
with cryptococcosis a positive liquor culture or antigen detection test was found, these 
patients were diagnosed cryptococcal meningitis.  
Data collection  
From 111 patients with cryptococcal meningitis additional data were obtained: 
demographic and epidemiological data (sex, age, hospital), clinical information (signs 
and symptoms, date of diagnosis, relevant medical history), laboratory data (source 
and date of culture-positive specimens, source and date of antigen detection, clinical 
chemistry of CSF), radiological findings (abnormalities on chest X-ray or CT scan), 
underlying conditions, treatment (initial therapy, duration, changes in treatment, use 
of antimycotic therapy), and complications and outcome (death related to 
cryptococcosis, clinical cure or improvement, relapse). Patients were considered to 
have died from cryptococcal meningitis if they had a positive CSF culture or antigen 
test for C. neoformans at the time of death, in combination with fitting clinical 
symptoms. Patients were classified as cured when clinical symptoms disappeared and 
CSF cultures were repeatedly negative during a follow-up period of at least one year. 
Patients were classified as improved when clinical symptoms disappeared and 
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cultures of CSF were negative when last examined, but follow-up was for less than 
one year, or when the patient died of other causes after successful treatment of 
cryptococcal infection. Relapse was defined as a negative culture after treatment 
followed by a positive culture for C. neoformans in combination with fitting clinical 
symptoms. Positive outcome was defined as cure or improvement, negative outcome 
as death from cryptococcal infection or relapse. Patients were scored only once; 
relapses were not counted as a separate event. 
Statistical analysis  
Variables were compared using chi-square test and univariate analysis (Mann-
Whitney U test). With potential prognostic factors from univariate analysis a multi 
variate analysis was performed. Differences were considered significant with a P 
value < 0.05. 
 
RESULTS 
Prevalence of cryptococcosis in the Netherlands  
During 14 years 268 patients were diagnosed with cryptococcosis. Cases of 
cryptococcosis were noted throughout the Netherlands, but the majority of patients 
originated from the two largest cities, Amsterdam and Rotterdam (fig. 1).  
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Figure 1: Geographical distribution of cryptococcosis in the Netherlands (1986-
1999). The number of patients with cryptococcosis is shown in different tones of
gray.  
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A sudden major increase in the number of patients with cryptococcosis was seen in 
1987, virtually completely due to the increasing number of HIV-related cases (fig. 2). 
During the first 10 years covered by the survey, the mean annual incidence of 
cryptococcosis was 21.3 cases per year. This declined by 55% to only 9 and 10 cases 
per year in 1996 and 1997, respectively, and 13 cases per year in 1998 and 1999. This 
decline was caused by reduction of HIV-infected patients with cryptococcosis.  
The number of non-HIV-infected patients with cryptococcosis remained stable 
throughout the 14-year period, varying from 1 to 6 cases a year (fig.2). The decline of 
cryptococcosis in HIV-infected patients could not be explained by a lower incidence 
of AIDS patients. There was however, a clear association with the introduction of 
HAART in the Netherlands in 1996. Most of the AIDS patients diagnosed before 
1996, and newly diagnosed patients were given HAART. Most of these patients were 
included in the ATHENA trial, a national multi center clinical cohort study started in 
1998 to evaluate the effect of HAART. 
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Figure 2: Number of patients with cryptococcosis, AIDS and patients on HAART 
during 1986-1999.
HIV-infected patients with cryptococcosis (left axis)
Non HIV-infected patients with cryptococcosis (left axis)
Patients with cryptococcosis with unknown underlying disease (left axis)
Total of HIV-infected patients using HAART, included in the ATHENA trial (right axis)
Number of AIDS diagnoses (right axis)
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Characteristics of patients 
Of 268 patients with cryptococcosis, 203 were diagnosed with HIV infection (table 1). 
No predisposing factors could be detected in 7 patients despite an extensive work-up. 
One of these patients was known to work in a bird sanctuary. Two patients were 
pregnant which is a known risk factor for cryptococcosis (10). 
 
Table 1: Age, sex and predisposing factors of 
268 cryptococcosis patients  
Age (median) 
 
Sex (male: female) 
 
Predisposing factors 
- None 
- Unknown 
- HIV-infection 
- Use of immunosuppressive 
drugs    
- Hematological malignancy 
- Cellular immune deficiency 
- Pregnant 
39 (range 15-78) 
 
8:1 
 
 
7 
24 
203 
14 
 
16 
2 
2 
 
 
Clinical manifestations of patients with cryptococcal meningitis  
Cryptococcosis is a systemic infection, commonly presenting as meningoencephalitis. 
In the next part of this chapter we focus on patients presenting with cryptococcal 
meningitis. Clinical presentation of patients with cryptococcal meningitis at the time 
of presentation at the hospital is counted up in table 2. The median duration of 
symptoms before presentation was 24.5 days (range 2-125 days), with 30% of patients 
having been symptomatic for more than 25 days. HIV-infected patients were 
diagnosed within 3 days after hospital admission whereas non-HIV-infected patients 
were diagnosed after 10 days (P<0.01). HIV-infected patients presented more often 
with headache than non HIV-infected patients (P<0.05). HIV-infected patients also 
tended to present more often with symptoms compatible with encephalopathy 
(photophobia, seizures) than those without HIV infection. Most of the HIV-infected 
patients had advanced disease with a median CD4+T-cell count of 30 cells/(l (range 
3-240). At the time of hospital admission 23 patients (21%) used azoles (mainly 
Fluconazole) because of recurrent mucosal candidiasis and were apparently not 
properly protected.  
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Table 2: Clinical presentation of patients with cryptococcal meningitis at 
time of hospital admission according to HIV status (n=111) 
 
Symptoms 
 
 
Fever 
Headache 
Cough 
Nausea 
Vomiting 
Malaise 
Rigidity of the neck 
Changes in consciousness 
Photophobia 
Papilledema 
Seizures 
Visual changes 
Cranial nerve lesion 
Hemi paresis  
 
Duration of symptoms at 
first presentation (days) 
Time between first 
presentation and diagnosis 
(days) 
 
HIV-infected patients 
(n=97) 
 
83 (85%) 
87 (90%) 
35 (31%) 
47 (48%) 
40 (41%) 
59 (61%) 
27 (28%) 
26 (27%) 
18 (18%) 
10 (10%) 
12 (12%) 
14 (14%) 
11 (11%) 
3 (3%) 
 
21 
 
3 
 
 
Non-HIV infected 
patients (n=14) 
 
12 (86%) 
8 (57%)* 
2 (14%) 
4 (27%) 
6 (43%) 
7 (50%) 
2 (14%) 
5 (36%) 
1 (7%) 
2 (14%) 
0 
3 (21%) 
0 
0 
 
18 
 
10† 
* P<0.05 
† P<0.01 (Mann Whitney U-test) 
 
Diagnostic features of patients with cryptococcal meningitis  
CSF cultures were positive for C. neoformans in 108 of 111 cases (97%). Blood 
cultures were performed in 66 patients and were positive for C. neoformans in 28 
patients (42%) (table 3). Opening pressure from lumbar puncture (normal: <12 
mmHg) was elevated in 96% of patients (median 30 mmHg, range 8-80 mmHg). The 
number of leucocytes in the CSF was 12 x 106 cells/3 per mm3 for HIV-infected 
patients, 269 x 106 cells/3 per mm3 for non-HIV-infected patients. 
A chest X-ray was made in 95 patients with cryptococcal meningitis and revealed 
abnormalities in 37 (39%). These ranged from very small, delicate lesions to massive 
infiltrates in the lungs. Cranial computer-tomographic (CT) scanning demonstrated 
abnormalities (ventricular enlargement, hypodense lesions, hyperdense spot-like 
lesions, and cortical atrophy) in 28 out of 86 patients. 
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Table 3. Laboratory and radiological findings according to HIV status of patients 
with cryptococcal meningitis  
  
Total 
 
 (n=111) 
 
HIV-infected 
patients  
(n=97) 
 
Non HIV-
infected patients  
(n=14) 
 
CSF (median, range) 
 -Opening pressure 
(mmHg) 
 -Glucose (mmol/l)  
 -Protein (g/l) 
 -Cell count (cells/3 per 
mm3) 
 -Cryptococccal antigen 
titer 
 -Pos. CSF-culture 
Blood 
 -Cryptococcal antigen 
titer 
 -Pos. blood culture 
Radiology 
Chest X-ray 
 -Abnormal 
Cranial CT-scan 
 -Abnormal 
 
 
30 (8-80) 
 
2.7 (0.1-4.8) 
0.68 (0.15-5.7) 
243 (0-1153) 
 
1:328 (1:1-
1:1x106) 
108/111 (97%) 
 
 
1:1024 (1:2-
1:2,6x105) 
28/66 (42%) 
 
 
 
37/95 (39%) 
 
28/86 (32%) 
 
 
30 (8-80) 
 
2.6 (0.1-4.8) 
0.66 (0.15-5.7) 
12 (0-1153) 
 
1:400 (1:1-1: 
1x106) 
95/97 (98%) 
 
 
1:1034 (1:2-1: 
2,6x105) 
25/58 (43%) 
 
 
 
33/85 (39%) 
 
24/76 (32%) 
 
 
ND 
 
3.8 (1.0-4.8) 
0.95 (0.3-2.13) 
269 (42-350)* 
 
1:64 (1:4-
1:6,6x105 ) 
13/14 (93%) 
 
 
1:256 (1:4-
1:1024) 
3/8 (38%) 
 
 
 
4/10 (40%) 
 
4/10 (40%) 
* P<0.05 (Mann-Whitney-U) test 
ND= not done 
 
Therapy of patients with cryptococcal meningitis  
Treatment data were available for 108/111 patients. Fifty-four patients were initially 
treated with intravenous amphotericin B (dose 0.3-0.7 mg/kg/day) in combination 
with either oral or intravenous 5-fluorocytosine (5-FC) (dose 150 mg/kg/day). Other 
commonly used initial therapies were intravenous amphotericin B (dose 0.5-0.7 
mg/kg/day) (n=16) or oral azoles (n=23). A liposomal formulation of amphotericin B, 
Ambisome®, was used in 7 patients, twice in combination with fluconazole.  
Cryptococcal meningitis was diagnosed post-mortem in 4 cases. Tuberculosis was 
suspected in one case and anti-tuberculosis treatment was started. Three cases were 
considered to have suffered from viral meningitis and were treated with acyclovir.  
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Toxic effects of initial treatment, such as thrombocytopenia and granulocytopenia for 
5-FC (n=9) and nephrotoxicity for amphotericin B (n=4), resulted in changes of 
therapy. No clinical improvement was observed in 7 patients using fluconazole as 
initial monotherapy, in these cases amphotericin B was added. Symptomatic relief 
was achieved by repeated lumbar punctures in 3 patients with severe headache and 
high lumbar opening pressures. All HIV-infected patients received long-term 
maintenance therapy with either fluconazole (88%) (dose 150-400 mg/day) or 
itraconazole (12%) (dose 200-600 mg/day). 
Outcome of patients with cryptococcal meningitis  
Mortality of cryptococcal meningitis was 19.5% (n=19) in HIV-infected and 28.5% 
(n=4) in non-HIV infected patients. Seven HIV infected patients were cured, 56 
patients improved clinically. Nine non-HIV infected patients improved clinically. In 5 
cases of HIV infected patients and in 1 non-HIV infected patient no information about 
outcome was available. Ten patients, all HIV infected, had a relapse. Altered 
consciousness (P<0.01), seizures (P<0.01), rigidity of the neck (P<0.05) and a high 
cryptococcal antigen titer in CSF at the moment presentation, were associated with a 
negative outcome in univariate analysis (table 4). Initial therapy with amphotericin B 
and 5-FC was associated with a positive outcome as compared to other therapies 
(P<0.05). In logistic regression only altered consciousness was associated with a 
negative outcome (P<0.05). 
 
DISCUSSION 
Changes in the occurrence of cryptococcosis are mainly caused by changes in the 
epidemiology of AIDS in the Netherlands since 1986. From 1996 on a sharp decline 
in the incidence of cryptococcosis was noticed. This decline was caused by reduction 
of HIV-infected patients with cryptococcosis. The estimated incidence of HIV 
infection in the Netherlands in this same period did, however, not decrease (11). Since 
the introduction of HAART in 1996 a decline in the number of patients with 
progression from HIV infection towards AIDS has been noticed (12). This is 
explained by the increase of CD4+-cells, which goes with a restored immune system 
and a better host defense against opportunistic infections (13-16). The decline of HIV-
infected patients with cryptococcosis is probably explained by the partial restoration 
of the immune system as a result of HAART (17). 
The decline in incidence of cryptococcosis starts in the beginning of 1996, around the 
introduction of HAART, could possibly also be explained by the introduction of 
azoles, mainly fluconazole, for recurrent mucosal candidiasis (18). However, in our 
study 23 patients became infected with C. neoformans despite the use of antifungal 
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agents. Furthermore in the Netherlands primary prophylactic antimycotic agents 
against recurrent mucosal candidiasis was not recommended.  
 
Table 4:  Prognostic features for cryptococcal meningitis 
 No. of 
patients 
 
No. of patients 
who 
died/relapsed 
P-value 
Clinical presentation 
 -Altered 
consciousness 
       Yes 
       No 
 -Seizures 
       Yes 
       No 
 -Rigidity of the neck 
       Yes 
       No 
Treatment 
 -Amphotericine B + 
5-FC 
 -Other 
Laboratory findings  
 -Antigen titer in CSF  
 
 
 
 
30 
75 
 
12 
93 
 
28 
77 
 
 
 
53 
50 
 
1:256 
 
 
 
 
16 
17 
 
8 
25 
 
13 
20 
 
 
 
11 
22 
 
1:1024 
 
 
<0.01*/<0.05† 
 
 
 
<0.01* 
 
 
<0.05* 
 
 
 
 
<0.05* 
 
 
 
<0.05# 
 
* derived by Fisher’s exact test 
#   derived by Mann Whitney U-test 
† multivariate analysis in a logistic regression model 
 
Severe neurological symptoms (like altered consciousness) and a high antigen titer at 
the time of presentation are both associated with negative outcome. The severity of 
the clinical symptoms is probably caused by infection of cryptococci with high fungal 
load. As a result of an impaired immune system, cryptococci get the chance to 
multiply and cause severe damage to surrounding tissues. Treatment of cryptococcal 
meningitis for both HIV, and non-HIV-infected patients with amphotericin B in 
combination with 5-FC is associated with a positive outcome, as compared to the 
other treatment options. Next to initial treatment life long secondary prophylaxes with 
oral azoles was indicated for patients with HIV-infection. Very recently, there are 
several studies suggesting that it is safe to stop secondary prophylaxis against C. 
neoformans in patients responding to HAART (increase in CD4+ T cell count to >50-
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100 cells/3 per mm3), without relapse of their cryptococcal disease (19;20). In our 
study 9 patients developed cryptococcal meningitis with a CD4+ T cell count >100 
cells/3 per mm3. Stopping secondary prophylaxis in a HIV-infected patient will, 
beside the increase of CD4 cells, also be dependent on the clinical condition of the 
patient. 
C. neoformans is worldwide one of the most important causes of meningitis, however 
in the Netherlands cryptococcosis is a rare finding. In all cases of sub-acute or chronic 
meningitis, and especially in patients with impaired immunity cryptococcal-associated 
disease belongs in the differential diagnosis. Because mortality rate of crytococcal 
meningitis for both HIV, and non-HIV-infected patients is high, fast recognition of 
clinical symptoms and awareness of risk factors for cryptococcosis remain important. 
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ABSTRACT 
Macrophages and monocytes are adherent phagocytic cells, which play an important role 
in host defence against the yeast-like fungus Cryptococcus neoformans. Before, 
phagocytosis by adherent phagocytes could only be measured by means of microscopy or 
by a radioactive assay, which both have obvious disadvantages. We have developed a 
new, rapid and objective method to measure phagocytosis of C. neoformans by adherent 
phagocytes (e.g. alveolar macrophages) using a fluorescence multi-well plate reader. This 
method allows us to discriminate accurately between adherence and internalisation of C. 
neoformans by macrophages during long-term incubation. In addition, the method was 
used to study the role of the mannose receptor in phagocytosis of the acapsular yeast in 
the absence of serum by human monocyte-derived macrophages (MDM). 
 
INTRODUCTION 
Cryptococcus neoformans is a yeast-like fungus that causes infections in 
immunocompromised patients, especially in those with AIDS. Cryptococcosis caused by 
C. neoformans, is worldwide the leading cause of life-threatening mycological disease of 
the central nervous systems (1).   
In nature, the yeast cells possess minimal capsules and are therefore easily aerosolized. In 
this state, the yeasts are of a smaller size and can be inhaled to the level of the alveolus 
(2). The initial site of infection is the lung, where (alveolar) macrophages represent the 
first line of host defence (3). One of the first steps in host defence, therefore, is the 
interaction between the acapsular C. neoformans and alveolar macrophages. This 
interaction takes place in the alveolar spaces, where only low concentrations of serum 
components are present (3). Cross et al. described that ingestion of acapsular C. 
neoformans by mice macrophages in the absence of serum occurs via constitutively 
present mannose- and β-glucan- receptors (4). 
Previously, we have described a quantitative analysis of phagocytosis of C. neoformans 
by peripheral blood mononuclear cells using flow cytometry (5). This method enables us 
assessment of phagocytosis by cells in suspension, but not by adherent cells. As 
macrophages, like monocytes, strongly tend to adhere to different surfaces, a method is 
needed to measure phagocytosis by adherent cells. Until now, interaction between 
adherent phagocytic cells and C. neoformans could be studied by means of microscopy, 
which has the major disadvantage of being cumbersome and interpretation of results is 
subjective, or by a radioactive assay. This last method has disadvantages for routine 
laboratory use concerning health hazards and costs associated with radioisotope use and 
disposal. Phagocytosis of C. neoformans by monocytes and macrophages, measured by 
these methods, has been described by several investigators (6;7). 
We describe a new, rapid and objective method to measure phagocytosis of C. 
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neoformans by adherent monocytes and macrophages during short and long term 
incubation. Fluorescein isothiocyanate (FITC)-labelled C. neoformans were added to 
adherent phagocytes in a 96-well microtiter plate. At the end of the incubation time, 
trypan blue was used as a quencher of the non-internalized FITC-labelled cryptococci. 
Interestingly, the fluorescence of the internalized cryptococci was unaffected. This 
concept lays the foundation of our novel phagocytosis assay. The fluorescent signal of the 
FITC-labeled C. neoformans was measured by a fluorescence multi-well plate reader 
before and after addition of trypan blue. This enabled us to distinguish yeast cells that had 
been taken up by adherent phagocytes from those that were simply attached.  
The new method was compared with microscopic evaluation of phagocytosis of acapsular 
C. neoformans by monocytes or monocyte derived macrophages (MDM). Finally, the 
method was used to study the role of the mannose receptors in phagocytosis of the 
acapsular yeast by human MDM in the absence of serum. 
 
MATERIAL AND METHODS 
Cryptococcus neoformans preparation and FITC labelling 
An acapsular mutant of C. neoformans (NIH B 4131) obtained from the National Institute 
of Health (NIH, Bethesda, MD, USA) was used throughout this study. The yeast cells 
were maintained on Sabouraud dextrose agar (Merck, Darmstadt, Germany) at 4°C. After 
harvesting, the cryptococci were heat-killed for 30 min at 80°C, the concentration was 
adjusted to 5 x 107 cells/ml and the cells were labelled with fluorescein isothiocyanate 
(FITC, Sigma, St. Louis, MO, USA) at 500 µg/ml in phosphate-buffered saline (PBS) for 
30 min at 22°C. The yeast cells were then washed twice and small aliquots were stored in 
Hanks’ balanced salt solution (HBSS; pH 7.4).  
Human bronchoalveolar lavage cells 
Bronchoalveolar lavage (BAL) was performed in different patients for diagnostic 
purposes. None of the patients suffered from cryptococcosis or was suspected of having 
this disease. Informed consent was obtained from participants. A total of 240 ml sterile 
saline was instilled in the right middle lobe in 60 ml aliquots and recovered by gentle 
aspiration. Rates of recovery ranged from 60 to 85%. Human bronchoalveolar lavage 
cells (HBALC) were then centrifuged (1200 rpm) and harvested. The supernatant was 
then removed. If the pellet contained erythrocytes, the pellet was treated for 5 seconds 
with 1 ml of 1:4 diluted PBS (sterile water). The pellet contained predominantly alveolar 
macrophages (>95%) as was determined by a differential cell count of a sample of the 
pellet using a Diff-Quik (Baxter, Unterschleissheim, Germany) stain. Viability of the 
cells was more than 95% as checked by trypan blue staining. The cells were adjusted to 
the desired concentration (1 x 107 cells/ml). 
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Isolation of monocytes and MDM 
Human monocytes were isolated from buffy coats, obtained from the Blood Bank 
Utrecht, The Netherlands. Firstly, peripheral blood mononuclear cells (PBMC) were 
separated from the polymorphonuclear cells (PMN) fraction by centrifugation on a Ficoll-
Paque gradient (Pharmacia, Uppsala, Sweden). Then monocytes were purified from 
PBMC by countercurrent elutriation as described before (8). For our experiments the 
>80% pure monocyte cell fractions (viability >95%) were used. For preparation of MDM, 
monocytes were cultured in complete medium for 7 days in Teflon erlenmeyer flasks 
(Nalgene, Rochester, NY, USA) at a concentration of 2 x 106/ml. Cells were recovered 
from Teflon flasks by washing, and resuspended to a final concentration of 5 x 107 
cells/ml in RPMI 1640. At this time >95% of these cells were MDM checked by Diff-
Quik (Baxter) stain and anti-CD 14 PE-labelled antibody (Beckon Dickinson, Mountain 
View, CA, USA). Viability (>90%) was checked by trypan blue exclusion. 
Determination of association of C. neoformans with macrophages or monocytes by 
multi-well plate reader 
Initial experiments showed optimal results with of 5 x 105 adherent cells per well. 
Purified macrophages or monocytes (100 µl, 5 x 106 cells/ml) were added to a flat-
bottomed 96-well microtiter plate (Costar). The plate was placed in a CO2 incubator for 
1h at 37°C.  
The FITC-labelled cryptococci were preopsonized with either 10 % human serum, 
including complement, or 10 % rabbit serum, including specific rabbit anti-cryptococcal 
antibodies (K1228), or only buffer (HBSS 1% BSA) for 30 min at 37°C. The K1228 
antiserum (a kind gift of Dr. J. Orendi, Leiden, The Netherlands) was raised in rabbits 
against a NIH 37, a thinly encapsulated cryptococcal strain. The concentration of the 
preopsonized cryptococci was adjusted to 5 x 106 cells/ml (effector to target ratio 1:1) and 
subsequently added to the adherent phagocytes. All experiments were performed in 
quadruplicate. The plates were incubated in a CO2 incubator for 1-24 h at 37°C. After this 
incubation period each well was washed twice with HBSS to remove non-bound yeast 
cells. The green fluorescence of the FITC-labelled C. neoformans was measured in a 
fluorescence multi-well plate reader, Cytofluor II (PerSeptive Biosystems) at 485 nm, and 
represents the association (binding and internalization) of C. neoformans with the 
adherent phagocytes. Supernatant was removed and 100 µl of 400 µg/ml Trypan Blue 
(Merck) in HBSS was added for 2 min and washed away to quench the FITC-labelled C. 
neoformans that have not been ingested by the phagocytes. The plate was read again by 
the fluorescence multi-well plate reader to measure the cryptococci that had been taken 
up by the adherent phagocytes. Only cryptococci that were inside a phagocyte still bear 
the fluorescent label (5). 
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Microscopy 
We compared phagocytosis between the new method using the multi-well plate reader 
and microscopy. Therefore, after measuring in the fluorescence multi-well plate reader, 
the plates were Diff-Quik (Baxter) stained. The number of macrophages or monocytes 
with C. neoformans per 100 macrophages/monocytes (phagocytosis index) was counted. 
To further distinguish yeast cells that had been taken up by adherent phagocytes from 
those that were simply attached, wells were treated with Fungiqual A, according to the 
manufacturer’s instructions (Reinehr/Rembold, Kandern, Germany). After washing, the 
wells were treated with 1% Fungiqual A in PBS for 15 minutes at 37oC, washed again 
and examined under the fluorescence microscope. Fungiqual A stains chitin in the plasma 
membrane of fungi and fluoresces under UV light excitation. Again, the number of 
macrophages or monocytes with internalized cryptococci -as determined by Fungiqual A 
staining- per 100 macrophages/monocytes was counted (phagocytosis-index) and 
compared to the result of the fluorescence multi-plate reader. 
Inhibition assay 
To study the role of the mannose receptors in phagocytosis of the acapsular yeast in the 
absence of serum, C. neoformans (5. 106 cells/ml) were added to adherent MDM (5.106 
cells/ml) in the presence and absence of 1 mg/ml mannan (derived from S. cerevisiae, 
Sigma). The plates were incubated in a CO2 incubator for 3 h at 37°C and phagocytosis 
was measured by reading the plates by a fluorescence multi-well plate reader. 
 
RESULTS 
Association of C. neoformans with elutriated monocytes.  
In order to study binding and uptake of acapsular C. neoformans by the adherent 
phagocytes, we pre-opsonized the yeast cells with either 10 % normal serum or K1228 
serum (including specific rabbit anti-cryptococcal antibodies), or buffer only. 
Subsequently cryptococci were added to the adherent monocytes for either 3 or 18 h. 
After 3 h of incubation, the yeast cells which were pre-opsonized with human pooled 
serum (HPS) showed enhanced binding and uptake by the adherent cells, as compared to 
the K1228 serum and buffer pre-opsonized C. neoformans (Fig 1A). However, incubating 
the adherent monocytes with C. neoformans for 18 h showed roughly the same 
fluorescence values for all conditions tested indicating that, despite the use of different 
opsonins for the yeast cells (either 10% HPS or 10% K1228 serum, or buffer), 
phagocytosis takes place to the same extent after prolonged incubation (Fig 1B).  
The same experiments were repeated with human alveolar macrophages. Different 
opsonized cryptococci were added to adherent human alveolar macrophages for 3 and 18 
h. After 3 hours of incubation, the yeast cells, which were pre-opsonized with K1228 
serum and normal serum, showed enhanced binding and uptake by the adherent cells, as 
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compared to the buffer treated C. neoformans. Again, after 18 h, the differences between 
fluorescence values for the differently opsonized cryptococci disappeared, indicating that 
phagocytosis rates were the same for all different circumstances tested (data not shown). 
 
FIG 1A, 1B: Binding and uptake of FITC-labelled C. neoformans by adherent monocytes. Acapsular 
FITC-labelled C. neoformans (5.106 cells), were preopsonized with either 10 % human pooled serum, or 
10% K1228 serum (including specific rabbit anti-cryptococcal antibodies), or buffer (unopsonized) for 1 h 
at 37ºC. Subsequently the yeasts were added to elutriated monocytes for 3 hours (A) or 18 hours (B) at an 
effector:target ratio of 1:1. Open bars represent binding of cryptococci, solid bars represent uptake of C. 
neoformans by monocytes. Data are presented as mean fluorescence plus SEM, and are the mean of four 
experiments performed in quadruplicate. 
 
Determination of association of C. neoformans with monocyte derived macrophages 
and comparison with light microscopy. 
In order to determine binding and uptake of C. neoformans by adherent MDM, the yeast 
cells were pre-opsonized as described above and added to the adherent phagocytes. After 
3 h of incubation, the C. neoformans opsonized with 10% K1228 serum showed higher 
binding and uptake by the macrophages as compared to 10% normal serum opsonized 
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and buffer opsonized cryptococci (Fig 2A). We compared the new method with the 
available standard technique: microscopy. Therefore, at the end of the incubation time, 
half of the number of wells was measured by multi-well plate reader and half of the 
number of wells was treated with Fungiqual A. We compared the result of the 3 h 
incubation of adherent MDM with different opsonized cryptococci measured by 
fluorescence reader (Fig 2A) with the result of the same experiment measured by 
microscopy (Fig 2B). The cryptococci incubated with 10% K1228 serum showed a 
phagocytosis index of 50, the normal serum pre-incubated yeast cells had an index of 25. 
The buffer incubated C. neoformans had a phagocytosis index of 3 (Fig 2B). Figs 2C and 
D show a representative phagocytosis experiment examined by standard light 
microscopy. 
 
FIG 2A-D: Binding and uptake of FITC-labelled C. neoformans by adherent MDM; a compari
Fungiqual A assay (A) to the microscopical analysis (B to D). Acapsular FITC-labelled C. neofo
106 cells), were preopsonized with either 10% human pooled serum, or 10% K1228 serum,
(unopsonized) for 1 h at 37ºC. Subsequently the yeasts were added to MDM for 3 hours at an effe
ratio of 1:1. Fig 2A: Open bars represent binding of cryptococci, solid bars represent upt
neoformans by MDM. The plotted data were taken from a representative experiment; n=3. Fig 
same experiment the plates were treated with Fungiqual A and uptake of different opsonized C. n
by MDM after incubation of 3 hours was assessed microscopically. The number of macroph
ingested yeast cells per 100 macrophages was counted. The plotted data are taken from a repr
experiment, n=3. Fig 2C and D: Phagocytosis experiment examined by standard light mi
Phagocytosis of C. neoformans non-opsonized (C) or opsonized with 10% human pooled seru
MDM (E:T 1:5) was allowed for 3 hours. 
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Inhibition of binding and uptake of acapsular C. neoformans by monocyte-derived 
macrophages with mannan 
To study if acapsular C. neoformans is bound and taken up by human MDM via the 
mannose receptor, phagocytosis experiments were performed in the presence or absence 
of 1 mg/ml mannan. Binding of cryptococci by MDM in the presence of mannan was 
inhibited by 25%, whereas the uptake of C. neoformans by MDM was inhibited by 32%. 
However, lower doses of mannan did not show any inhibitory effect on either binding or 
uptake of C. neoformans by MDM (data not shown). 
 
DISCUSSION 
The acapsular form of Cryptococcus neoformans is inhaled by the respiratory tract, and 
can, because of its size, reach the alveolar spaces. There the yeast will meet the first cells 
involved in host response: the alveolar macrophages. In vitro these cells, like monocytes, 
tend to adhere strongly to surfaces. Therefore, to study the first line of host defence 
against C. neoformans, a system is needed to measure the interaction between cryptococci 
and adherent phagocytes. A new, rapid and objective method, to measure interaction 
between the yeast C. neoformans and adherent phagocytic cells is described here. A 
strong advantage of the described technique compared to flow cytometry is that 
phagocytosis of adherent cells can be measured instead of cells in suspension and, 
therefore, long term incubations can be studied – which is necessary when phagocytosis 
by non-professional e.g. endothelial cells (9). This way of studying this interaction 
probably resembles the in vivo situation more closely.  
The results of the phagocytosis experiments performed with heat-killed acapsular C. 
neoformans and adherent monocytes (Fig. 1) showed that differences in opsonic 
conditions in combination with the phagocytosis time influence the rate of phagocytosis. 
After 3 h of incubation differences in phagocytosis rates of differently opsonized 
cryptococci could be detected. However, after 18 h of incubation, these differences 
disappeared. This could mean that opsonins play their role early in the phagocytosis 
process. We used heat-killed cryptococci since we (5) and others (10; 11) have previously 
shown that heat-inactivation does not affect binding nor uptake by various effector cells.  
Up to now the interaction between adherent phagocytes and C. neoformans was measured 
by means of microscopy or radioactivity assays. Both methods have disadvantages. The 
results we obtained using this new method was very comparable with the results obtained 
by the routinely used microscopy (Fig 2A-D). However, this novel method is much faster, 
less cumbersome and less objective. The only disadvantage of the displayed technique is 
that the provided values are, albeit quantitative, relative instead of absolute.  
To study whether the mannose receptor also plays a role in the phagocytosis of acapsular 
C. neoformans by adherent human macrophages, phagocytosis studies in the presence of 
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mannan were performed. The results showed that only 25% of the binding and 32% of the 
uptake of acapsular cryptococci by human alveolar macrophages was inhibited in the 
presence of mannan. In mice macrophages ingestion of C. neoformans was inhibited by 
more than 90% in the presence of the same concentration mannan (4). This possibly 
indicates that the expression of the mannose receptor is regulated differently in 
macrophages from mice to men.  
In conclusion, we have developed a new and reliable method to measure phagocytosis of 
C. neoformans by different kinds of adherent phagocytes using a fluorescence multi-well 
plate reader. This method can be used to study the interaction between C. neoformans and 
adherent cells, during long-term incubation. In addition, the method could be used to 
study the interaction between other micro-organisms and adherent phagocytes. 
Furthermore, if a vaccine for cryptococcosis would become available, the method could 
for example be used to screen the opsonisation capacity of sera of vaccinated people. 
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ABSTRACT 
Background: Evidence is accumulating that the alveolar collectin surfactant protein 
A (SP-A) plays an important role in the first line of defense against infiltrating 
pathogenic micro-organisms and viruses. The ability of SP-A to facilitate the binding 
and uptake of acapsular Cryptococcus neoformans by monocyte-derived macrophages, 
human alveolar macrophages, monocytes and polymorphonuclear leucocytes was 
investigated.  
Materials and Methods: Binding, competition, and phagocytosis experiments were 
performed using a flow cytometry technique. 
Results: SP-A bound to both the acapsular and the encapsulated form of C. 
neoformans in a concentration-dependent manner. SP-A showed a 3-fold better 
binding to the acapsular yeast, this binding was partly calcium dependent and could be 
inhibited by mannose (ID 50=3 mM) and glucose (ID 50=2.1 mM), but not by 
galactose (ID 50= 391 mM). SP-A did not function as an opsonin in phagocytosis of 
acapsular C. neoformans for any of the phagocytes studied.  
Conclusion: Our results indicate that SP-A binds in a concentration-dependent 
manner to both encapsulated and acapsular C. neoformans. Despite SP-A binding to 
the acapsular C. neoformans phagocytosis by various phagocytes was not enhanced. 
 
INTRODUCTION 
Cryptococcus neoformans is a yeast-like fungus that causes infections in the 
immunosuppressed host. C. neoformans infection starts in the lung and can 
disseminate to other parts of the body (1). In nature, the yeast cells posses minimal 
capsules and are therefore easily aerosolized. In this state, the cells are of a smaller 
size and can be inhaled to the level of the alveolus (2). The initial step in host defense, 
therefore, is the interaction between the acapsular C. neoformans and alveolar 
macrophages (3).  
Phagocytosis of encapsulated and acapsular C. neoformans by alveolar macrophages 
and other phagocytes has been examined by several investigators (4-6). The 
deposition of IgG and C3b and their degradative products on C. neoformans are 
essential for optimal phagocytosis (7). However, the concentration of these serum 
opsonins is low in the lungs and may, therefore, be insufficient for the effective 
phagocytosis of C. neoformans by (alveolar) macrophages and by other infiltrating 
leucocytes (3). Beside opsonins present in serum, other opsonic molecules present in 
the alveolar spaces might play a role in the first step of host defense against the yeast 
C. neoformans. We focused on two molecules present in the lung that have been 
described to posses opsonic functions in phagocytosis of many microorganisms; 
surfactant protein A (SP-A) and surfactant protein D (SP-D). 
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SP-A and SP-D are collagenous C-type lectins present in the surfactant layer of the 
lung. These two surfactant proteins, together with the plasma-defense proteins 
mannose-binding protein (MBP) and conglutinin, belong to the collectin superfamily, 
which exhibits calcium dependent mannose-specific carbohydrate binding activity (8). 
Previously, we showed that a member of this superfamily, the collectin human MBP, 
is involved in TNF-α production by monocytes stimulated by cryptococcal 
components (9). SP-A has been reported to act as an opsonin for a number of 
pathogens such as Escherichia coli (10), Mycobacterium tuberculosis (11), 
Staphylococcus aureus (12), HSV-1 (13) and the influenza A virus (14). In contrast, 
SP-A does not act as an opsonin for the phagocytosis of Candida albicans by alveolar 
macrophages (15), nor does it promote the phagocytosis of Haemophilus influenzae 
type B (16), Streptococcus pneumoniae (17), or smooth-type E. coli (10).  
The cell wall of Cryptococcus neoformans is composed of a capsular polysaccharide 
(glucuronoxylomannan (GXM)), a minor polysaccharide (galactoxylomannan 
(GalXM)), and mannoproteins (MP). Each of these, respectively, consists of 
polymannose, polygalactose, and a protein backbone substituted with, among other 
saccharides, mannose (18). C. neoformans may therefore be recognized by the 
carbohydrate-binding domain of SP-A or SP-D.  
Recently, Schelenz et al. described the binding of SP-A and SP-D to C. neoformans 
and noted that SP-D, but not SP-A, acted as an agglutinin for acapsular yeast cells 
(19). However, the ability of SP-A or SP-D to function as an opsonin for C. 
neoformans was not evaluated. 
C. neoformans reach the alveolar spaces in an acapsular form, where resident 
macrophages represent the first line of defense. We examined the role of SP-A to act 
as an opsonin in phagocytosis of acapsular C. neoformans by monocyte-derived 
macrophages (MDM) and human alveolar macrophages (HAM). In a cryptococcosis 
model in CBA/J mice, Curtis et al. described that the composition of the leucocytic 
infiltrate in the lung after cryptococcocal infection consisted of 
monocytes/macrophages, lymphocytes (CD4+ T, CD8+ T) and neutrophils (20). 
Therefore, we examined the role of SP-A to act as an opsonin in phagocytosis of 
acapsular C. neoformans by infiltrating leucocytes and performed phagocytosis 
experiments with acapsular C. neoformans and either polymorphonuclear leucocytes 
(PMN) or monocytes. 
Recently, Madan et al. showed that SP-A enhanced the binding of A. fumigatus 
conidia to PMN and monocytes (21). In order to understand more about differences in 
opsonic capacity of SP-A between these comparable clinically important fungi, we 
compared FITC-SP-A binding to acapsular C. neoformans and A. fumigatus conidia 
and its calcium dependency.  
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In this report, we discuss the binding characteristics of SP-A and SP-D to 
encapsulated C. neoformans NIH 37 and an acapsular mutant NIH B4131, using a 
flow cytometry technique. In addition, the role of SP-A as an opsonin in the 
phagocytosis of acapsular C. neoformans by a number of effector cells such as MDM, 
HAM, monocytes, and PMN was examined. 
 
MATERIALS AND METHODS  
Cryptococcus neoformans preparation and FITC labeling 
Encapsulated C. neoformans isolate NIH 37 and an acapsular mutant NIH B 4131 
were used throughout this study. The organisms were obtained from the National 
Institute of Health (NIH, Bethesda, MD, USA). NIH 37 is a thinly encapsulated 
clinical isolate (serotype A) from cerebrospinal fluid obtained from K.J. Kwon-
Chung. The yeast cells were maintained on Sabouraud dextrose agar (Merck, 
Darmstadt, Germany) at 4º C. After harvesting, the cryptococci were heat-killed for 30 
min at 80º C, the concentration was adjusted to 5 x 107 cells/ml and labeled with 
fluorescein isothiocyanate (FITC, Sigma, St. Louis, MO, USA) at 1 µg/ml in 
phosphate-buffered saline (PBS, pH 7.4) for 30 min at 22º C. The yeast cells were 
then washed and small aliquots were stored in Hanks’ balanced salt solution (HBSS; 
pH 7.4) at -20º C until use. 
Influenza A virus preparation and FITC labeling 
The influenza A/DELFT/2696/89 (H3N2) virus strain was kindly provided by Dr. J.C. 
de Jong (Research Laboratory for Infectious Diseases, National Institute of Public 
Health and the Environment (RIVM), Bilthoven, The Netherlands). The virus was 
grown on the LLC monkey kidney (MK2D) cell line (LLC cells) obtained from ICN 
International (Irvine, UK) as described previously by Benne et al. (22). The virus 
preparation contained 8.6 x 107 plaque-forming units/ml as determined using the 
immunoplaque assay described by Harder et al. (23) For labeling purposes, 1 ml 
influenza virus was mixed with 0.1 ml 1 M sodium carbonate buffer (pH 9.6) 
containing 1 mg FITC/ml (Isomer I; Sigma) and incubated for 1 hour at room 
temperature. FITC-labeled influenza virus was layered on top of a gradient of 50-20% 
sucrose (wt/vol) at a total volume of 12 ml. Gradients were centrifuged at 10,000 x g 
for 5 h at 10º C. The virus fractions were then pooled and stored at -70º C until use. 
Aspergillus fumigatus preparation and FITC labeling 
Spores were obtained from clinical A. fumigatus isolates (Academic Hospital Utrecht, 
The Netherlands). Cultures were maintained on Sabouraud dextrose agar slants. After 
harvesting, the conidia were heat-killed for 30 min at 80º C, the concentration was 
adjusted to 5 x 107 cells/ml. The conidia were labeled by incubating 5 x 107 conidia 
with 0.03 mg/ml FITC (Sigma) in 1 M carbonate buffer (pH 9.0) overnight at 4º C 
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under mild agitation. After labeling, the conidia were washed twice with HBSS 1% 
BSA and stored in HBSS at -20º C until use. 
Pulmonary SP-A, SP-D, FITC-SP-A, and FITC-SP-D 
SP-A and SP-D preparations were a kind gift of Dr. F. van Iwaarden (Utrecht). 
Pulmonary SP-A was isolated by bronchoalveolar lavage fluid of patients with 
alveolar proteinosis as described by Haagsman et al. (24). The surfactant in water (1.5 
mg of protein/ml) was extracted in 1-butanol (1:50, v/v) at room temperature. The 
surfactant/butanol mixture was centrifuged twice at 10,000 x g for 20 min. The 
precipitated protein was dried under nitrogen and washed twice in 20 mM octyl-ß-D-
glucopyranoside, 100 mM NaCl, 10 mM HEPES buffer (pH 7.4) (Life Technologies, 
GIBCO BRL, Paisley, UK). The proteins that were insoluble in this buffer were 
suspended in 5 mM HEPES, pH 7.4, and dialyzed against the same buffer for 48 h. 
The insoluble material was removed by centrifugation at 100,000 x g for 30 min. The 
supernatant contained the purified SP-A. The purity was checked by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). FITC labeling of SP-A was 
then performed according to Van Iwaarden et al. (13). Prior to labeling of SP-A with 
FITC, SP-A was dialyzed against distilled water. SP-A (3 mg) was incubated with 
FITC (0.3 mg) in 200 mM bicarbonate buffer, pH 8.5 (final volume, 8 ml), for 90 min 
at room temperature on a rotator. After incubation, the mixture was dialyzed against 
distilled water for 48 h at 4º C to remove the free FITC. FITC-SP-A was stored in 200 
µg/ml aliquots at -70º C until use. For isolation of SP-D, rats were instilled 
intratracheally with silica to increase the yield (25). SP-D was isolated and purified as 
described and stored at -70º C in small aliquots (26). FITC labeling of SP-D was 
performed as described by Crouch et al. (25) and van Iwaarden et al.(26). 
Carbohydrate binding domain of SP-A 
As C. neoformans is potentially recognized by the carbohydrate-binding domain of 
SP-A, we evaluated the binding capacity of the carbohydrate-binding domain of SP-A 
used in our assays. Avidin (1µg/ml) in 0.1 M NaHCO3-buffer (pH 9.6) was coated on 
a polystyrene 96 well microtiter plate 100 µl/well, 16 h, 4º C (Maxisorb, NUNC, 
Roskilde, Denmark). After coating, the microtiter plate was blocked with 2% BSA in 
washing solution 200 µl/well (50 mM Tris-HCL, 150 mM NaCl, 5 mM CaCl2, 0.05% 
Tween 20, pH 7.4,) for 60 min at 22º C. Then the plate was washed 6 times in 
washing solution. 100 µl of mannose-polyacrylamide-biotin conjugate (Synthsome, 
Munich, Germany) (1 µg/ml in washing solution containing 0.1% BSA) was added to 
each well and incubate for 60 min at 22º C. Then the plate was washed 6 times in 
washing solution. SP-A samples were diluted in buffer (100 mM Tris-HCL, 5 mM 
CaCl2, 0.05% Tween 20 containing 0.1% BSA) in the presence or absence of 10 mM 
EDTA and 100 µl of the sample was applied to each well. After 1 h incubation at 
22ºC the plate was washed 6 times and a rabbit anti-SP-A polyclonal antibody, was 
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applied to the plate (0.5 µg/ml, 100 µl/well, 22° C, 1h). After washing the plate, the 
bound antibodies were detected with horseradish peroxidase conjugated goat anti 
rabbit IgG (Nordic Immunol. Lab. BV, Tilburg, NL), 100 µl/well. After 1 h incubation 
at 22º C the plate was stained with 150 µl/well tetramethylbenzide reagent, 100 µg/ml 
(Merck), 1 mM H2O2 in 0.1 M citric acid buffer, pH 4.0). The reaction was stopped by 
adding 50 µl 2 M H2SO4 and absorption was measured at 450 nm. A concentration- 
and calcium-dependent binding of the SP-A was observed (ANOVA, p<0.05, data not 
shown) 
Determination of FITC-SP-A and FITC-SP-D binding to C. neoformans and 
competition by various monosaccharides 
Acapsular or encapsulated C. neoformans (105 organisms) were washed twice in 
HBSS supplemented with 1% (wt/vol) bovine serum albumin (BSA) and 1.5 mM 
CaCl2 (HBSS-BSA-Ca) and centrifuged at 3200 rpm for 10 min at 4º C. FITC-SP-A 
(conc: 0-25 µg/ml) or FITC-SP-D (conc: 0-10 µg/ml) was then added to acapsular or 
encapsulated C. neoformans, mixed gently, and incubated for 1 h at 37º C. The 
unbound FITC-SP-A or FITC-SP-D was then washed away and the samples were 
diluted in PBS and analyzed by flow cytometry. In kinetics experiments performed 
with acapsular C. neoformans and FITC-SP-A incubation times varied (0-360 min.). 
In the competition experiments FITC-SP-A (concentration 10 µg/ml) was added to 
acapsular C. neoformans (105) in the presence of different concentrations (500, 5.0, 
0.5 mM) of either mannose (purity 95%, Sigma) or glucose (purity 95%, Sigma) or 
galactose (purity 95%, Sigma). The unbound FITC-SP-A and monosaccharides were 
then washed away and the samples were analyzed by flow cytometry. 
Isolation monocytes and MDM 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats, obtained 
from the Blood Bank Utrecht, The Netherlands. PBMC were isolated by 
centrifugation on a Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden) as described 
by Böyum (27). The mononuclear cell layer was then washed and resuspended in 
RPMI 1640 (Gibco BRL, Gaithersburg, MD, USA) medium supplemented with 5 mM 
Hepes, 19 mM sodium bicarbonate, 10 µg/ml gentamicin, and 10% heat-inactivated 
human AB serum at a final concentration of 5 x 107/ml. Monocyte clumping was 
induced by rotating at 8 rpm for 1 h at 4° C. After a 30 min incubation on ice, the 
resulting pellet was gently dispersed. Cells were then layered onto 4 ml of ice-cold 
fetal bovine serum (FBS, Gibco) and monocytes were separated from lymphocytes by 
sedimentation for 5-10 min at 4º C. Monocytes were washed twice in complete 
medium and seeded into fibronectin coated tissue culture flasks. The next day 
adherent cells were washed with PBS (37° C), trypsinized, and again washed. 
Viability (>90%) was checked by trypan blue (Merck) exclusion (live cells will not 
stain inside). Purity of the monocytes was always > 80% checked by microscopic 
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evaluation of the isolated cells stained by Diff-Quik (Baxter, Unterschleissheim, 
Germany). For preparation of MDM, monocytes were cultured in complete medium 
for 7 days in hydrophobic teflon bags (Fluoroplast Ned. BV Raamsdonksveer, The 
Netherlands) at a concentration of 2 x 106/ml. Cells were recovered from teflon bags 
by washing, and resuspended to a final concentration of 5 x 107 cells/ml in RPMI 
1640. At this time >95% of these cells were MDM checked by Diff-Quik (Baxter) 
stain and anti-CD 14 PE-labeled antibody (Beckon Dickinson, Mountain View, CA, 
USA). Viability (>90%) was checked by trypan blue exclusion. 
Human bronchoalveolar lavage cells 
Bronchoalveolar lavage (BAL) was performed in different patients for diagnostic 
purposes. Informed consent was obtained from participants. A total of 240 ml sterile 
saline was instilled in the right middle lobe in 60 ml aliquots and recovered by gentle 
aspiration. Rates of recovery ranged from 60 to 85%. Human bronchoalveolar lavage 
cells (HBALC) were then centrifuged (1200 rpm). The pellet was treated with 1 ml (1 
mg/ml) DTT (DL-Dithriothreitol, Cleland’s reagent; Sigma, D-0632) in PBS. After 1 
minute at room temperature 2 ml RPMI was added and the DTT was then washed 
away by centrifuging the cells for 10 min at 1200 rpm. The supernatant was then 
removed. If the pellet contained erythrocytes, the pellet was treated for 5 seconds with 
1 ml of 1:4, PBS: sterile water. The pellet contained predominantly alveolar 
macrophages (>95%) as was determined by a differential cell count of a sample of the 
pellet using a Diff-Quik stain. Viability of the cells was more than 95% as checked by 
trypan blue staining. The cells were adjusted to the desired concentration (1 x 107 
cells/ml). 
Isolation of human PMN 
Heparinized venous blood, obtained from our own mini blood donor service, was 
diluted in PBS. The PMN were then separated by Ficoll (Pharmacia)-Histopaque 
(Sigma) density gradient centrifugation. After centrifugation (20 min at 1390 rpm, 
RT), the neutrophil fraction was collected and washed with RPMI with 0.05% human 
serum albumin (HSA). The remaining erythrocytes were lysed for 45 s with sterile 
water, after which concentrated PBS was added to reestablish an isotonic condition. 
After washing, cells were counted, resuspended in RPMI at 1 x 107 neutrophils/ml and 
checked for viability and purity. The viability always exceeded 95% using trypan blue 
exclusion. Purity was checked by Diff-Quik stain (Baxter) cytospin slides and was 
always >98%.  
Rat bronchoalveolar lavage cells 
Rat bronchoalveolar lavage cells (RBALC) were isolated as described previously by 
van Iwaarden et al (28). Rats (male, specific pathogen-free Wistar rats) were injected 
intra peritoneally with a lethal dose of Nembutal. Rat lungs were lavaged via the 
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trachea with sterile HBSS (8 portions of 10 ml/rat). The lavage fluid was centrifuged 
(800 rpm, 15 min 4º C). If the pellet contained erythrocytes, the pellet was treated for 
5 seconds with 1 ml of 1:4, PBS: sterile water. The pellet contained predominantly 
alveolar macrophages (>95%) as was determined by a differential cell count of a 
sample of the pellet using a Diff-Quik stain. Viability of the cells was over 95% as 
checked by trypan blue exclusion. The macrophages were resuspended in HBSS 1% 
BSA and diluted to a concentration of 1 x 107 cells/ml. 
Determination of the association between acapsular C. neoformans and 
phagocytes by flow cytometry 
For use in the phagocytosis assay, FITC-labeled acapsular C. neoformans were pre-
opsonized with either 10% HPS (positive control), buffer (HBSS 1% BSA) (negative 
control), or SP-A in various concentrations (1-25 µg/ml) (1 h, 37º C), and then 
washed once. Opsonized acapsular C. neoformans (100 µl; 107  cells/ml) were then 
incubated with 100 µl phagocytes, (107  cells/ml MDM, HAM, monocytes, or PMN,) 
for 2 h at 37º C. Experiments in our laboratory showed that increasing phagocytosis 
time (0, 15, 30 60 and 120 min) resulted in enhanced binding and uptake of 
cryptococci, reaching a maximum after 1 h (6). In subsequent experiments, a 
phagocytosis time of 2 hours was used in order to ensure optimal phagocytosis (6). 
After washing, half the suspension was used to determine uptake by quenching the 
fluorescence of the adhered yeasts (see below). Acapsular C. neoformans and most of 
the phagocytes are of the same size, which makes it difficult to distinguish between 
free FITC-labeled C. neoformans and phagocyte-associated C. neoformans in the flow 
cytometer.  
In order to distinguish between phagocytes and acapsular C. neoformans the different 
phagocytes were labeled specifically using phycoerythrin (PE)-labeled monoclonal 
antibodies (Mab) against specific surface proteins. The following Mab were used: 
anti-CD 14 PE-labeled monoclonal antibody (Beckon Dickinson) for monocytes and 
MDM; anti-CD 71 PE-labeled monoclonal antibody (Caltag Laboratories, 
Burlingame, CA, USA) for human alveolar macrophages, and anti-CD 45 PE-labeled 
monoclonal antibody (Caltag Laboratories) for rat alveolar macrophages. Labeling 
was performed as follows: the acapsular C. neoformans phagocyte suspension was 
centrifuged and the supernatant recovered. Then 5 µl Mab was added to the pellet, 
mixed gently, and incubated for 30 min at 4º C on ice. The pellet was then 
resuspended in PBS and washed once. The association of FITC-labeled yeast cells 
(FL1) to antibody labeled phagocytes (FL2) was subsequently analyzed with a 
FACScan flow cytometer (Beckon Dickinson) with computer-assisted evaluation of 
data (LYSYS 2). PMN could be distinguished from cryptococci in the FACScan on 
the basis of their scatter plots. Data were expressed as the percentage of FITC-positive 
cells (6).  
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Determination of uptake of acapsular C. neoformans by flow cytometry 
Uptake of acapsular C. neoformans by the different phagocytes was determined as 
previously described by Chaka et al. (6). In order to differentiate between extracellular 
adhering acapsular C. neoformans from those that had been taken up, we used trypan 
blue as a quenching agent for the FITC labeled acapsular C. neoformans. An equal 
volume of trypan blue (Merck) was added to each test suspension and incubated for 
10 min. Optimal quenching of acapsular C. neoformans (>95%) was achieved at 200 
µg/ml. The green fluorescence of acapsular C. neoformans that have been taken up by 
phagocytes will not be removed by quenching as trypan blue is excluded from 
monocytes. After 10 min the unbound trypan blue was removed by centrifugation. The 
supernatant was discarded and the pellet was resuspended in 200 µl PBS. These 200 
µl were used to measure in the flow cytometer. Uptake was therefore determined as 
the difference in the percentage of phagocytes associated with FITC labeled acapsular 
C. neoformans (FL1) before and after quenching. 
Comparison of FITC-SP-A binding to acapsular C. neoformans and conidia of A. 
fumigatus 
Acapsular C. neoformans and conidia of A. fumigatus were washed twice in HBSS-
BSA-Ca buffer and centrifuged at 3200 rpm for 10 min at 4º C. FITC-SP-A (conc: 0-
25 µg/ml) was then added to acapsular C. neoformans (105) or conidia of A. fumigatus 
(105 ) in the presence or absence of 5 mM EDTA, mixed gently, and incubated for 30 
min at 37º C. The unbound FITC-SP-A was then washed away and the samples were 
diluted in PBS and analyzed by flow cytometry. 
Serum 
Sera from 30 healthy donors were collected, pooled, and stored in small aliqouts at -
70º C (human pooled serum, HPS). 
Statistics 
Student’s T-test and ANOVA were used for statistical evaluation. A p<0.05 was 
considered significant. 
 
RESULTS 
Characteristics of binding isolated pulmonary SP-A and SP-D to acapsular and 
encapsulated C. neoformans 
Different concentrations of FITC-SP-A were incubated with acapsular (NIH B 3141) 
and encapsulated (NIH 37) C. neoformans for one hour, in a calcium ion-containing 
buffer, and the binding was detected by flow cytometry. A dose-response curve was 
observed when the acapsular mutant was incubated with various concentrations of 
FITC-SP-A (Fig. 1A). FITC-SP-A also interacted with encapsulated C. neoformans in 
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a dose dependant manner, but this binding was about 3- fold less as compared to the 
acapsular mutant (Fig. 1A). FITC-SP-D binding to acapsular C. neoformans was also 
concentration dependent (ANOVA p<0.05), but about 10-fold lower than FITC-SP-A 
binding to acapsular cryptococci (Fig. 1B). FITC- SP-D did not bind (ANOVA 
p>0.05) to encapsulated C. neoformans (Fig. 1B).  
 
 
 
 
 
 
 
 
 
 
Figure 1 
Concentration-dependent binding of FITC-SP-A (A) and FITC-SP-D (B) to acapsular (open squares) 
and encapsulated (solid squares) C. neoformans. C. neoformans (105 cells) were incubated with various 
concentrations of FITC-SP-A (0-25 µg/ml) or FITC-SP-D (0-10 µg/ml) for 1 h and analyzed by flow 
cytometry. Data are presented as mean fluorescence plus standard deviation, and are the mean in three 
experiments performed in duplicate. 
 
Because SP-A and SP-D have been described as proteins which play a role in the first 
line of defense against infiltrating micro-organisms and the fact that C. neoformans is 
entering the body in an acapsular form, we choose the acapsular C. neoformans for 
subsequent experiments. In addition we choose to investigate the role of SP-A 
involving this first line of defense against C. neoformans because FITC-SP-A showed 
better binding to acapsular cryptococci than FITC-SP-D (Fig 1). 
Next, experiments were performed to study the kinetics of binding of SP-A to the 
acapsular cryptococcus. FITC-SP-A (10 µg/ml) was incubated with the cryptococci 
for different time points (0, 7.5, 15, 30, 60, 120, 180, 240, and 360 min.). Figure 2 
shows that practically no binding of FITC-SP-A was observed after 7.5 min 
incubation, whereas after 1 hour >95% of the FITC-SP-A had bound. Longer 
incubation did not enhance FITC-SP-A binding to the acapsular cryptococcus. For 
subsequent phagocytosis experiments we choose 1 h pre-incubation time to ensure 
optimal binding of SP-A to the acapsular C. neoformans. 
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Figure 2 
Acapsular C. neoformans (105
 
cells) were incubated with 10 µg/ml FITC-SP-A for 0 min, 7.5 min, 15 
min, 30 min, 1h, 2h, 3h, 4h, and 6h and analyzed by flow cytometry. Data are presented as mean 
fluorescence plus standard deviations, each time point was performed in duplicate. 
 
Carbohydrate binding domain of SP-A 
Competition studies were performed to confirm that SP-A bound via the 
carbohydrate-binding domain to acapsular C. neoformans. SP-A has previously been 
reported to have affinity for glucose and mannose, but not for galactose residues (29).  
Therefore, these three monosaccharides were used in the competition assay. For 50% 
inhibition (ID 50) of the FITC-SP-A binding to acapsular C. neoformans, 3.0 mM 
mannose and 2.1 mM glucose was required, whereas about a 100-fold higher 
concentration of galactose was needed (393 mM) (Fig 3). These data are consistent 
with the literature, and are suggesting that SP-A can bind to acapsular C. neoformans 
by its carbohydrate-binding domain. 
 
 
 
 
 
 
 
 
Figure 3 
Competition of FITC-SP-A binding by various monosaccharides to acapsular cryptococci. FITC-SP-A 
(10 µg/ml) was incubated in the presence of different concentrations (500, 5.0 and 0.5 mM/l) of either 
mannose or glucose or galactose with 105 C. neoformans for 1 h and analyzed by flow cytometry. Data 
are presented as mean fluorescence plus standard deviations; each sample was performed in duplicate. 
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Opsonic activities of SP-A in phagocytosis of acapsular C. neoformans by 
macrophages 
Acapsular yeast cells incubated with 10% HPS (including complement and IgG) were 
used as a positive control and acapsular yeast cells incubated with buffer were used as 
a negative control. Acapsular C. neoformans were also incubated with 20 µg/ml SP-A 
for 1 h (pre-opsonization) followed by incubation with MDM for 2 h. The serum-
opsonized acapsular C. neoformans showed a significantly higher binding (p<0.05) 
and uptake (p<0.05) than the buffer-pre-opsonized acapsular C. neoformans. In 
contrast, SP-A pre-opsonisation of acapsular C. neoformans did not enhance binding 
and uptake by MDM when compared to the buffer pre-opsonized control (Fig. 4A).  
 
 
 
 
 
 
 
 
 
Figure 4 
Binding and uptake of FITC-labeled acapsular C. neoformans by MDM (A), and human alveolar 
macrophages (HAM) (B). Acapsular FITC-C. neoformans (106 cells) were pre-opsonized with 10% 
HPS, buffer (unopsonized) or 20 µg/ml SP-A for 1 h at 37° C, washed once, and added to 106 MDM 
(Fig 4A) or 106 HAM (Fig 4B) for 2 h. After washing, the pellets were incubated with PE-labeled 
monoclonal antibody for 30 min at 4° C. After washing the pellets were resuspended in PBS and 
analyzed. Open bars represent binding of acapsular C. neoformans to phagocytes; solid bars represent 
uptake of acapsular C. neoformans by phagocytes. Data are the mean of duplicate incubations and 
standard deviations in four experiments. 
4A: Differences in binding (*p<0.05) and uptake (**p<0.05) between HPS and buffer pre-opsonized 
cryptococci by MDM are statistically significant. Differences in binding and uptake between buffer and 
SP-A pre-opsonized cryptococci by MDM is not statistically significant. 
4B: Differences in binding (*p<0.05) and uptake (**p<0.05) between HPS and buffer pre-opsonized 
cryptococci by HAM are statistically significant. Differences in binding and uptake between buffer and 
SP-A pre-opsonized cryptococci by HAM is not statistically significant. 
 
Pre-incubating the acapsular C. neoformans with 10% serum together with 20 µg/ml 
SP-A showed the same percentages binding and uptake by the MDM as cryptococci 
that were pre-incubated with 10% serum only (n=2, data not shown). When different 
concentrations of SP-A were tested (0.5-50 µg/ml) or different effector-to-target cell 
ratios (1:5, 1:10) were used, identical results were observed (data not shown). The 
phagocytosis experiments were repeated with human alveolar macrophages. 
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Acapsular C. neoformans pre-incubated with 10% serum showed 65% binding and 
around 25% uptake by HAM. Both the non-opsonized negative control and the SP-A 
pre-opsonized cryptococci showed similar percentages of binding of around 30%, and 
uptake of around 10% (Fig 4B). This means that SP-A did not enhance phagocytosis 
of acapsular C. neoformans by either MDM or human alveolar macrophages.  
Opsonic activities of SP-A in phagocytosis of C. neoformans by monocytes and 
PMN 
We also tested the role of SP-A in the phagocytosis of acapsular C. neoformans by 
infiltrating leucocytes, monocytes and PMN. Monocytes showed 79% binding and 
57% uptake of acapsular cryptococci that were pre-opsonized with 10% serum. 
Twenty five percent of the monocytes bound acapsular C. neoformans that were pre-
opsonized with buffer, 23% of the monocytes bound acapsular C. neoformans that 
were pre-opsonized with SP-A. Uptake by monocytes of acapsular C. neoformans was 
also not enhanced by pre-incubating the yeasts with SP-A compared to the buffer 
control (Fig 5A).  
 
 
 
 
 
 
 
 
Figure 5 
Binding and uptake of FITC-labeled acapsular C. neoformans by monocytes (A) and PMN (B). 
Acapsular FITC-C. neoformans (106 cells) were pre-opsonized with 10% HPS, unopsonized (buffer), or 
20 µg/ml SP-A, for 1 h at 37° C, washed once, and added to 106 monocytes (Fig 5A) or 106 PMN (Fig 
5B). Open bars represent binding of acapsular C. neoformans to phagocytes; solid bars represent uptake 
of acapsular C. neoformans by phagocytes. Data are the mean of duplicate incubations in four 
experiments. 
5A: Differences in binding (*p<0.05) and uptake (**p<0.05) between HPS and buffer pre-opsonized 
cryptococci by monocytes are statistically significant. Differences in binding and uptake between buffer 
and SP-A pre-opsonized cryptococci by monocytes is not statistically significant. 
5B: Differences in binding (*p<0.05) and uptake (**p<0.05) between HPS and buffer pre-opsonized 
cryptococci by PMN are statistically significant. Differences in binding and uptake between buffer and 
SP-A pre-opsonized cryptococci by PMN is not statistically significant. 
 
PMN showed 78% binding and 58% uptake of acapsular cryptococci pre-opsonized 
with serum. The cryptococci that were pre-opsonized with buffer only showed 12% 
binding, the ones pre-opsonized with SP-A showed 14% binding. This difference is 
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not significant (p>0.05). Uptake by PMN of acapsular C. neoformans was not 
enhanced by pre-incubating the yeasts with SP-A compared to the buffer control (Fig 
5B). 
Opsonic function of SP-A in other organisms. 
Since SP-A is an opsonin for influenza A virus phagocytosis by rat alveolar 
macrophages (14) FITC-labeled influenza A virus was included as an extra positive 
control to confirm the biological activity of the SP-A preparations used during this 
study. In this set of experiments, influenza A virus was pre-opsonized with either 
buffer, or 20 µg/ml SP-A before the rat cells were added. SP-A significantly enhanced 
phagocytosis (binding and uptake) of influenza A virus when compared to the buffer 
control. Rat alveolar macrophages (RAM) showed 11.6+/-1.8% binding of influenza 
A virus pre-opsonized with buffer, and 19.0+/-3.4% binding of SP-A pre-opsonized 
influenza A virus (p<0.05). RAM showed 7.15+/-1.2% uptake of buffer pre-opsonized 
influenza A virus, and 15.05+/-0.77% binding of SP-A pre-opsonized influenza A 
virus (n=3, p<0.05) (data not shown). Recently, Madan et al. showed that SP-A 
enhanced the binding of A. fumigatus conidia to PMN and monocytes (21). In contrast 
to C. neoformans, SP-A enhanced the binding of A. fumigatus to monocytes by 42% 
when compared to non-opsonized control (n=4, p< 0.05) (data not shown). 
Experiments were conducted to understand more about the observed differences in 
opsonic capacity of SP-A between the two fungi. We investigated the binding of 
FITC-SP-A to acapsular C. neoformans and A. fumigatus conidia. FITC-SP-A binding 
to A. fumigatus conidia was at least twofold higher than the binding to C. neoformans, 
p<0.05 (Fig. 6).  
 
 
 
 
 
 
 
 
Figure 6 Acapsular C. neoformans (105 cells) and conidia of A. fumigatus (105 cells) were incubated 
with different concentrations of FITC-SP-A (0-25 µg/ml) for 30 min and analyzed by flow cytometry. 
Gray bars represent binding of different concentrations of FITC-SP-A to acapsular C. neoformans or A. 
fumigatus in the presence of 1.5 mM calcium buffer; black bars represent binding of 25 µg/ml FITC 
SP-A to acapsular C. neoformans or A. fumigatus in the presence of 5 mM EDTA buffer. Data are 
presented as mean fluorescence and are the mean of duplicate incubations and standard deviation in 
three experiments. Differences in mean fluorescence values between acapsular C. neoformans and 
conidia of A. fumigatus are significant (*p<0.05) after incubation of 6, 12.5, and 25 µg/ml FITC SP-A 
in the presence of calcium buffer. 
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FITC-SP-A binding to both fungi was calcium dependent, but a difference was 
observed. EDTA inhibited FITC-SP-A binding to A. fumigatus by 51%, whereas the 
binding to C. neoformans was only reduced by 21% (Fig. 6). However, no enhanced 
uptake of A. fumigatus conidia by either cell type tested (HAM, monocytes or PMN) 
by SP-A was seen as compared to the negative buffer control. (n=3, data not shown). 
 
DISCUSSION 
SP-A is one of the hydrophilic proteins present in the surfactant layer of the lung. It 
plays a crucial role in the dynamics and metabolism of the extracellular surfactant 
(30). Beside these functions, SP-A has also been described to act as an opsonin for a 
number of pathogens (10;11;13;17). SP-A concentration in BALs from healthy 
individuals is estimated 1-2 µg/ml but these levels are probably a 10-100 times 
dilution of the concentration present in the surfactant layer itself. SP-A levels in HIV-
infected pneumonia patients are found to be significantly elevated with a mean of 5.23 
µg/ml (31). Around 80% of patients infected with C. neoformans are infected with 
HIV (32). Therefore, we were interested in the role of SP-A in the host defense 
against C. neoformans.  
FITC-SP-A bound in a concentration-dependent manner to both acapsular and 
encapsulated C. neoformans. FITC-SP-D also bound in a concentration-dependent 
manner to the acapsular C. neoformans. However, this binding was about 10-fold 
lower as compared with FITC-SP-A binding. FITC-SP-D did not bind to encapsulated 
C. neoformans. Therefore, subsequent experiments were performed with SP-A. In the 
present study, we investigated the hypothesis that SP-A enhanced the phagocytosis of 
acapsular C. neoformans by different phagocytes. This is relevant because C. 
neoformans enters the human lung in an acapsular form, before it synthesizes its 
capsule and disseminates throughout the body (1). 
The FITC-SP-A binding to acapsular C. neoformans could be inhibited by glucose and 
mannose, but not by galactose. This means that SP-A binding to acapsular C. 
neoformans can occur via its carbohydrate-binding region. Despite SP-A binding to 
acapsular C. neoformans, SP-A did not enhance the phagocytosis of acapsular C. 
neoformans in experiments conducted with different types of effector cells. The SP-A 
preparations used in this study, were biologically functional. SP-A did enhance the 
binding and uptake of influenza A virus by rat alveolar macrophages and the binding 
of A. fumigatus conidia to monocytes. Therefore, we conclude that SP-A does not 
promote the phagocytosis of acapsular C. neoformans by phagocytes. This is in 
contrast to a number of bacterial and viral pathogens, such as E. coli (10), M. 
tuberculosis (11), S. aureus (17), HSV 1 (13) and influenza A virus (14) but is in 
agreement with the results found with the yeast Candida albicans (15). 
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Van Iwaarden et al. described that pre-incubation of rat alveolar macrophages with 
surfactant increased the phagocytosis of rat-serum opsonized S. aureus by 70% 
compared to the control macrophages. This was probably due to an upregulation of 
the involved receptors (28). Pre-incubation or opsonization of S. aureus with 
surfactant did not result in enhanced phagocytosis by the alveolar macrophages. We 
also performed phagocytosis experiments in which the phagocytes were pre-incubated 
with SP-A, but again no enhanced opsonic function for the SP-A could be detected 
(data not shown). 
Schelenz et al. described that both SP-A and SP-D bind to Cryptococcus neoformans, 
but only SP-D induces agglutination of acapsular yeast cells (19). In addition, they 
found that SP-D consistently resulted in a 10- to 17-fold higher fluorescence intensity 
than SP-A. We found only low binding of FITC-SP-D to encapsulated and acapsular 
C. neoformans. However, as stated by the authors themselves, it is not clear in their 
method, whether this higher fluorescence intensity reflects a greater affinity of SP-D 
for the yeast cell wall since different anti-collectin antisera were used for detection. In 
our method, we could directly compare FITC-SP-A and FITC-SP-D binding to the 
cryptococcus. Since a higher FITC-SP-A binding to C. neoformans was observed in 
our initial experiments compared to FITC-SP-D, the phagocytosis experiments were 
only performed with SP-A.  
It is not clear whether SP-A can only bind with its carbohydrate-binding region to 
acapsular C. neoformans. SP-A is a member of the lectin family, characterized by a 
carbohydrate recognition domain, which binds ligands in a calcium dependent 
manner, and a collagen tail involved in their biological function (8). Comparing the 
binding characteristics of FITC-SP-A to A. fumigatus conidia and acapsular C. 
neoformans showed that FITC-SP-A bound about twofold better to conidia than to 
acapsular C. neoformans, and that the FITC-SP-A binding to conidia was more 
calcium dependent. This could mean that beside SP-A binding to acapsular C. 
neoformans via its carbohydrate-binding region, another region of the molecule may 
be involved, that does not posses calcium specific binding. However, despite 
enhanced binding of SP-A to conidia of A. fumigatus, no enhanced uptake could be 
found by a number of phagocytes tested. There are, beside conidia of A. fumigatus, to 
our knowledge, no reports in literature that describe the opsonic function of SP-A in 
phagocytosis of a fungus.  
In conclusion, our results demonstrate that SP-A can bind to C. neoformans but it 
does not function as an opsonin for the acapsular yeast’s phagocytosis. Possibly, 
escaping SP-A mediated phagocytosis makes it more easily for C. neoformans to grow 
in the alveolar spaces, before disseminating through the rest of the body.  
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SUMMARY 
The capsule of the yeast Cryptococcus neoformans consists of glucuronoxylomannan 
(GXM), and two minor carbohydrate antigens, galactoxylomannan (GalXM), and 
mannoprotein (MP). Although the structure of these cryptococcal components is 
biochemically different, three strains of C. neoformans and its purified capsular 
components induced a similar cytokine pattern in peripheral blood mononuclear cells 
(PBMC). High levels of TNF-α and substantial levels of IFN-γ were present after 3 hours 
of stimulation and decreased at 18 hours. In contrast, appreciable levels of IL-10 were 
detected at 18 hours, whereas only low levels were found at 3 hours. IL-1 β, IL-6 and IL-8 
levels were high throughout the experiment. Neither whole cryptococci nor its capsule 
components induced an exclusive type 1 cytokine profile (associated with cellular 
immune functions) or a type 2 cytokine profile (associated with enhanced antibody 
production from B cells). Although a more type 1 like cytokine pattern was observed at 
the beginning of stimulation, the pattern shifted toward a more type 2 pattern at 18 hours. 
The time kinetics of cytokine induction by strains of C. neoformans and cryptococcal 
components might therefore provide a time-window that facilitates induction of cellular 
immunity.  
 
INTRODUCTION  
Cryptococcus neoformans is an encapsulated yeast-like fungus, which can cause a 
systemic infection, mainly in patients with impaired cell mediated immunity, especially 
those with AIDS (1). The capsule of C. neoformans is composed of a capsular 
polysaccharide, glucuronoxylomannan (GXM), and two minor carbohydrate antigens, 
galactoxylomannan (GalXM), and mannoproteins (MP) (2). These capsular components 
of C. neoformans have been shown to induce or modulate immune responses (3;4). While 
GXM is generally thought to be antiphagocytic and a poor immunogen, cryptococcal 
mannoprotein is immunogenic in rabbits and is the antigen largely responsible for the 
observed DTH (5). In addition, PBMC of healthy volunteers proliferate when stimulated 
by cryptococcal MP suggesting that MP may be one of the molecules to which cellular 
immunity is directed (6). Levitz et al. showed that C. neoformans with small sized 
capsules induce TNF-α in whole blood (7). We have also reported that cryptococcal 
components induce TNF-α in PBMC (8). The presence of these antigens may thus be 
important in eliciting protective cell mediated immune responses, a major defense 
mechanisms against C. neoformans. Induction of an adequate cellular immunity requires 
the presence of a type 1 cytokine profile e.g. IFN-γ, IL-2 and IL-12 (9). Type 2 cytokines 
(e.g. IL-6, IL-10) enhance antibody production from B cells, and for C. neoformans the 
supportive evidence for the role of natural antibody immunity has remained uncertain 
despite several decades of study. In the present study we investigated whether cryptococci 
and its isolated capsular components stimulate PBMC to secrete a cytokine profile which 
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facilitates an adequate cellular immunity in normal healthy subjects. 
 
MATERIALS AND METHODS  
Strains 
Encapsulated strain C. neoformans NIH 37 serotype A was obtained from the National 
Institute of Health (NIH, Bethesda, Md) and clinical strains W11 and W22 were acquired 
from Parirenyatwa Hospital, Zimbabwe. The different strains were maintained on 
Sabouraud dextrose agar (Merck, Darmstadt, Germany) at 4 oC. All encapsulated strains 
were thinly encapsulated as determined by Indian ink examination (<0.5 µM). Prior to the 
experiments, cells were freshly grown in to Sabouraud glucose liquid, washed, counted, 
heat-killed for 30 minutes at 80°C and resuspended at a concentration of 108 per ml.  
Capsular components  
GXM NIH 37 (serotype A) was isolated and purified as previously described (10). GXM 
B3502 (serotype D) was a gift from Dr. J.E. Bennett (National Institute of Health, 
U.S.A.). GalXM and MP fractions were a kind gift from Dr. R. Cherniak (Georgia State 
University, Atlanta, Georgia, U.S.A.).  
Isolation of PBMC  
PBMC were isolated by centrifugation on a Ficoll-Paque density gradient (Pharmacia, 
Sweden). The mononuclear cell layer was then washed and resuspended in RPMI 1640 
(Gibco, Gaithersburg, Md) containing 0.1% human serum albumin, to a final 
concentration of 107 cells ml-1. 
Stimulation of PBMC by C. neoformans and its capsular components  
Isolated cells were stimulated with whole cryptococci (108 ml-1) or the capsule 
components (25 µg ml-1 ) in the presence of 10 µg ml-1 polymyxin B sulphate as described 
by Chaka et al. (11). Negative control PBMC were incubated with RPMI 1640 with 
normal human serum (NHS) in presence of 10 µg ml-1 polymyxin B sulphate. Prior to 
incubation with PBMC (106) cryptococci and capsular components were incubated with 
NHS at 37°C for 30 minutes. After incubation (3, 6 and 18 h), samples were centrifuged, 
supernatants collected and stored at -70° C prior to cytokine assays. 
Cytokine determination 
TNF-α, IL-6, IL-8, IFN-γ and IL-10 levels in supernatants were assayed by enzyme linked 
immunosorbent assay (ELISA) kits (CLB, Amsterdam, The Netherlands), according to 
the manufacturer’s instructions. The detection limits (lowest positive standard) were: 
TNF-α, 1.4 pg ml-1; IL-6, 0.6 pg ml-1, IL-8, 1 pg ml-1, IFN-γ, 2.5 pg ml-1 and IL-10, 1.2 pg 
ml-1. The IL-1 β ELISA used in the study was developed within our laboratory. The 
detection limit of the ELISA was 25 pg ml-1. The amount of the various cytokines 
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produced by the PBMC incubated with polymyxin B and NHS was subtracted from the 
values obtained with the PBMC stimulated with either the whole cryptococci or the 
cryptococcal components, both in the presence of polymyxin B. 
RESULTS 
Cytokine profiles induced by C. neoformans strains in PBMC  
C. neoformans strains were opsonized with NHS for 30 min. and subsequently incubated 
with PBMC. TNF-α, IFN-γ, IL-1β, IL-6, IL-8 and IL-10 levels were determined after 3, 6 
and 18 h of incubation by ELISA. At t=0, no cytokines could be detected in the fresh 
culture medium. Control PBMC incubated with RPMI 1640 with NHS in presence of 10 
µg ml-1 polymyxin B produced background levels of the different cytokines (data not 
shown). All three strains induced similar patterns of cytokines (Fig.1 A, B, C). After 3 h, 
high levels of TNF-α were observed, which were strongly diminished after 18 h for 
strains NIH 37 (p<0.05) and W11 (p< 0.0025 ); and to a lesser extent for W22 (not 
significantly). Low levels of IL-10 were detected after 3 h, which slowly increased during 
the course of the experiment (significantly for NIH 37: p<0.05). IFN-γ was elicited by all 
the three strains. The cytokine patterns for IL-1β, IL-6 and IL-8 were similar for all 
strains: constantly high levels of IL-8 and somewhat lower levels of IL-1β and IL-6.  
Cytokine patterns evoked by GXM and GalXM in PBMC 
GXM NIH 37 (serotype A) and GXM B3502 (serotype D) were utilized in this study. 
Both types GXM evoked a similar type of cytokine patterns as compared to the whole 
cryptococci (Fig. 1 and Fig. 2A and 2B). Significant decreases of TNF-α levels (p< 0.05 
for GXM NIH 37 and B3502), small (not significant) decreases in IFN-γ and increases of 
IL-10 levels (significant for GXM NIH 37; p<0.01) were observed. IL-8 levels induced 
by GXM from two different serotypes were similar when compared to whole cryptococci, 
the IL-1β and IL-6 levels were, in general, higher (Fig. 1, Fig 2A and 2B). GalXM, one of 
the minor carbohydrate components of the cryptococcal capsule, has a completely 
different structure when compared to GXM. Nevertheless, stimulation of PBMC by 
GalXM in the presence of NHS, evoked similar cytokine profiles as compared to whole 
strains and GXM (Fig. 2C). 
Cytokine patterns evoked by MP in PBMC  
PBMC were finally stimulated with MP1 (Fig. 3A) MP2 (Fig. 3B) and MP4 (Fig. 3C) 
and cytokine levels were determined after 3, 6 and 18 h. Again similar cytokine patterns 
as for all the other stimuli studied (whole cryptococci, GXM and GalXM) were elicited 
by the three mannoprotein fractions: decreases of TNF-α levels (p < 0.01 for all three 
MP) and IFN-γ levels after 18 h of stimulation, and an increase of IL-10 during the course 
of the experiment. In general, after stimulation with all MP high IL-1β, IL-6 and IL-8 
levels were observed, which were constant and similar to the levels induced by GXM.  
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Fig. 1A,B,C. Cytokine profiles induced in PBMC by C. neoformans. PBMC (106) were incubated with 
either strain NIH 37 (A), W11 (B) or W22 (C) (all 108 cryptococci) for 3, 6 or 18 h in the presence of 10% 
NPS. Supernatants were collected and the cytokines IFN-γ, TNF-α, IL-1β, IL-6, IL-8 and IL-10 were 
determined by ELISA. The amount of the various cytokines produced by the PBMC incubated with 
polymyxin B and NHS alone was subtracted of the values obtained with the PBMC stimulated with whole 
cryptococci in the presence of polymyxin B. Results are the mean of 3 experiments ± SEM.  
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Fig. 2A,B,C. Cytokine profiles induced by GXM or GalXM in PBMC. PBMC (106) were incubated with 
either 25µg ml-1 GXM NIH 37 (A), 25µg ml-1 GXM B3502 (B) or 25 µg ml-1 GalXM (C) for 3, 6 or 18 h in 
the presence of 10% NPS. Supernatants were collected and the cytokines IFN-γ, TNF-α, IL-1β, IL-6, IL-8 
and IL-10 were determined by ELISA. The amount of the various cytokines produced by the PBMC 
incubated with polymyxin B and NPS alone was subtracted of the values obtained with the PBMC 
stimulated with either the GXM or GalXM in the presence of polymyxin B. Results are the mean of 3 
experiments ± SEM.  
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Fig. 3A,B,C. Cytokine profile induced by mannoprotein fractions in PBMC. PBMC (106) were incubated 
with either MP1 (A), MP2 (B) or MP4 (C) (all 25 µg ml-1) for 3h, 6h or 18h in the presence of 10% HPS. 
Supernatants were collected and the cytokines IFN-γ, TNF-α, IL-1β, IL-6, IL-8 and IL-10 were determined 
by ELISA. The amount of the various cytokines produced by the PBMC incubated with polymyxin B and 
NPS alone was subtracted of the values obtained with the PBMC stimulated with MP in the presence of 
polymyxin B. Results are the mean of 3 experiments ± SEM.  
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DISCUSSION 
Given the ubiquitous presence of C. neoformans in the environment, it is very likely that 
host resistance in normal healthy subjects to infection is very high. Host resistance to 
cryptococci undoubtedly involves complex interactions between host defense 
mechanisms and yeasts. The immunoregularory effects of C. neoformans would be 
mediated in part through selective induction of phagocyte derived cytokines. Here, we 
analyzed the cytokine patterns evoked by C. neoformans and its isolated capsular 
components in PBMC. 
We showed that C. neoformans and its different capsule components induce TNF-α 
release by PBMC (11). The results of the present study show that different strains of C. 
neoformans and its purified capsular components stimulate expression of pro-
inflammatory cytokines IFN-γ, IL-1β, IL-6 and IL-8 and anti-inflammatory cytokine IL-
10. Whole cryptococci and all cryptococcal components studied induced a very similar 
pattern of cytokine release. The time kinetics of release for the various cytokines, 
however, were different with IFN-γ and TNF-α showing early release at 3 hours with 
levels dropping at 18 hours. After 3 hours of stimulation the release of IL-10 was low, but 
levels steadily increased over time.  
The observed similarity of the cytokine patterns induced by the various strains and 
components of C. neoformans was unexpected. GXM, GalXM and MP differ in protein 
content, amino acid composition, and monosaccharide composition (10;12). Moreover, 
cytokine induction in PBMC by GXM depends on the presence of an intact complement 
system, whereas for GalXM and MP this process is partially facilitated by human 
mannose binding lectin, a heat stable component (8;11). Part of the observed and not 
foreseen similarity in cytokine release might be caused by indirect effects. For example, 
the observed cytokine profile, might be strongly influenced by the autocrine-paracrine 
cytokine network, since the presence of e.g. high levels of TNF-α induces IL-10 
independent of the type of stimulus (13). Moreover, polysaccharides, glycolipids, and 
glycoproteins with a large variety of carbohydrate structures are known to induce 
cytokines in PBMC (14-16). GXM and GalXM are completely composed of carbohydrate 
and the model proposed for cryptococcal MP, a protein backbone substituted with a large 
number of short oligosaccharides, suggests that these molecules are seen by the host-
defense system more as carbohydrate than as a protein.  
The different cytokines induced by whole cryptococci and by the components can either 
play a beneficial or a detrimental role in host defense against C. neoformans. In vitro 
studies have shown that the antiphagocytic potential of C. neoformans could be overcome 
by macrophages activated by TNF-α and granulocyte macrophage colony stimulating 
factor (GM-CSF) (17), and that administration of neutralizing antibody against TNF-α 
was deleterious for C. neoformans infected mice (18). In another study, the ability to clear 
a pulmonary C. neoformans infection in mice was shown to correlate with high IFN-γ 
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secretion by lung associated lymph nodes (19), whereas decreased levels of IL-6 were 
associated with an abrogation of pulmonary clearance of C. neoformans in mice (20). IL-
10 probably has a detrimental role in host-defense against cryptococcal infection. This 
cytokine has been shown to inhibit synthesis of TNF-α, IL-1β and IL-6 in mononuclear 
cells, it down regulates Class II MHC expression on macrophages and may alter T cell 
responses through inhibition of TNF-α (21). In this study all strains and the capsular 
components of C. neoformans induced IL-10 release by PBMC. Vecchiarelli et al., 
demonstrated that GXM prepared from a C. neoformans type A strain induced IL-10 by 
human monocytes (22). They also showed that IL-10 was involved in regulating TNF-α 
and IL-1β secretion by monocytes in response to C. neoformans, and Levitz et al. 
demonstrated the ability of IL-10 to inhibit PBMC responses to C. neoformans (23).
In conclusion, the time kinetics of cytokine release in this study indicate an autocrine-
paracrine network regulation of the cytokines, with proinflammatory cytokines TNF-α 
and IFN-γ being released early while IL-1β, IL-6 and IL-8 showed a more sustained 
release and IL-10 clearly increasing over time. We did not observe the tendency for a 
particular cryptococcal strain or capsular component to induce a type 1 or a type 2 
cytokine response, but in the first 3 hours a more type 1 pattern was observed. The time 
kinetics of the cytokine induction by C. neoformans and its capsular components might 
therefore provide a time-window that facilitates the induction of cellular immunity, which 
is the corner stone of host-defense against cryptococci. 
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SUMMARY 
The object of this study was to analyze the ability of C. neoformans and its major capsule 
component glucuronoxylomannan (GXM) to induce the C-C chemokines macrophage 
inflammatory protein (MIP)-1α, MIP-1β, and regulated upon activation normal T-cell 
expressed and secreted (RANTES) in primary HIV-infected human macrophages. 
Reverse transcriptase-polymerase chain reaction was used to detect mRNA of these 
chemokines after stimulation of both HIV-infected and uninfected macrophages with C. 
neoformans or GXM. In addition, protein levels of these chemokines were determined by 
ELISA. In contrast to RANTES, MIP-1α and MIP-1β levels were higher in the HIV-
infected C. neoformans- or GXM-stimulated macrophages as compared to stimulated 
uninfected cells. These data show that both HIV and C. neoformans elicit the production 
of C-C chemokines by macrophages allowing mononuclear cell recruitment to tissue. 
 
INTRODUCTION 
C. neoformans is an encapsulated yeast like fungus and the leading cause of mycological 
infections of the central nervous system (CNS) in patients with impaired cell-mediated 
immunity, especially in those with AIDS. Despite antifungal therapy, between 10-25% of 
cryptococcosis patients die during initial therapy, and between 30-60% succumb within 
12 months (1). In order to design improved intervention strategies, better understanding 
of the host defense mechanisms against these yeasts is needed. 
The capsule of C. neoformans is composed of at least three well characterized antigens: a 
capsular polysaccharide glucuronoxylomannan (GXM), a minor polysaccharide 
galactoxylomannan (GalXM), and mannoproteins (MP) (2). GXM, the major capsule 
polysaccharide of C. neoformans, is known to be anti-inflammatory, anti-phagocytic, and 
immunosuppressive (1). Moreover, GXM can induce IL-8 production in cultured human 
microglia cells (3), and has been described to interfere with neutrophil migration towards 
the CNS in cryptococal meningitis patients, despite the presence of chemokines like IL-8 
in the CSF (4;5). 
Lee et al. analyzed, postmortem, brain tissue from 21 patients with cryptococcal 
meningoencephalitis (CME). Distribution of GXM in regions that are known to localize 
HIV gp41 antigen raised the possibility of a symbiotic relationship between HIV and C. 
neoformans (6). In HIV encephalitis massive infiltration of macrophages into the brain 
compartment can be detected and HIV-1-infected macrophages and microglia have been 
identified as the virus reservoirs in brain tissue (7). In AIDS-related cryptococcal 
meningoencephalitis brain macrophages and microglia were identified as principal 
inflammatory cells (8). The means by which these cells are attracted into the brain 
compartment have not been elucidated, but chemokines have been suggested to be 
involved (9). Chemokines constitute a super gene family of small inducible peptides that 
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possess potent chemotactic activity for leukocytes. Two major chemokine families can be 
distinguished based on the position of conserved cysteine residues in the molecules. The 
C-C chemokines include among others, MIP-1α and MIP-1β and RANTES. The C-C 
chemokines, in general, do not act on neutrophils but attract monocytes, eosinophils, 
basophils, and lymphocytes by binding to specific CC chemokine receptors (CCR) on 
these cells, including CCR5 (10). CCR5 also functions as a coreceptor for macrophage-
tropic, nonsyncytium-inducing strains of HIV. MIP-1α and MIP-1β and RANTES 
suppress replication of macrophage-tropic HIV strains in vitro, presumably by 
competitive inhibition of HIV attachment to CCR5 (11). In a mouse model, the 
chemokines MIP-1α and MCP-1 have been described to play a major role in leukocyte 
recruitment into the lungs following infection with C. neoformans (12-14). In the present 
study MIP-1α and MIP-1β and RANTES gene expression and release in both HIV-
infected and uninfected macrophages stimulated with C. neoformans and GXM was 
investigated.  
 
MATERIAL AND METHODS 
Cryptococcus neoformans 
Encapsulated C. neoformans (NIH 37) was used throughout this study. The organisms 
were obtained from the National Institute of Health (NIH, Bethesda, MD). NIH 37 is a 
thinly encapsulated clinical isolate (serotype A) from cerebrospinal fluid obtained by K.J. 
Kwon-Chung. The yeast cells were maintained on Sabouraud dextrose agar (Merck, 
Darmstadt, Germany) at 4°C. After harvesting, the cryptococci were heat-killed for 30 
min at 80°C. 
Cryptococcal capsular polysaccharide 
Purified GXM, obtained as previously described (15) from C. neoformans serotype A 
(ATCC 62066), was a generous gift from Prof. Dr. R. Cherniak, Georgia State University 
(Atlanta, GA). Experiments were carried out aseptically to avoid endotoxin 
contamination. Preliminary experiments were performed in the presence and absence of 
Polymyxin B sulphate (Sigma) at a final concentration of 10 µg/ml. This concentration of 
polymyxin B sulphate completely abolishes stimulatory effects of endotoxin from E.coli 
O111:B4 at concentrations up to 100 ng/ml. 
HIV-1 infection of macrophages 
Peripheral blood mononuclear cells were isolated from heparinized blood from HIV-1-, 
HIV-2-, and hepatitis B-seronegative donors and obtained on Ficoll-Hypaque density 
gradients. Cells were washed twice and monocytes were purified by countercurrent 
centrifugal elutriation. Cells were >98% monocytes by criteria of cell morphology on 
May-Grünwald-Giemsa-stained cytosmears and by nonspecific esterase staining using α-
naphtylacetate (Sigma Chemical Co., St. Louis, MO) as substrate. Monocytes were 
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cultured in suspension at a concentration of 2 x 106 cells/ml in Teflon flasks (Nalgene, 
Rochester, NY) in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-
inactivated human AB serum negative for anti-HIV antibodies, 10 µg/ml gentamicin, and 
10 µg/ml ciprofloxacin (Sigma). After 7 days monocyte-derived macrophages (MDM) 
were recovered from the Teflon flasks and infected with HIV-1Ba-L at a multiplicity of 
infection of 0.01 for two hours. HIV-infected and mock-infected MDM were washed 
twice to remove unbound virus and cultured in Teflon flasks for an additional five days to 
establish a chronic infection. Then, MDM were washed and added in a 24-well plate. 
Stimulation of HIV-infected macrophages 
HIV infected and uninfected macrophages (both 3 x 105/well) were stimulated with buffer 
(negative control), or C. neoformans (3 x 106/well) or GXM A (25 µg/ml), in the 
presence of 10% HPS. After 8 h incubation samples were collected and stored at -700C 
prior to chemokine-ELISA’s and stimulated macrophages were lysed for the purpose of 
RT-PCR detection of chemokines. 
Chemokine determination by RT-PCR and ELISA 
Macrophages were homogenized and lysed in 1 ml TRIzol (Life Technologies 
Gaithersburg, MD) according to the manufacturer’s guidelines. When lysates of all time 
points were obtained, total RNA was isolated. Total RNA was dissolved in 
diethylpyrocarbonate (DEPC)-treated water and 1 µg of RNA was used for the synthesis 
of complementary DNA and PCR reactions were performed as described previously (16). 
For semi-quantification every primer pair was tested at different cycle numbers to 
determine the linear range. GAPDH mRNA levels were measured at 20 cycles, whereas 
cDNA had to be subjected to 23 cycles to be in the linear range to detect MIP-1α, MIP-
1ß, and 26 cycles for RANTES. Aliquots of 5 µl of the biotinylated PCR product were 
semi-quantitatively analyzed using a fluorescent digoxigenin detection ELISA kit 
(Boehringer Mannheim) according to manufacturer’s protocol as described previously 
(16). All data were normalized against GAPDH mRNA levels. The 5'-3' sequences of the 
oligonucleotide primers and probes in reverse transcriptase polymerase are: GAPDH 
(195bp), sense CCATGGAGAAGGCTGGGG, antisense CAAAGTTGTATGGATACC, 
probe CTGCACCACCAACTGCTTAGC; MIP-1α (333 bp) sense TGCATCACT-
GCTGCTGACACG antisense CAACCAGTCCATAGAAGAGG probe CTGACTA-
TTTGAGACGAGC; MIP-1ß sense CCAAACCAAAAGAAGCAAGC antisense 
AGAAACAGTGACAGTGGACC probe ACATCTCCTCCATACTCAGG; RANTES 
sense CTTTGTCACCCGAAAGAACC antisense GTTTCATCATGTTGGCCAGG 
probe TTGCTCTTGTCCTAGCTTGG. MIP-1α, MIP-1β, and RANTES levels in 
supernatants were assayed by enzyme linked immunosorbent assay (ELISA) kits (MIP-
1α, MIP-1β: R&D Systems Minneapolis, Mn. RANTES Endogen, Woburn, MA), 
according to the manufacturer’s instructions. The absorbance at 450 nm was measured 
with a micro plate reader (Biorad, Tokyo, Japan). 
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RESULTS 
C-C chemokines mRNA production by HIV-infected macrophages stimulated with 
C. neoformans and GXM 
A 3-fold induction of mRNA levels of MIP-1α was seen after stimulation of uninfected 
macrophages with C. neoformans or GXM. HIV-1 infection of macrophages increased 
mRNA levels of MIP-1α 2-fold. C. neoformans or GXM stimulation of HIV-infected 
macrophages upregulated mRNA levels of MIP-1α 3.3-fold, as compared to unstimulated 
HIV-infected macrophages (Fig. 1A). 
 
 
 
 
 
 
 
 
Figure 1A. mRNA expression levels, expressed in relative fluorescence units (RFU) of MIP-1α in 
uninfected (open bars) and HIV-infected (solid bars) macrophages. The means plus standard errors of the 
mean (SEM) of three experiments are shown. 
 
HIV-1 infection of the macrophages increased mRNA levels of MIP-1β 1.4-fold. 
Stimulation of uninfected macrophages with C. neoformans or GXM showed a 4-fold 
induction of mRNA levels of MIP-1β. However, a 7.2-fold induction was seen after 
stimulation of HIV-infected macrophages with C. neoformans or GXM (Fig 1B). 
 
 
 
 
 
 
 
 
Figure 1B. mRNA expression levels, expressed in relative fluorescence units (RFU) of MIP-1β in 
uninfected (open bars) and HIV-infected (solid bars) macrophages. The means plus standard errors of the 
mean (SEM) of three experiments are shown. 
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In contrast to mRNA levels of MIP-1α and MIP-1β, no effect of stimulation with C. 
neoformans or GXM of uninfected macrophages on mRNA levels of RANTES could be 
detected. HIV-1 infection of macrophages increased mRNA levels of RANTES 1.4-fold. 
Stimulation of HIV-infected macrophages with GXM resulted in a 1.8-fold induction of 
mRNA RANTES levels as compared to unstimulated HIV-infected cells (Fig 1C). 
 
 
 
 
 
 
 
 
 
 
Induction of protein levels of C-C chemokines by HIV-infected macrophages 
stimulated with C. neoformans and GXM  
Next, we investigated whether mRNA levels of the three C-C chemokines reflected 
protein levels of these molecules. Therefore, ELISA’s for MIP-1α, MIP-1β, and 
RANTES were performed (Table 1). Unstimulated uninfected macrophages produced 
361 pg/ml MIP-1α. HIV infection of macrophages increased this level 3.2 fold. GXM-
stimulated HIV infected macrophages produced 7160 pg/ml, a 6-fold induction as 
compared to unstimulated HIV-infected cells. MIP-1β levels in unstimulated uninfected 
macrophages were comparable with the levels of HIV-infected unstimulated macrophages 
(319 pg/ml, 329 pg/ml respectively). GXM enhanced the production of MIP-1β 7.4 fold, 
whereas cryptococci increased this level to 679 pg/ml (a 2-fold induction), both as 
compared with unstimulated HIV-infected cells. mRNA levels for RANTES were 2849 
pg/ml in unstimulated uninfected macrophages. These levels increased after stimulation 
of uninfected cells with C. neoformans or GXM (1.2 and 1.6 fold respectively). 
Stimulation of HIV-infected cells with GXM only increased RANTES levels as 
compared to HIV infected unstimulated macrophages 1.2 fold. 
 
Figure 1C. mRNA expression levels, expressed in relative fluorescence units (RFU) of RANTES in
uninfected (open bars) and HIV-infected (solid bars) macrophages. The means plus standard errors of
the mean (SEM) of three experiments are shown. 
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DISCUSSION  
Cryptococcal meningoencephalitis (CME) in the setting of AIDS is frequently 
distinguished by a marked lack of an inflammatory response (17). AIDS patients with 
cryptococal meningitis have been reported to have low CSF leukocyte counts, despite 
high levels of the neutrophil-attracting chemokine interleukine–8 in the cerebrospinal 
fluid (4). Human polymorphonuclear neutrophils (PMN) have been reported to effectively 
kill C. neoformans (18). However, PMN are not found in brain parenchyma of these 
patients suggesting that the process of host cell recruitment to the CNS is carefully 
regulated by C. neoformans. Indeed, it has been shown that a low leukocyte count in 
cryptococcal meningitis patients affects prognosis negatively (19). 
In this and in other studies (16), it was shown that HIV-1 infection of macrophages 
increases mRNA levels of MIP-1α, MIP-1β, and RANTES. Moreover, both HIV 
infection and C. neoformans or GXM stimulation of macrophages resulted in an 
additional enhancement of chemokine expression. Huang et al. showed the same pattern 
of chemokine release in Peripheral Blood Mononuclear Cells from persons with and 
without HIV infection (11). Furthermore we show that mRNA levels of MIP-1α, MIP-1β, 
and RANTES roughly reflect protein levels of the three chemokines. These data suggest 
that the lack of inflammatory response is not caused by defective chemokine release. 
Apparently high levels of chemokines fail to attract sufficient numbers of effective 
leukocytes to C. neoformans infected places.  
Paucity of inflammatory cells despite sufficient amounts of chemokines could be 
explained by more specific inhibitory mechanisms as are described for neutrophils. Dong 
and Murphy described that cryptococcal polysaccharides can cause shedding of L-
selektine from the surface of neutrophils in mice (20) and GXM binds to CD18 adhesion 
Table 1: Protein levels of MIP 1α, MIP 1β, and RANTES of C. neoformans and GXM 
stimulated HIV- and uninfected human macrophages (pg/ml). Data are the mean of a 
representative experiment (plus standard error), performed in triplicates. 
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molecules thereby blocking interaction of activated neutrophils with ligands on the 
endothelium (21).  
Animal models show that chemokines play an important role in cryptococcosis. The 
chemokines MIP-1α and MCP-1 have been described to play a major role in leukocyte 
recruitment into the lungs following infection with C. neoformans (12-14). Recently, it 
was shown in a mouse model that a Th1 cell mediated inflammatory response that 
requires chemokines for the recruitment of effector cells is needed for clearance of C. 
neoformans from the CNS (22). 
Acapsular C. neoformans enter the body via the respiratory tract and in the lung cells of 
the host defense system phagocytize them (1). In cases of dissemination from the lungs, 
cryptococci are able to escape local (impaired) innate and adaptive immunity and gain 
access to the bloodstream. The production of C-C chemokines by stimulated HIV-
infected macrophages suggests the possibility that monocytes/macrophages are 
specifically attracted from the bloodstream into the brain parenchyma. Subsequently this 
may result in the delivery of yeasts into the brain tissue by C. neoformans infected- 
monocytes/macrophages as intracellular survival of cryptococci in macrophages has been 
described (23). Very recently, not only intracellular survival but even replication of C. 
neoformans in macrophages has been described (24). In HIV encephalitis massive 
infiltration of macrophages into the brain compartment can be detected and HIV-1 
infected macrophages and microglia have been identified as the virus reservoirs in brain 
tissue (7). The CC chemokine attracted cells from the mononuclear system could be 
responsible for the maintenance of both HIV and C. neoformans reservoir in the CNS.  
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The encapsulated yeast like fungus Cryptococcus neoformans is the leading cause of 
mycological infection in the central nervous system (CNS) in patients with 
compromised cell-mediated immunity (1). Before, we demonstrated that the 
cerebrospinal fluid (CSF) of patients with cryptococcal meningitis contains high 
levels of the neutrophil chemoattractant IL-8 despite the fact that the CSF contains 
few neutrophils (2). The cryptococcal capsular polysaccharide glucuronoxylomannan 
(GXM) is both present in serum and in CSF of patients with cryptococcal meningitis, 
and GXM is known to interfere with neutrophil migration (3). We demonstrated in 
vitro that GXM is capable of inducing the production of IL-8 by brain cells, whilst 
GXM also prevents neutrophils from migrating towards IL-8 (4). Consequently, a 
high ratio of GXM in serum/CSF should correlate with a low CSF leukocyte cell 
count in patients with cryptococcal meningitis. Therefore, we compared 
retrospectively the GXM titers in serum and CSF with the CSF leukocyte cell counts 
of 35 Dutch HIV-infected patients with a culture-proven diagnosis of cryptococcal 
meningitis between 1986 and 1996. Antigen titers had been measured with 
commercial kits routinely used for diagnostic detection of cryptococcal antigen, 
(mainly Murex Cryptococcus Test, Kent, UK), and were obtained within 5 days of 
CSF leukocyte cell counts. Since GXM can attract neutrophils itself (4), the GXM 
concentration gradient over the blood brain barrier, expressed as the ratio of titers in 
serum versus CSF, is expected to be more critical to the CSF cell count than absolute 
GXM concentrations. Figure 1 demonstrates a significant inverse correlation between 
the (log) GXM ratio and the (log) CSF leukocyte cell count in patients with 
cryptococcosis. (Correlation coefficient of log values: -0.54, n=35; two-sided 
P<0.001). These data suggest that the in vitro finding of interference of GXM with 
neutrophil migration may indeed represent a pathogenitic mechanism in cryptococcal 
meningitis.  
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Figure 1 
Inverse correlation between the ratio of cryptococcal glucuronoxylomannan titers in 
serum ([GXM]se) over cerebrospinal fluid ([GXM]csf) and the CSF leukocyte cell 
count in 35 patients with cryptococcal meningitis. 
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ABSTRACT 
Cryptococcal capsular antigens induce the production of pro-inflammatory cytokines 
in patients with cryptococcal meningitis. Despite this, their cerebrospinal fluid 
typically contains few neutrophils. Capsular glucuronoxylomannan (GXM) is 
generally considered to mediate the inhibition of neutrophil extravasation. In the 
current study culture supernatant harvested from the non GXM-producing strain 
CAP67 was found to be as potent as supernatant from wild-type strains in preventing 
migration. We identified capsular mannoprotein-4 (MP-4) as the causative agent. 
Purified MP-4 inhibited migration of neutrophils toward platelet-activating factor 
(PAF), IL-8 and fMLP, probably via a mechanism involving chemoattractant receptor 
cross-desensitization as suggested by its direct chemotactic activity. Supporting this 
hypothesis, MP-4 elicited Ca2+ transients that were inhibited by pre-incubation with 
fMLP, IL-8 or C5a, but not PAF - and vice versa. Moreover, MP-4 strongly decreased 
the neutrophil surface expression of L-selectin and induced shedding of TNF 
receptors p55/p75, while CD11b/18 increased. Finally, MP-4 was clearly detectable in 
both serum and cerebrospinal fluid of patients suffering from cryptococcal meningitis. 
These findings identify MP-4 as a novel capsular antigen prematurely activating 
neutrophils and desensitizing them toward a chemoattractant challenge. 
 
INTRODUCTION 
Neutrophil infiltration into the central nervous system is a dual-edged sword in that it 
protects the tissue from infection and injury but is also detrimental to the host. In 
diseases such as bacterial meningitis (BM) or cerebrovascular ischemia there is 
evidence that a high influx of polymorphonuclear neutrophils (PMN) plays an adverse 
role in the pathogenesis of neurological damage (1;2). In BM, the phagocytic capacity 
of PMN in the cerebrospinal fluid (CSpF) is often insufficient and the harmful effects 
of their cytotoxic products may outweigh their beneficial effects (3). Accordingly, it is 
now assumed that adjunctive therapeutic strategies with anti-inflammatory agents 
may favor neurological recovery (4-6). Interestingly, the opportunistic fungus 
Cryptococcus neoformans has developed a means of infection evoking only minimal 
PMN infiltration.  
Disseminated cryptococcosis is characterized by the presence of high levels of 
capsular glucuronoxylomannan (GXM), galactoxylomannan (GalXM), mannoprotein-
1 (MP-1), and MP-2, in the CSpF and serum of affected patients (7;8). Titers in both 
serum and CSpF from AIDS patients reach levels equivalent to several hundred 
micrograms per milliliter, in exceptional cases rising to 20 mg/mL (9). GXM, GalXM 
and MP have been shown to induce the production of the early pro-inflammatory 
cytokines TNF-α and IL-1β by peripheral blood monocytes (10-12) and PMN (13) in 
the presence of pooled human serum (PHS). TNF-α then plays a pivotal role (14) in 
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initiating a protective cell-mediated immune response. In healthy subjects, TNF-α 
enables the host to overcome the anti-phagocytic properties of the fungus, which 
usually suffices to clear systemic infection (15). In patients in whom this accurate 
response is hampered, the disease disseminates and induces inflammation. This 
reaction theoretically could be a very purulent one since the induced TNF-α has 
several properties that strongly promote PMN extravasation. First, TNF-α can cause 
profound systemic vasodilatation and subsequent hypotension via the induction of 
prostaglandins (16). Hypotension is a prerequisite to allow the transient L-selectin 
(CD62L)-mediated adherence of leukocytes to endothelial cells (17-19). In addition, 
TNF-α and IL-1β can induce the expression of adhesion molecules on endothelial and 
glial cells (4). Furthermore, TNF-α and IL-1β activate mononuclear cells, endothelial 
cells, and astrocytes to produce IL-8 (20) in the brain of patients with meningitis. 
Despite the elevated IL-8 CSpF/serum ratio (13;21) and the elevated serum levels of 
TNF-α and IL-1β, the CSpF of patients with cryptococcal meningitis typically 
contains few mononuclear cells and virtually no PMN. To date GXM is considered to 
account for this inhibition of leukocytosis. In a mouse model study, Dong and 
Murphy showed that the inhibition of PMN infiltration elicited by intravenous 
administration of the cryptococcal culture filtrate (CneF) is due mainly to GXM (22). 
Using a modified Boyden chamber, we previously demonstrated that GXM 
significantly inhibited PMN migration toward IL-8 (23). In addition, we confirmed 
Dong and Murphy’s earlier observation that GXM mediates the chemotactic activity 
for PMN of whole encapsulated yeast cells and unfractionated CneF derived from 
these cells (24). Moreover, we found a significant inverse correlation between the 
GXM ratio (serum/CSpF) and the CSpF leukocyte count in patients with 
cryptococcosis (25). More recently, we showed that GXM delays translocation of 
PMN across the blood-brain barrier in a rabbit BM model (26). Therefore, the initial 
aim of this study was to investigate the molecular mechanism by which GXM 
prevents PMN migration toward chemoattractants.  
Several studies have investigated the mechanisms regulating the passage of 
leukocytes through endothelial cells and their infiltration at inflammatory foci. The 
exact nature of the signaling mechanisms in brain inflammation still remains to be 
elucidated but undoubtedly involves TNF-α and IL-1β, chemoattractants (IL-8, PAF), 
as well as the expression of adhesion molecules and proteases that together promote 
cell recruitment and vascular permeability (6). Initially, localized inflammation results 
in hypotension allowing selectin-mediated tethering and rolling of PMN along the 
vessel wall (17;18). Rolling precedes a further functional up-regulation of PMN 
following exposure to pro-inflammatory cytokines and chemoattractants (27), 
resulting in firmer integrin-mediated adherence and shedding of CD62L (17;27). 
Further stimulation of PMN phenotypically high in CD11b/CD18 (CR3, Mac-1) 
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initiates migration through the interendothelial junctions (28). Finally, chemotactic 
gradients guide PMN to the site of infection.  
Currently, the discrepancy between raised cytokine levels and hampered PMN influx 
into the brains of patients is explained by the observation that GXM is able to induce 
shedding of CD62L and TNF-α receptor (TNF-R) molecules from PMN (29). The 
key observation underlying this paper, i.e. a quantitatively similar prevention of PMN 
migration by CneF harvested from GXM-producing and non-producing (∆CneF) 
strains, seriously questions the opinion that GXM is the sole cryptococcal antigen 
preventing extravasation. Therefore, we set out to characterize the component of 
∆CneF responsible for the inhibition. To assess this, we first optimized the current 
protocol for isolating capsular antigens and purified the most important constituents 
of ∆CneF (GalXM, MP-1, MP-2 and MP-4) to near homogeneity (30). We found that 
MP-4 was primarily responsible for the inhibition of PMN migration. We then 
investigated the intrinsic chemotactic capacity of MP-4 and analyzed its ability to 
influence the expression of PMN surface-receptors involved in PMN migration. As a 
result of the action of MP-4 the surface expression of CD62L was down-regulated and 
both TNF-R p55 and p75 were shed into the surrounding medium. Furthermore, MP-
4-induced signaling caused Ca2+ transients that could regulate inflammatory reactions 
by desensitizing chemoattractant receptors. 
 
MATERIALS AND METHODS 
Cryptococcal strains and antigen preparations 
The cryptococcal culture filtrate antigens ∆CneF and CneF were prepared from 
cultures of the non-GXM-producing C. neoformans mutant strain, CAP67 (E.S. 
Jacobson, Medical College of Virginia), or the isogenic capsular strain NIH B3501, 
respectively. Inocula (108 colony forming units) of these strains were added to 500 ml 
RPMI-1640 supplemented with 10 µg/ml gentamycin and allowed to propagate for 5 
days at 37oC. Next, supernatant fluids were isolated by centrifugation and 
concentrated by ultra-filtration (Stirred Cell Concentrator Millipore, 3.5 kDa cut-off). 
The concentrated (∆)CneF was filtered sterilized and adjusted to 0.1 mg of protein per 
ml as determined by the BCA (Pierce; Rockford, Illinois, USA) protein concentration 
assay. (∆)CneF used in the assays was diluted threefold. Mannoproteins were purified 
from ∆CneF as described recently (30). Briefly, ∆CneF was dialyzed against excess 
mQ water, freeze-dried and applied to a 100 ml Con A Sepharose-4B column. The 
column was washed and stepwise eluted with α-methyl-D-mannose pyranoside 
(αmDm). GalXM flows through this column, whereas MP-1 and -2 are eluted at 0.2 
M and MP-4 at 0.4 M αmDm. These fractions were concentrated (MP-4) or further 
separated (MP-1 and -2) by DE52 or source Q anion exchange columns. All purified 
components were finally dialyzed against excess PBS and kept frozen at -20oC. 
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Maintenance of endotoxin-free conditions 
Preparations of the various cryptococcal components were negative for endotoxin 
contamination using a Limulus assay (Kabi Diagnostica, Mölndal, Sweden) with a 
sensitivity of 100 pg/ml E. coli LPS. Nevertheless, all experiments were carried out at 
least once in the presence of 10 µg/ml polymyxin B sulfate in order to neutralize any 
undetected LPS contamination. 
Isolation of human PMN 
PMN were isolated as previously described (31). Briefly, blood from healthy 
volunteers was collected into Vacuette tubes containing sodium heparin, diluted with 
an equal volume of pyrogen-free PBS and centrifuged through a gradient of Ficoll and 
Histopaque. PMN were collected from the Histopaque phase, briefly shocked with 
mQ water, washed and suspended at 5 x 106 cells/ml in RPMI supplemented with 
0.05% human serum albumin (RPMI-HSA). 
Transwell assay for measurement of chemotaxis 
PMN were labeled by incubating them for 30 min. at 20oC with 3.3 µM 2',7'-bis-(2-
carboxyethyl)-5-(6)-carboxyfluorescein acetoxymethyl ester (BC-ECF AM; 
Molecular Probes Europe, Leiden, Netherlands) in RPMI-HSA. Cells were washed 
and suspended in HBSS-HSA; 200 µl aliquots were incubated with an equal volume 
of each of the cryptococcal antigens being assessed for chemoattractive activity or 
buffer control for 30 min. at 37oC under constant agitation. Just prior to the end of this 
incubation transwell filters (pore size 3.0 µm; Costar type 3415, Cambridge, MA) 
were pre-wetted in HBSS/HSA. To each bottom compartment we added 600 µl of the 
indicated chemoattractants: human recombinant IL-8 (10 nM; Pepro Tech Inc., Rocky 
Hill, NJ-USA); fMLP (10 nM; Sigma Chem. Co., St. Louis, MO-USA) or PAF 
(platelet activating factor, 100 nM; Calbiochem, Cambridge, MA-USA). Filter 
compartments containing 100 µl of PMN suspension were placed on top of the bottom 
compartments. Migration was allowed to proceed for 1h at 37oC (5% CO2) and 
analyzed by reading the fluorescence of the wells with a Cytofluor II multi-well Plate-
reader (PerSeptive Biosystems; Farmingham, MA-USA) equipped with a 485 nm 
excitation and a 530 nm emission filter. Control wells containing BCECF-labeled 
cells were included to obtain the maximal fluorescence value. The fluorescence values 
of the samples are expressed relative to this maximum. Fluorescence was linear with 
cell number with a detection limit of 2,500 cells (1% of input), as determined by serial 
dilution. 
Immunostaining and FACS® analysis of PMN antigen expression  
To measure the expression of selected surface antigens, 5 x 105 PMN were suspended 
in 40 µl RPMI-HSA containing purified cryptococcal antigens at the designated 
concentrations. Mixtures were incubated for 30 min. at 37oC on a rotation wheel after 
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they had been heated for 3 min. in a water-bath at 37oC. Then 10 µl of RPMI-HSA 
containing 0.25 - 0.5 µg of FITC-conjugated mAbs directed against CD11b (IgG1; 
ATCC 44a), CD18 (IgG2a; BD, Mountain View, CA-USA), or CD62L (IgG2a; Leu-8, 
BD) was added and the incubation was continued for 30 min. on ice. Heparinized or 
EDTA-treated whole blood samples were analyzed using an identical staining 
protocol with a final incubation step in Lysing solution (BD) to eliminate red cells. 
Neutrophils were distinguished from other leukocytes by differences in forward (FSC) 
and side scatters (SSC) in FACS® analyses. 
Expression levels of chemoattractant and TNF receptors on PMN were measured 
using the same methodology. We determined the expression of IL8-R type A and 
PAF-R using mAbs to CDw128A of the IgG2b subclass and to PAF-R (IgG), both 
from Alexis Corp. (San Diego, USA). Surface expression levels of C5a-R and fMLP-
R were determined using an anti CD88 mAb (IgG2a, Serotec, Oxford, UK) and anti-
fMLP-R mAb (IgG1, PharMingen/BD), respectively. Since these different mAbs were 
not FITC-labeled, binding was visualized by incubation with FITC-conjugated goat 
F(ab') anti-mouse IgG (DAKO, Carpinteria, CA USA) as a secondary reagent to 
recognize the mAbs. To quantify the surface expression of the two receptors for TNF 
(p55 and p75) we used FITC-labeled antibodies of IgG1 and -2a subclasses, 
respectively, which were purchased from R&D Systems (Minneapolis, MN USA). 
Isotype-matched conjugated mAbs (mouse IgG1-FITC and mouse IgG2a/b-RPE) not 
specifically reacting with PMN were purchased from DAKO and used as controls to 
exclude non-specific or Fc-related binding. The labeled cells were washed twice and 
analyzed with a FACS® or incubated with the secondary antibodies prior to analysis.  
Recording of cytosolic Ca2+ concentration  
To measure chemoattractant-induced Ca2+ fluxes, PMN were loaded with 2 µM Fluo-
3-AM in RPMI/HSA for 15 min. at 37oC under agitation, washed with buffer and 
suspended at 106/ml in RPMI/HSA. The fluorescence (530 nm) of each 0.5-ml sample 
was measured to determine the basal Ca2+ level. Since Ca2+ fluxes are very rapid and 
transient, 5 µl reagent was added under vortexing and the sample was analyzed 
immediately by FACS®. For each sample nine measurements (0 through 8) of 2,000 
cells were performed, each requiring an average time of ten seconds for sampling and 
data saving before the next acquisition was started. Samples were analyzed after 
gating the PMN population, thereby excluding cell debris and nonspecific staining. 
TNF-R ELISA 
Soluble TNF-R p55 and p75 shed from the surface of PMN were measured using a 
commercially available human ELISA kit (R & D Systems Europe, Abingdon, UK) 
according to the manufacturer's protocol. The minimum detectable doses of sTNF-R 
for these assays were typically less than 3 pg/ml for p55 or 1 pg/ml for p75. All data 
are expressed as means ± SEM. 
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Generation of antibodies directed against MP-4 and immunodetection 
A rabbit antiserum directed against MP-4 was prepared by primary subcutaneous 
injection of two New Zealand White rabbits with 100 µg of MP-4 in complete 
Freund's adjuvant followed by a booster of 50 µg MP-4 in incomplete FA. The serum 
specifically recognized MP-4 migrating between 25 and 28 kDa, as shown (Figure 5 
panel A) by standard Western blotting and ECL detection (Amersham Pharmacia 
Biotech, Uppsala, Sweden). When indicated, samples were pre-adsorbed to rabbit IgG 
purified from pre-immune serum using a protein G Sepharose 4 Fast Flow column 
(Amersham Pharmacia Biotech). Shortly, isolated pre-immune IgG was coupled to 
CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech) beads. Immobilized 
IgG was added to the patient serum and CSpF samples and non-specific IgG-antigen 
interactions were allowed to occur for 30 min. at room temperature (batch binding). 
 
RESULTS 
Effects of cryptococcal capsular antigens on PMN migration toward IL-8, PAF 
and fMLP   
IL-8, fMLP and PAF are examples of inflammatory mediators causing neutropenia 
because of rapid sequestration of PMN within the post-capillary venules of target 
organs. We evaluated the relative potency of capsular antigens to inhibit the migration 
of PMN toward these chemoattractants. Therefore, we first purified GalXM and three 
different MP from ∆CneF. Next, we confirmed that PMN were able to migrate toward 
IL-8, PAF, or fMLP in a dose-dependent manner (not shown). In our initial 
experiments we obtained almost identical results with CneF and ∆CneF, which was 
unexpected since GXM is considered to be the antigen exclusively responsible for the 
inhibition of PMN migration into the CSpF. We were able to detect a statistically 
significant inhibition of migration by adding ∆CneF to PMN migrating toward fMLP 
(18% inhibition, P=0.002) or IL-8 (23% inhibition, P=0.025; Figure 1A). We then 
added PMN incubated with MP-4 or other capsular antigens at the indicated optimal 
concentrations to the upper chamber and compared the inhibitory effect on PMN 
migration for each of them. GalXM (89%), GXM (46%) and MP-4 (98%) all caused 
significant (P<0.01) inhibition of migration toward IL-8, with MP-4 being the most 
potent (Figure 1A). GXM, GalXM and MP-4 all impaired migration toward fMLP, 
albeit to a somewhat lesser extent, with migration being inhibited by 66% (P=0.05), 
60% (P=0.006) and 56% (P=0.0004), respectively. Migration toward PAF was 
completely blocked by MP-4 (P=0.015) and significantly inhibited by MP-2 (51%, 
P=0.007), GalXM (28%, P=0.0003) and GXM 70% (P=0.004). Because this 
inhibition could be caused by down-regulation of the receptors for these 
chemoattractants by MP-4, we analyzed the expression of the receptors for IL-8, 
fMLP, and PAF on PMN. There were no significant changes in the expression of 
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these receptors, although the number of fMLP and PAF receptors was slightly 
increased and the number of IL-8 receptors slightly decreased (not shown). Addition 
of polymyxin B to exclude any possible influence of trace amounts of LPS yielded 
identical results. 
 
FIGURE 1. Cryptococcal capsular antigens affect PMN migration.  
A. Inhibition of PMN migration toward chemoattractants. BCECF-AM-labeled PMN in the presence or 
absence of fungal antigens were added to the upper chamber of a transwell device. The migration of 
cells toward chemoattractants added to the lower chamber was quantified after 1 hour. MP were added 
to a concentration of 100 µg/ml, at which inhibition reached a plateau. GXM and GalXM were present 
at a final concentration of 1 mg/ml. Y-axis values represent migration toward chemoattractants in the 
presence of the indicated antigens relative to migration in the presence of buffer only (value = 1). Data 
are the means ± SEM derived from 3 (PAF; 100 nM final concentration), 5 (fMLP; 10 nM final 
concentration) to 7 (IL-8; 10 nM final concentration) independent experiments, except for GXM and 
GalXM (n = 2). Statistically significant data (2-tailed Student's t-Test) are marked by asterisks. B. MP-
4 has intrinsic chemotactic activity. A concentration series of MP-4 was added to the lower 
compartment. Values (± SEM; n = 6) represent migration as percentage of the total amount of PMN 
(value = 1) added to the upper chamber. 
 
MP-4 has intrinsic chemotactic properties  
To determine the nature of the potent blocking effect of MP-4 on PMN migration we 
assayed the intrinsic chemoattractive activity of MP-4. MP-4 attracted PMN in a 
concentration-dependent manner (Figure 1B). Maximum migration (61% of input; 
P=0.007) was reached at an MP-4 concentration of 30 µg/ml whereafter migration 
started decreasing, probably due to saturating diffusion of MP-4 into the upper 
chamber. This observation was confirmed by the conventional under-agarose assay 
(32) for detection of chemotaxis (not shown). In this assay, the potency of MP-4 at 
200 µg/ml equaled that of the positive control (PHS). Chemotaxis toward GXM (1 
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mg/ml) could not be detected with this less-sensitive assay. Importantly, the under-
agarose assay permits measurement of both chemotaxis and spontaneous migration. 
The directed migration toward MP-4 observed in this assay, demonstrates that MP-4 
is truly a chemoattractant and not simply acting as a chemokinetic agent. Furthermore, 
when 0.1 ng to 10 µg LPS/ml was added to the medium, in both assays no migration 
of PMN was observed, thus ruling out the possibility that the effects of MP-4 were 
caused by LPS contamination (not shown). 
Ca2+ mobilization data indicate cross-desensitization of chemoattractant 
receptors by MP-4  
The above results indicated that MP-4 might exert its effect by acting as a 
chemoattractant or by mimicking the action of chemoattractants. We therefore 
determined whether MP-4 could trigger an intracellular Ca2+ signal as occurs when 
chemoattractants bind to their G-protein coupled receptors. Figure 2A shows a steep 
increase in [Ca2+]i in Fluo-3-AM-loaded PMN following stimulation by MP-4. 
       
 
 
 
FIGURE 2. Interference of MP-4 with chemoattractant-induced intracellular Ca2+ mobilization. 
A. MP-4 transiently increases [Ca2+]i in human PMN. Fluo-3-AM-loaded PMN were stimulated with 
MP-4 (10 µg/ml) and immediately analyzed for the induction of Ca2+-fluxes. Y-axis represents 
fluorescence values (E530 nm). Nine subsequent measurements (0 through 8) were performed (X-axis); 
time point zero refers to the non-stimulated control. Each time point required an average time of ten 
seconds for sampling and data saving before the next acquisition was started. B. Desensitization by 
MP-4 of Ca2+ mobilization induced by fMLP, C5a and IL-8, but not PAF. Duplicate samples of PMN 
were incubated with MP-4, after which one tube was immediately used for Ca2+-flux measurements. 
Once fluorescence decreased to baseline levels fMLP (10 nM), C5a (200 nM), IL-8 (10 nM), or PAF 
(100 nM) was added to the parallel tube and responses were recorded. Depicted is the Ca2+ 
mobilization elicited by the indicated chemoattractants after pre-incubation with MP-4 relative to the 
Ca2+ pattern obtained after chemoattractant stimulation alone, calculated by the following equitation: 
Relative Ca2+ mobilization = (response value after preincubation–direct response value)/ response 
value after preincubation. Depicted data are from one representative experiment of at least 3 
independent experiments with qualitatively similar results. 
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Activation of chemoattractant receptors can result in homologous and heterologous 
desensitization, i.e. down-regulation of cellular responses after a second challenge 
with a G-protein coupled receptor ligand (33). In desensitization experiments, 
pretreatment of PMN with MP-4 almost completely prevented the IL-8-, fMLP- or 
C5a-, but not PAF-induced Ca2+ flux (Figure 2B). Inversely, pretreatment of PMN 
with the mentioned chemoattractants abrogated the Ca2+ flux induced by MP-4. These 
results suggest that MP-4 exerts its anti-inflammatory activity by interfering with 
chemoattractant-receptor signal transduction pathways. 
Effects of cryptococcal antigens on the expression of CD11b/18 and L-selectin in 
the presence or absence of serum and bivalent cations   
Stimulation of leukocytes with different chemoattractants such as fMLP, C5a and 
LTB4 causes a rapid decrease in the number of surface CD62L molecules and a 
concomitant inverse regulation of Mac-1/CR3 (27). Given the observed functional 
resemblance of MP-4 and other chemoattractants, we investigated whether MP-4 
resembles these true-type chemoattractants in this respect. Culture of isolated PMN 
with purified MP-4 at 2 µg/106 cells resulted (Figure 3C-D) in a significant decrease 
in the amount of cell-surface CD62L (68%; P=6E-5) and in up-regulation of surface 
Mac-1 (2.2-fold; P=7E-4). MP-4 was more potent than GXM or CneF in evoking this 
response (Figure 3A-B). The MP-4 response almost equaled that induced by fMLP, 
which caused a decrease in surface CD62L of 74% and an almost 3-fold increase in 
Mac-1 expression. ∆CneF caused a significant down-regulation of CD62L (47%, 
P=4E-9) and up-regulation of CD11b (64%, P=9E-8). Neither GXM, GalXM (not 
shown), MP-1 (not shown), MP-2 (not shown), nor CneF induced significant CD62L 
loss or CD11b gain in the absence of serum. These data provide evidence that MP-4 is 
the capsular component that has the greatest effect on the expression of CD62L and 
Mac-1. 
In order to study the effect of MP-4 on PMN under physiological conditions, we 
incubated heparinized blood with purified MP-4 and compared the observed effects to 
those obtained with CneF, ∆CneF, and GXM. Under these circumstances, ∆CneF 
(75%; P=0.02), GXM (149%; P=0.02), and MP-4 (195%; P=0.008) significantly 
increased the expression of CD11b (Figure 3A and C). The relative values for CD18 
(not shown) were similar to those observed for CD11b. In addition, GXM (37%; 
P=0.02) and MP-4 (43%; P=2E-4) induced a significant loss of CD62L (Figure 3B 
and D). However, both have been reported to activate the complement cascade in 
serum to generate C5a, which then can induce the observed effects on the expression 
of surface molecules (24;29). To investigate the contribution of complement 
activation to MP-4 activity, we studied the regulation of CD62L and Mac-1 
expression in the absence of bivalent cations by using EDTA-treated blood. Apart 
from fMLP, which was used as positive control, MP-4 was the only component able  
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FIGURE 3. Cryptococcal capsular antigens induce CD62L shedding and up-regulation of CR3 
expression on human PMN by a mechanism not requiring serum or bivalent cations.  
The surface expression of CD62L and CR3 of PMN either isolated as described, or present in 
heparinized or EDTA-treated blood was compared. A, B. Bars indicate the expression (± SEM) of L-
selectin and CD11b after incubation of PMN with fMLP (10 nM), GXM (1 mg/ml), CneF, or ∆CneF 
relative to the expression after incubation with RPMI/HSA (value = 1). C, D. Lines represent the level 
of expression of the indicated surface molecules after incubation with MP-4 at 0, 1, 3, 10, 30, or 100 
µg/ml. Changes in the expression of CD18 were similar to those measured for CD11b. For clarity 
reasons, expression values in heparinized blood are depicted - SEM, values in EDTA blood are 
depicted + SEM and values of isolated PMN ± SEM. Statistically significant data (2-tailed Student's t-
Test) are marked by asterisks. 
 
 
to alter the expression of CD11b or CD62L significantly under these circumstances 
(Figure 3). MP-4 dose-dependently increased the expression of CD11b to a maximum 
of 3.8-fold (P=0.015; Figure 3C) and decreased surface CD62L expression by 48% 
(P=0.005; Figure 3D). The same data for GXM were 7% and 2%, respectively. To 
exclude any donor-specific influence, isolated PMN, heparinized blood and EDTA-
treated blood were collected from the same donors. For heparinized blood and PMN 
absolute fluorescence values were in the same range. EDTA-treated blood showed an 
almost 2-fold reduction in basal CD11b/CD18 expression, whereas CD62L levels 
were 2-fold higher. These observations demonstrate that MP-4 affects PMN function 
by a mechanism not requiring serum proteins nor extracellular Ca2+ or Mg2+. 
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MP-4 induces shedding of TNF-R from the surface of PMN   
Results showed that MP-4 desensitized PMN, which explains the inhibited PMN 
influx into the brains of patients with meningitis. In conflict with this clinical 
observation is the induction of TNF-α expression observed in vitro (10-13) because 
TNF-α is generally assumed to promote extravasation. Since at least two reports 
(34;35) demonstrated a substantial reduction in PMN influx at the site of infection 
after neutralization of TNF, we investigated the possible involvement of TNF 
scavenging in reducing CSpF leukocyte counts. To examine the possible role of TNF-
R in cryptococcal meningitis, we measured the influence of capsular antigens on the 
generation of soluble TNF-R for the two types of TNF-R expressed on the surface of 
PMN: p55 and p75 (36). With a soluble TNF-R ELISA kit, the medium from freshly 
isolated PMN cultured for 1 h at 37oC contained clearly detectable levels of TNF-R 
(108 pg/ml and 186 pg/ml p55 and p75, respectively), suggesting that cell surface  
 
FIGURE 4. Effects of cryptococcal capsular antigens on the expression of TNF-α receptors 
on PMN: shedding causes down-regulation.  
(A) Quantification of soluble TNF-R levels in supernatants (20 µl) of PMN (4.105) by ELISA. Data are 
concentrations of soluble TNF measured after incubation of PMN with GXM (0.5 mg/ml) or MP (50 
µg/ml) for 1 h at 37oC minus the matched control value (PMN from the same donor incubated with 
PBS alone) and represent four independent experiments with blood from different donors and ELISA 
performed in duplicate. (B) Effect of MP-4 on the PMN surface expression of TNF-α receptors. Bars 
indicate the expression (± SEM) of TNF-R p55 and p75 after incubation of PMN with MP-4 (30 µg/ml) 
or RPMI/HSA (control) in arbitrary fluorescence units. Statistically significant data (2-tailed Student's 
t-Test) are marked by asterisks. 
 
proteolysis is part of the normal turnover of TNF-R. Stimulation of PMN with MP-4 
resulted in a significant increase of both sTNF-R p55 (4-fold; P = 0.0002) and p75 
(1.8-fold; P = 0.002) in the supernatants (Figure 4A). None of the other tested 
capsular components had an effect on TNF-R shedding. Since soluble TNF-R 
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compete with TNF-α at the cellular receptor, we also measured the density of p55 and 
p75 on PMN after treatment with MP-4. We observed a significant (P = 0.01) down-
regulation of surface p55 on PMN after addition of MP-4. p75 was also down-
regulated however due to the large variability between individual donors this was not 
significant (Figure 4B). 
MP-4 levels in Cryptococcosis patients 
Using a rabbit polyclonal antiserum directed against MP-4, we measured the levels of 
MP-4 present in the serum and CSpF of patients suffering from cryptococcal 
meningitis by standard Western blot analysis.  
 
FIGURE 5.   Detection of MP-4 in the serum and CSpF of patients suffering from 
cryptococcal meningitis. Immunoblotting. (A). Comparison of the amount of MP-4 detectable in 
serum collected from a cryptococcosis patient and pooled human sera; separation by SDS-PAGE on a 
15% PA gel. (B). Quantification of MP-4 in the serum and CSpF of patients suffering from 
cryptococcal meningitis. Lanes 1-4 contain 7.5 µl of purified MP-4 in a concentration of 30, 10, 3 and 
1 µg/ml, respectively, resolved by SDS-PAGE on a 20% gel. In lanes 5 to 14 - which were all pre-
adsorbed to pre-immune IgG - we added matched CSpF (7.5 µl initial volume; lanes 5-9) and serum 
(1.5 µl; lanes 10-14) samples. Lane 15 contains PHS (1.5 µl initial volume). Patient samples are from 
HIV-infected cryptococcosis patients (5-8; 10-13) and from a non-HIV-infected patient (9; 14). 
Proteins were electroblotted to nitrocellulose membranes and incubated with the described primary 
antiserum in a 1:100 dilution. Filters were subsequently incubated with goat ant-rabbit IgG linked to 
HRP. Bound HRP was visualized by ECL. Arrowheads indicate the position of MP-4. 
 
In panel A, we analyzed and compared the amount of MP-4 detectable in serum 
collected from a cryptococcosis patient and pooled human sera. Although the non-
adsorbed antiserum directed against MP-4 is cross-reactive to several serum proteins 
we clearly detected a specific band at the putative molecular weight of MP-4 in 
patient- but not pooled serum. The identity of this putative MP-4 band was confirmed 
in panel B lanes 1 to 4 where we applied purified MP-4 in a concentration of 30, 10, 3 
and 1 µg/ml, respectively, as a reference. In this panel, all samples were pre-adsorbed 
to pre-immune IgG, which removed all cross-reactive proteins except for one doublet 
at a high molecular weight position. In lanes 5-14 we analyzed and compared the 
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amounts of MP-4 detectable in paired samples of CSpF and serum collected from 
HIV-infected cryptococcosis patients (5-8, 10-13) or a non-HIV-infected patient (9 
and 14). MP-4 is clearly detected in the serum of these patients at a level strongly 
exceeding that present in CSpF, providing evidence for the formation of a gradient of 
MP-4 over the blood-brain barrier. The amount of MP-4 present in the serum of these 
patients was calculated relative to the standards after densitometric scanning of the 
blots and ranged between 10 and 55 µg/ml, respectively, by densitometric scanning of 
the autoradiograph. The concentration present in CSpF varied between < 1 µg/ml and 
7 µg/ml. 
 
DISCUSSION 
The potency of C. neoformans culture supernatants to inhibit leukocyte migration was 
recognized almost half a century ago (37). Using purified cryptococcal antigens we 
now show that MP-4 is the most active capsular antigen in inhibiting migration 
toward chemoattractants. Moreover, we provide direct evidence for the presence of 
MP-4 in the serum of patients with disseminated cryptococcosis. Below we discuss 
the role of these and other recent findings in the pathogenesis of the disease and focus 
on the mechanism of action of MP-4.  
MP-4 strongly inhibited PMN migration toward fMLP, PAF and IL-8 (Figure 1A). 
Conversely, MP-4 was found to be a potent chemoattractant in vitro (Figure 1B). The 
paradox emerging here can be explained by a phenomenon called cross-
desensitization of chemoattractant receptors, as initially described by Sabroe et al 
(33). This hypothesis was confirmed by our observation that pre-incubation of PMN 
with MP-4 impaired Ca2+ mobilization by fMLP, IL-8 and C5a - but not PAF (Figure 
2B). Although speculative at present, this difference in the regulation of 
chemoattractant-mediated responses is likely to be related to G-protein usage, as 
suggested by the distinct pertussis toxin sensitivity of the receptors for IL-8, fMLP, 
and C5a versus PAF, with the former being sensitive and the latter at least partially 
resistant (38;39). 
The pathophysiological role of MP-4 is thus to functionally mimic the action of 
chemoattractants, resulting in a premature activation of PMN. Such a role for MP-4 is 
consistent with the observed loss of CD62L and concomitant up-regulation of 
CD11b/18 (Figure 3), because chemoattractants affect the expression of these 
molecules (27;40;41). Kishimoto et al. showed that PMN shed CD62L from the cell 
surface within minutes after activation with chemotactic factors. Both the expression 
and activity of CD11b/18 were greatly increased (27). This work founded the current 
view that by the time chemoattractants arrive in the circulation, CD62L-mediated 
neutrophil rolling has already taken place and the integrin-mediated attachment takes 
over. In addition, Luscinskas et al. showed that IL-8, fMLP and C5a, besides 
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inhibiting the attachment of PMN to cytokine-activated endothelial monolayers, 
promoted the rapid detachment of tightly adherent PMN from activated endothelial 
cells, and abolished transendothelial migration (40). Finally, in IL-8 transgenic mice, 
but not in non-transgenic littermates, PMN migration into the inflamed peritoneal 
cavity was severely inhibited (41). Thus, although fMLP, IL-8, and C5a have been 
characterized primarily as chemoattractants, they can exert a wide range of 
modulatory effects on PMN-endothelial adhesive interactions. 
The association between MP-4 and down-regulation by shedding of surface TNF-R 
(Figure 4) is also in agreement with the proposed role of MP-4 as chemoattractant. 
Several in vitro studies (42;43) demonstrated that within minutes of chemoattractant 
incubation both TNF-R p55 and p75 were down-regulated from the surface of PMN. 
At the same time, soluble TNF-R appeared in supernatants, in amounts proportional to 
the extent of down-regulation. This suggests that shedding is the major mechanism 
leading to the loss of p55 and p75 upon chemoattractant activation. Our 
demonstration of increased amounts of shed receptors in conditioned media of 
neutrophils exposed to MP-4 supports this hypothesis. In vivo, scavenging of TNF-α 
by soluble TNF-R is likely to contribute to the observed lack of leukocytes in the 
CSpF of patients for at least two reasons. First, others and we have shown that 
cryptococcal antigens stimulate the production of TNF-α by leukocytes in the 
presence of serum (12;13). Second, TNF-α is known to play a crucial role in the 
control of organ infiltration. TNF-α activates the endothelium to cause leukocyte 
adherence (4;44) and triggers leukocyte infiltration of lung, liver, and kidney in 
control mice but not p55-deficient mice (44). Finally, TNF-α can cause profound 
systemic vasodilatation and subsequent hypotension (16), allowing CD62L-mediated 
adherence of leukocytes to the vessel wall (17-19). Together, these in vivo data 
indicate that the presence of TNF-α positively correlates with leukocyte organ 
infiltration. 
In a series of studies by Dong and Murphy and our group, GXM has been shown to 
possess anti-inflammatory properties that prevent PMN from accumulating in C. 
neoformans infected tissues (22-25;45). The present work shows that MP-4 shares 
most of these properties with GXM, but is more potent. Although analyzed before 
(22;24;45) no direct effects of MP on PMN migration have been reported. These 
conflicting results can be explained by differences in the purification strategy used 
here. Previously, MP were eluted from the Con A column using a 0.2 M α-methyl-D-
mannopyranoside (α-mDm) step elution protocol. Recently, however, we reported 
that MP-4 elutes from this column at 0.4 M α-mDm (30), thus indicating that MP-4 
was never present in the previously used MP preparations. Since analysis of MP-4 
reveals a signal eluting between polysaccharide calibration standards of 18 and 26 
kDa in gel filtration chromatography (not shown), this component also was not 
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present in ∆CneF used in the studies mentioned above, because the culture filtrates 
were concentrated using a 30 kDa cut-off cassette. 
Our analysis of the concentrations of MP-4 present in the serum of patients with 
cryptococcal meningitis has revealed a concentration range matching that required to 
obtain the described in vitro effects - thereby confirming the biological significance of 
our data. The concentrations required are high when compared to serum 
concentrations for mannoproteins from other fungi but are in line with experiments - 
both in vitro and in vivo - performed with other mannoproteins from C. neoformans 
(46;47). The relatively high concentrations of MP-4 detected in 4 out 5 patients can be 
partly explained by the fact that these patients were all newly admitted patients for 
whom treatment had not been started at the moment of sampling. In order to further 
explain the relatively high concentrations required for cryptococcal mannoproteins, 
experiments are in progress to determine the biological activity and half-life of MP-4 
in vivo as well as in vitro. 
In summary, we have shown that MP-4 has potent anti-inflammatory activity that may 
be responsible for the poor cellular infiltration of PMN into the CSpF of 
cryptococcosis patients. Given our hypothesis that MP-4 exerts its action largely by 
its intrinsic chemoattractive properties, the balance between pro-inflammatory and 
anti-inflammatory effects will depend critically on the temporal and spatial 
distribution of MP-4. Interestingly, even in patients with cryptococcal meningitis MP-
4 concentrations in serum strongly exceed the levels detected in CSpF. We 
hypothesize that this distribution might be due to active drainage of MP-4 from CSpF 
to blood, resulting in increasing blood concentrations of MP-4 in the course of the 
disease. Active drainage will prevent both the migration of PMN toward MP-4 
present in the CSpF, as well as the proper response to extra-vascular chemoattractants 
because of the premature activation of PMN. Alternatively, MP-4 expression might be 
strongly up-regulated during cryptococcal trafficking in the vascular compartment, 
before the brain section is reached. Environmentally induced expression of capsule 
genes is not unprecedented. Several nutrients, e.g. iron and CO2, have been 
demonstrated to affect the composition of the cryptococcal capsule (48). We are 
currently testing the ability of MP-4 to limit neutrophil infiltration in vivo using a 
rabbit model for BM. 
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Cryptococcosis is the leading cause of life-threatening mycological disease of the 
central nervous system, with a high worldwide mortality and morbidity in 
immunocompromised patients (1). In the Netherlands from 1996 on incidence 
numbers are declining, in parallel with incidence numbers in the rest of the Western 
world (2). This decline is due to the introduction of highly active antiretroviral 
therapy (HAART), as described in chapter 2. In countries that can not afford costs of 
HAART, like for example in Sub Saharan Africa and India, cryptococcal related 
infection are an enormous problem (3;4), in Zimbabwe C. neoformans is the most 
important cause of meningitis in adults. Healthy subjects rarely become infected by C. 
neoformans. In the Dutch surveillance study of cryptococcosis patients, in only 7 
patients out of 268 (2.6%) no underlying disease could be determined despite 
extensive work-up. Apparently, in healthy individuals host defense against 
cryptococci is very efficient, considering the ubiquitous presence of the yeast in 
nature. On the other hand in some immunocompetent patients the diagnose might 
remain undiagnosed. 
C. neoformans enters the body by inhalation of poorly encapsulated yeast cells. In the 
lungs innate immune responses like phagocytosis of C. neoformans by resident 
macrophages (alveolar macrophages) take place. In chapter 3 a new, rapid and 
objective method is described, to measure interaction between the yeast C. 
neoformans and adherent phagocytic cells. The major advantage compared to flow 
cytometry is that phagocytosis of adherent cells can be measured instead of cells in 
suspension and therefore, long term incubations can be studied. This way of studying 
this interaction probably resembles the in vivo situation more closely.  
Phagocytosis and killing of C. neoformans, in the presence of complement, by 
neutrophils, monocytes, and macrophages is very effective (5-7). As described in 
chapter 4, in contrast to many other micro-organisms like E. coli (8), M. tuberculosis 
(9), and influenza A virus (10), pulmonary surfactant proteins do not support 
phagocytosis of C. neoformans. FITC-SP-A bound in a concentration-dependent 
manner to acapsular C. neoformans. This binding was inhibited by glucose and 
mannose, meaning that SP-A binding can occur via its carbohydrate-binding region, 
but does not result in enhanced phagocytosis. It is not known how C. neoformans 
escapes surfactant protein mediated phagocytosis, but this escape makes it easier for 
cryptococci to grow and synthesize its capsule in alveolar spaces.  
Cytokines and chemokines  
Cytokines that are present during the initiation of an immune response will determine 
whether CMI or B-cell development will take place (11). Pulmonary clearance of the 
encapsulated yeast C. neoformans is considered to be primarily controlled by CMI 
suggesting a predominantly type 1 cytokine response is essential. Type 1 cytokines 
include IFN-γ, IL-12, and TNF-α, whereas type 2 cytokines include IL-4, IL-5, IL-6, 
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IL-10, and IL-13 (11). In chapter 5 the time kinetics of cytokine release in PBMC of 
healthy donors stimulated with cryptococcal capsular polysaccharides indicate an 
autocrine-paracrine network regulation of the cytokines. Proinflammatory cytokines 
like TNF-α and IFN-γ were released early while IL-1ß, IL-6 and IL-8 showed a more 
sustained release, and IL-10 was clearly increasing over time. We did not observe the 
tendency for a particular cryptococcal strain or capsular component to induce a type 1 
or type 2 response, but in the first 3 hours a more type 1-like pattern was observed for 
all the different strains and components. This profile would facilitate an adequate 
cellular mediated immunity in normal healthy donors. Stimulation of PBMC for 18 h 
was associated with an increase in IL-10 levels, and a decline in TNF-α and IFN-γ 
release. This corresponds to a shift towards a more type 2 cytokine response, 
stimulating the induction of humoral immunity.   
Cytokine induction in the host defense against C. neoformans might be a double-
edged sword, playing beneficial or detrimental roles, especially in the setting of HIV 
infection. TNF-α for example, despite its pivotal role in initiating and amplifying 
anti-cryptococcal immune responses (12;13), has been described to accelerate HIV 
progression (14;15). On the other hand, IL-10 can down regulate HIV replication (16) 
but potentially dampens important protective immune responses against cryptococcal 
infection. This will have important implications for designing cytokine-based 
therapeutic strategies against cryptococcal infections in HIV-infected patients.  
HIV-1 infection of macrophages increases mRNA levels of the chemokines MIP-1α, 
MIP-1β, and RANTES as described in chapter 6. Moreover, both HIV infection and 
C. neoformans or GXM stimulation of macrophages resulted in an additional 
enhancement of chemokine expression. MIP-1α, MIP-1β, and RANTES attract 
activated T cells, dendritic cells, and monocytes by binding to specific CC chemokine 
receptors (CCR) on these cells, including CCR5 (17). CCR5 also functions as a 
coreceptor for macrophage-tropic, nonsyncytium-inducing strains of HIV. MIP-1α, 
MIP-1β, and RANTES suppress replication of macrophage-tropic (but not lympho-
tropic) HIV strains in vitro, presumably by competitive inhibition of HIV attachment 
to CCR5 (18;19). Previously, it was demonstrated that C. neoformans induce HIV 
replication in latently infected monocytic cell lines (20-22). In clinical studies, an 
increase in HIV viral load was observed in patients suffering from cryptococcosis 
(23). Our finding that HIV-infected macrophages, and Huangs finding that HIV-
positive PBMC produce MIP-1α, MIP-1β, and RANTES would suggest that HIV 
viral load should decrease, rather than increase, during fungal infections. Two factors 
of this apparent paradox have been suggested (17). First, as HIV infection progresses 
to AIDS, there tends to be a change in corecptor usage. This results from macrophage-
tropic HIV strains (which use CCR5) being replaced by lympho-trophic strains 
(which prefer CXCR4) (18;19). MIP-1α, MIP-1β, and RANTES bind CCR5 but not 
CXCR4. Moreover, for lympho-trophic strains, MIP-1α, MIP-1β and RANTES may 
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directly stimulate HIV replication (19). Thus, as cryptococcosis usually occurs in 
advanced HIV infection, release of MIP-1α, MIP-1β, and RANTES stimulated by C. 
neoformans increase HIV viral load rather than decrease it. Second, C. neoformans 
stimulate release of TNF-α and the nuclear translocation of the transcription factor 
NF-κB, both of which induce HIV replication (22;24).  
Cryptococcal capsular polysaccharides  
Chaka et al. found that, in contrast to bacterial meningitis, the local production of high 
levels of IL-8 is not associated with leukocyte infiltration allowing proliferation of 
yeast cells (25). The potency of C. neoformans culture supernatant to inhibit 
leukocyte migration was first described in 1956 (26). In a mouse model study, Dong 
and Murphy showed that the inhibition of PMN infiltration elicited by intravenous 
administration of the cryptococcal culture filtrate (CneF) is mainly due to GXM (27). 
Lipovsky et al. previously demonstrated that GXM significantly inhibited PMN 
migration toward IL-8 (28). Furthermore, it was shown that GXM delays 
translocation of leukocytes across the blood-brain barrier in a rabbit meningitis model 
(29). In chapter 7 we have demonstrated a significant inverse correlation between the 
GXM ratio (serum/CSF) and the CSF leukocyte count in Dutch patients with 
cryptococcosis. These results could possibly be explained by the fact that GXM has 
been described to be a chemoattractant by itself (28). Second, a more specific 
interference with transendothelial migration of PMN could as well be expected. GXM 
sheds L-selectin from neutrophils (30), and can bind to CD18 adhesion molecules 
thereby blocking interaction of activated neutrophils with ligands on the endothelium 
(31). Thirdly, in patients in which cryptococcosis is suspected C. neoformans cultures 
and latex agglutination tests for cryptococcal antigen (GXM) in blood and CSF is 
performed. Antigen titers that were measured for diagnostic purposes were used in 
this study. There is a possibility that other capsular polysaccharides, like MP4, 
divided over the brain/blood compartment in the same ratio as GXM, is responsible 
for the observed effect, but this has not been measured until now. 
Initially, aim of further study was to investigate the molecular mechanism by which 
GXM is able to prevent leukocyte migration toward chemoattractants. Surprisingly, 
we found that cryptococcal culture filtrate (CneF) from GXM-producing and 
genetically modified nonproducing (∆CneF) strains, both prevented PMN migration 
towards PAF, IL-8 and fMLP (chapter 8). Using a rabbit polyclonal antiserum 
directed against MP-4, evidence was provided for the presence of MP-4 in serum and 
CSF of patients with disseminated cryptoccocosis. The paradox that MP-4 strongly 
inhibited PMN migration toward PAF, IL-8 and fMLP and that MP-4 was found to be 
a potent chemoattractant in vitro itself, can be explained by a phenomenon called 
cross-desentization of chemoattractant receptors. This hypothesis was confirmed by 
our observation that preincubation of PMN with MP-4 impaired Ca2+ mobilization by 
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IL-8, fMLP, and C5a, but not PAF. Thus, the pathophysiological role of MP-4 is to 
functionally mimic the action of chemoattractants, resulting in a premature activation 
of PMN. The association between MP-4 and downregulation by shedding of surface 
TNF-R is also in agreement with the proposed role of MP-4 as chemoattractant. 
Several studies demonstrated that within minutes of chemoattractant incubation, both 
TNF-R p55 and p75 were down-regulated from the surface of PMN. At the same 
time, soluble TNF-R appeared in supernatants, in amounts proportional to the extent 
of down-regulation. This suggests that shedding is the major mechanism leading to 
the loss of p55 and p75 upon chemomattractant activation (32;33). Our demonstration 
of increased amounts of receptors shed in conditioned medium of neutrophils exposed 
to MP-4 supports this hypothesis. Several studies provide evidence that TNF-α 
correlates positively with leukocyte organ infiltration (34;35). In vivo, scavenging of 
TNF-α by soluble TNF-R is likely to contribute to the observed lack of leucocytes in 
the CSF of patients.  
Future research  
Neutrophil infiltration into the central nervous system is a dual-edged sword in that it 
protects the tissue from infection and injury but can also be detrimental to the host. In 
diseases such as bacterial meningitis or cerebrovascular ischemia there is evidence 
that a high influx of PMN plays an adverse role in the pathogenesis of neurological 
damage (36;37). In bacterial meningitis, the phagocytic capacity of PMN in CSF is 
often insufficient and the harmful effects of their cytotoxic products may outweigh 
their beneficial effects (38). Accordingly, it is now assumed that adjunctive 
therapeutic strategies with anti-inflammatory agents may favor neurological recovery 
(39-41). Therefore we will investigate the possibilities to use GXM and MP4 
therapeutically.  
At least two capsular components of the fungus C. neoformans have been identified to 
interfere with neutrophil migration into the CSF. Initially only GXM was used as a 
therapeutic agent to reduce the influx of PMN into the CSF during pneumococcal 
meningitis in a rabbit model (29). In GXM treated rabbits, there was a substantial 
delay in CSF total leukocyte count and percentage of PMN at 6h, as compared to non-
treated animals. The histopathology of the brain at 8h demonstrated less inflammation 
and less margination of PMN in the GXM treated animals. Furthermore, the effects of 
GXM on both neutrophils and endothelium using a static adhesion models were 
studied (42). Pretreating PMN with GXM inhibited neutrophil adhesion to TNF-α-
stimulated endothelium up to 44%. Treatment of TNF-α-stimulated endothelium with 
GXM led to a 27% decrease in PMN adhesion. Based on the findings that no additive 
inhibition of PMN adhesion was found when blocking mAbs against E-selectin were 
added after GXM pretreatment of PMN while these mAbs did decrease adhesion in 
the absence of GXM, GXM most likely exerts its effect on PMN by interfering with 
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E-selectin mediated binding. The use of blocking antibodies also showed that the 
inhibitive effect found after GXM treatment of endothelium probably involves 
interference with both ICAM-1 and E-selectin binding.  
A second capsular component, MP-4 was identified as a potent inhibitor of neutrophil 
migration. For future research, further chemical identification, and methods to obtain 
sufficient amounts of MP-4 will have to be developed. For example, the expression of 
the protein part of MP-4 in an E. coli expression and purification system would 
upscale MP-4 production enormously. This will create the possibility to test MP-4 as 
an anti-inflammatory agent in for example a pneumococal meningitis model in 
rabbits, or in an ischemia/reperfusion damage model in rats. Future research will have 
to include the search to a possible MP-4 receptor on PMN. The effect of MP-4 on the 
expression of adhesion molecules on endothelial cells like ICAM-1, P-selectin and 
VCAM will provide insight in additional mechanisms by which MP-4 interferes with 
neutrophil migration.  
Developing MP-4 as a possible therapeutic agent will raise questions of unwanted 
side effects. As described in chapter 5, MP-4 does stimulate PBMC of healthy donors 
to produce TNF-α, IFN-γ, IL-1ß, IL-6 and IL-8. These experiments were performed 
in the presence of 10% normal human serum, which resembles the situation in vivo. 
Part of the observed cytokine release by the different components of C. neoformans 
might be caused by indirect effects. Cytokine induction in PBMC by GXM depends 
on the presence of an intact complement system, whereas for GalXM and MP this 
process is partially facilitated by human mannose binding lectin, a heat stable 
component (43;44). The observed cytokine profile might be strongly influenced by 
the autocrine-paracrine cytokine network, since the presence of e.g. high levels of 
TNF-α induces IL-10 independent of the type of stimulus (45). 
Be that as it may, MP-4 is able to activate PBMC in various ways. These activation 
mechanisms could possibly interfere with the application of MP-4 as an anti-
inflammatory drug. However, the question remains how relevant the in vitro 
observations are for the in vivo situation. For example, in healthy non-anesthetized 
rabbits, intravenous administration of GXM was well tolerated (29). GXM is, like 
MP-4, able to activate PBMC in vitro (chapter 5). Furthermore, treating animals with 
GXM resulted in a reduction of the TNF-α peak levels in the CSF at 2 h after 
intracesternal inoculation of heat-killed pneumococci. Testing MP-4 in an animal 
model will be necessary to find out if activating properties of MP-4 are present and 
clinically important.  
Further identification of MP-4 might reveal different parts of the molecule, which are 
responsible for different biological activities. Identification of the part specifically 
interfering with neutrophil migration will provide a safe and powerful anti-
inflammatory agent. 
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This thesis describes several aspects of the human immune response against C. 
neoformans on its route from inhalation from the environment to the central nervous 
system. Studying the mechanisms by which cryptococci defend themselves against 
the human host, revealed components of C. neoformans which are able to inhibit 
neutrophil migration. The use of these defense mechanisms from cryptococci, 
provides possibly a new anti-inflammatory drug.  
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Cryptococcose is een ziekte die wordt veroorzaakt door de gekapselde gist 
Cryptococcus neoformans. Bij patiënten met verminderde afweer is het een van de 
belangrijkste veroorzakers van ernstige infecties van het centrale zenuwstelsel, zoals 
hersenvliesontsteking. De afweer van een patiënt kan verminderd zijn door infectie 
met het HIV virus, gebruik van immunosuppressieve medicatie, of door het hebben 
van een hematologische maligniteit. In Nederland komt cryptococcose sinds 1996 
steeds minder voor. In hoofdstuk 2 beschrijven we dat dit wordt veroorzaakt door de 
introductie van krachtige antivirale therapie (highly active antiretroviral therapy, 
HAART) voor de behandeling van HIV. In landen die de hoge kosten voor HAART 
niet kunnen betalen, bijvoorbeeld in Afrika en India, is cryptococcose een enorm 
groot probleem.  
Gezonde mensen raken nauwelijks geïnfecteerd met C. neoformans. In de studie die 
in hoofdstuk 2 wordt beschreven hebben we naar (bijna) alle Nederlandse patiënten 
met cryptococcose gekeken van 1986 tot 2000. In slechts 7 van de 268 patiënten 
(2,6%) konden we geen onderliggende ziekte vinden, ondanks uitgebreid aanvullend 
onderzoek. Blijkbaar is bij gezonde mensen de afweer tegen cryptococcen erg 
efficiënt zeker als je in overweging neemt dat cryptococcen veelvuldig in de natuur 
voorkomen.  
C. neoformans komt het menselijk lichaam binnen door het inhaleren van dun 
gekapselde gist cellen. In de long komt de aspecifieke afweer op gang, zoals 
fagocytose (‘opeten’) van C. neoformans door de daar aanwezige macrofagen 
(alveolaire macrofagen). In hoofdstuk 3 beschrijven we een nieuwe, snelle en 
objectieve methode om de interactie tussen de cryptococ en vastgehechte fagocyten te 
meten. Het grootste voordeel ten opzichte van een andere veel gebruikte methode om 
fagocytose te meten (flow cytometrie) is, dat de cellen naast elkaar vastgehecht zitten 
op de bodem van een plaatje in plaats van cellen in een reageerbuisje in oplossing, en 
dit biedt de mogelijkheid om gedurende langere tijd fagocytose te bestuderen. Deze 
situatie bootst de situatie in het menselijk lichaam beter na dan metingen in oplossing.  
De aanval tegen binnengedrongen cryptococcen door het menselijk afweersysteem, in 
de aanwezigheid van complement (het complement systeem bestaat uit factoren in het 
bloed die in staat zijn om lichaamsvreemde indringers te herkennen en kapot te 
maken), door witte bloed cellen zoals neutrofiele granulocyten, monocyten en 
macrofagen is heel efficiënt. Zoals beschreven in hoofdstuk 4 onttrekken 
cryptococcen zich aan fagocytose gefaciliteerd door de long surfactant eiwitten. Dit in 
tegenstelling tot vele andere micro-organismen zoals E. coli, M. tuberculosis en het 
influenza A virus. FITC-SP-A (een van de long surfactant eiwitten gelabeld met een 
groene kleurstof) bindt concentratie-afhankelijk aan niet gekapselde cryptococcen. 
Deze binding werd geremd door glucose en mannose, wat betekent dat SP-A binding 
plaatsvindt via het koolhydraat-bindende deel van het molecuul, maar dit resulteert 
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niet in versterkte fagocytose. Het is onbekend hoe de cryptococ zich aan de surfactant 
gemedieerde fagocytose onttrekt, maar door deze ontsnapping zal het makkelijker zijn 
voor de gist om te groeien en zijn kapsel aan te maken in de alveolaire ruimtes in de 
long.  
Als de cryptococ zich eenmaal in de long heeft genesteld kan deze zich verder door 
het lichaam verspreiden. In het bloed zal de cryptococ in aanraking komen met witte 
bloedcellen, zoals monocyten. Dit proces leidt tot de productie van signaal moleculen, 
cytokinen genaamd. Cytokinen zijn een groep van serumeiwitten die zowel een 
beschermende als een ziekte modulerende rol kunnen spelen. Hele cryptococcen en 
gezuiverde kapsel componenten induceren in monocyten een vergelijkbaar 
cytokinenspectrum (hoofdstuk 5). Wel verschilde de kinetiek van de bestudeerde 
cytokines op de verschillende tijdpunten (3 en 18 uur). Een belangrijke suggestie 
voortkomend uit deze studie is dat gedurende het acute contact tussen het 
afweersysteem en cryptococcen een cytokine-spectrum wordt geïnduceerd dat gunstig 
is voor de opwekking van de cellulaire afweer en dat gedurende een langduriger 
contact het geïnduceerde cytokine spectrum zorgt voor een afbouw van de cellulaire 
immuniteit, ons belangrijkste afweermechanisme tegen C. neoformans. 
Vanuit de bloedbaan gaan cryptococcen op weg naar de hersenen. Eenmaal in de 
hersenen aangekomen zijn de gisten relatief onbereikbaar voor het afweersysteem en 
kunnen ze zich vermenigvuldigen en zo grote schade aan het brein toebrengen. 
Waarom de cellen van het afweer systeem de met cryptococcen geïnfecteerde 
hersenen niet kunnen bereiken is niet goed bekend. Voor het migreren vanuit de 
bloedbaan naar de plaats van de cryptococcen infectie hebben witte bloedcellen een 
signaal nodig zodat ze weten waar de indringers zich bevinden. Dit signaal bestaat uit 
stoffen die ter plekke vrijkomen zodra de cryptococ en het afweersysteem 
samenkomen. Een groep van deze signaal stoffen heet chemokinen. Chemokinen 
trekken witte bloedcellen aan zodra ze herkend worden als alarmsignaal door 
receptoren op het oppervlak van witte bloedcellen. Zodra de witte bloedcellen het 
alarmsignaal op hun receptor opvangen worden ze actief en migreren ze vanuit de 
bloedbaan naar de plaats waar de chemokinen vandaan komen. MIP-1α, MIP-1β, en 
RANTES zijn chemokinen die voornamelijk monocyten aantrekken. In hoofdstuk 6 
hebben we bestudeerd of deze signaalstoffen daadwerkelijk vrijkomen als er contact 
is tussen cryptococcen en al dan niet met HIV geïnfecteerde macrofagen. HIV-1 
infectie zelf zorgt voor een verhoging van de bestudeerde chemokinen MIP-1α, MIP-
1β, en RANTES. Daarnaast werd een additionele verhoging van deze chemokinen 
gevonden als de macrofagen tevens werden gestimuleerd met C. neoformans of een 
van de gezuiverde kapselbestanddelen. Dit betekent dat er dus wel signaalstoffen 
worden aangemaakt die witte bloedcellen kunnen aantrekken, maar er is uit eerder 
onderzoek van onze groep gebleken dat er maar zeer weinig witte bloedcellen, en in 
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het bijzonder neutrofielen granulocyten, in de hersenvloeistof van patiënten met 
cryptococcose aanwezig zijn.  
Al meer dan 50 jaar is bekend dat het polysaccharide kapsel van de cryptococ, en in 
het bijzonder de belangrijkste bouwsteen daarvan glucuronoxylomannan (GXM), in 
staat is om het migreren van witte bloedcellen te remmen. In hoofdstuk 7 hebben we 
in patiënten met cryptococcose gekeken naar het verband tussen de aanwezigheid van 
GXM en het ontbreken van witte bloedcellen. Er blijkt dat wanneer de concentraties 
GXM in bloed ten opzichte van hersenvloeistof - dus de GXM gradiënt over de bloed-
hersen-barrière - wordt vergeleken met het absolute cel aantal in de hersenvloeistof, 
een sterke GXM gradiënt gepaard gaat met weinig cellen in de hersenvloeistof.  
Aanvankelijk was het doel van verder onderzoek het achterhalen van het moleculaire 
mechanisme waarmee GXM in staat is om witte bloedcel migratie naar een 
signaalstof (chemoattractant) te remmen. Om dit te onderzoeken hebben we 
C.neoformans laten groeien in een vloeibare oplossing met voedingsstoffen 
(medium). Na 5 dagen groei, waarin de gisten zich vele malen hebben 
vermenigvuldigd, werden alle gisten verwijderd uit het medium. De overgebleven 
vloeistof die cryptococcen supernatant wordt genoemd werd gebruikt om GXM uit te 
isoleren. Geheel onverwacht vonden we dat genetisch gemodificeerde 
cryptococcenstammen die geen GXM produceren evengoed granulocyten migratie 
konden remmen als GXM-producerende stammen (hoofdstuk 8). Vervolgens hebben 
we alle bekende kapselcomponenten: galactoxylomannan (GalXM), en de 
mannoproteinen 1, 2 en 4 (MP1-4) getest op hun capaciteit te interfereren met 
granulocyten migratie. Uiteindelijk bleek MP-4 de meest krachtige remmer te zijn. 
We vonden verder dat MP-4 zelf ook in staat is om granulocyten aan te trekken. Deze 
ogenschijnlijke paradox (het feit dat een zelfde stofje zowel in staat is om 
granulocyten af te stoten als aan te trekken) wordt verklaard door een fenomeen dat 
we kruis-desensitisatie (cross-desentization) van receptoren noemen. Dit betekent dat 
als een witte bloedcel geconfronteerd wordt door een eerste aantrekkende 
(chemoattractieve) stof, de cel zodanig geactiveerd raakt, dat hij niet meer kan 
reageren op een tweede chemoattractief signaal. Wanneer we een granulocyt 
confronteren met een chemoattractieve stof, reageert deze in een reageerbuisje door 
calcium te mobiliseren. Door dit calcium als het ware van te voren te kleuren met een 
kleurstof kunnen we dit kleursignaal meten. De kruis-desensitisatie hypothese werd 
bevestigd door experimenten waarbij we granulocyten incuberen met MP-4 en 
vervolgens confronteren met een tweede chemoattractieve stof (zoals IL-8, fMLP, en 
C5a). Bij de tweede confrontatie reageerden de granulocyten niet meer met de 
gebruikelijke calcium mobilisatie. 
Witte bloedcellen vervullen in het lichaam een belangrijke afweerfunctie tegen 
binnendringende micro-organismen. Echter, in bepaalde gevallen kunnen witte 
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bloedcellen ook ernstige schade aan het lichaam toebrengen, zoals bij ziektebeelden 
als bacteriële hersenvliesontsteking, neurotrauma of cerebrovasculaire aandoeningen. 
Daarom wordt nu aangenomen dat in deze gevallen aanvullende 
ontstekingsremmende medicijnen neurologisch herstel kunnen bevorderen. Omdat 
bestanddelen van het cryptococcen kapsel in staat zijn om witte bloedcel migratie te 
remmen, is onderzoek naar de bruikbaarheid van deze componenten als therapeuticum 
een belangrijke stap verder. Er blijven echter nog een heleboel vragen te 
beantwoorden over het mechanisme van (bij)werking. Dit zal ook het onderwerp 
moeten zijn van toekomstig onderzoek.
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Het beste bewijs dat het schrijven van een proefschrift teamwerk is ligt hier voor U. 
Gelukkig zijn deze pagina's er om iedereen die tot steun is geweest te bedanken. 
Allereerst mijn promotor Prof. Dr. I.M. Hoepelman. Lieve Andy, jouw grenzeloos 
enthousiasme is inspirerend. Toen ik als co-assistent het boek met keuze-stages 
doorbladerde zag ik jouw naam bij Infectieziekten/Tropengeneeskunde, publicatie 
gegarandeerd stond erbij. Dat leek mij wel wat !! Jij creëerde mogelijkheden voor mij om 
zelfstandig wetenschappelijk onderzoek te doen, contacten te leggen en samenwerking 
met andere groepen aan te gaan. Ik leer enorm van je, bedankt. 
Lieve Jelle, rots in de branding in de cryptococcen groep. Zonder Jelle geen stammen, 
ELISA’s FACS-experimenten en MP4. Wij delen de opvatting dat werken eigenlijk 
alleen iets is om je (andere) hobby’s te bekostigen. Dromend van verre landen en witte 
stranden heb jij altijd veel werk verzet, dank je wel. 
Beste Frank Coenjaerts, jij kwam in de groep toen ik eigenlijk alweer op het punt stond 
om naar Amersfoort te vertrekken. De goede samenwerking leidde tot hoofdstuk 8 in dit 
boekje. Bedankt voor het laatste nakijkwerk. Andre Verheul, dank voor de begeleiding in 
de eerste maanden.  
Kok en vooral Jos, bij jullie kon ik vaak terecht met de dagelijkse vragen (en tranen). 
Altijd bereid tot uitleg, even naar de totaal onbegrijpelijke data kijken en altijd weer een 
nieuwe assay en een nieuwe oplossing, thanks. Hans Nottet, jij weet enorm veel van HIV 
en brein cellen vandaar de logische samenwerking. Leonie, bedankt dat jij de 
cryptococcen meenam naar het HIV-lab (en mij soms ook), en........wij weten zeker dat 
het een bergleeuw was. Bertie, jij deed veel GXM/MP-4 werk toen ik al in Amersfoort 
zat, dank je wel. Quirijn en Reinoud bedankt voor het pipetteerwerk. Leontine, de lange 
discussies hebben uiteindelijk wel wat opgeleverd! Myriam, toen jij in mijn plaats naar 
New York vertrok wisten jij en ik nog niet wat die 3 maanden voor mij 
betekenden...Dank je.  
Kamergenoten van het eerste uur Carla, Ellen, Tjomme, Helke en Saskia bedankt voor 
alle gezelligheid, hulp met computer en support. Later kon ik weer in 'mijn' oude kamer 
terecht, opnieuw gezelligheid nu ook met Pauline en (heel kort) Marjolein, Hanneke en 
Michiel. Niki, bedankt voor de spoedcursus PDF-en. Henk Versteeg dank ik voor alle 
eerste hulp bij computerproblemen. Verder wil ik alle medewerkers van het EWI 
bedanken. Het EWI is een bijzonder instituut. Veel gezelligheid op borrels (verzin een 
gelegenheid het EWI geeft er een borrel voor), koepels, buitendagen etc. maar vooral elke 
dag opnieuw in en om het lab. 
Lieve Eveline, paranimf, jij was de eerste die op 4 mei 2000 hoorde dat Robert was 
overleden, en zat naast me in de politieauto op weg naar Nieuwegein. Jij hebt me enorm 
gesteund in de periode daarna, en doet dat nog steeds (met onze koffietjes bij de 
verwarming!). Seetje, grote lieve zus, paranimf, wat moest ik bedenken om iets als eerste 
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te doen. Geneeskunde studeren en specialiseren kon ik een beetje van je afkijken, 
promoveren niet. Nu jij !! De vanzelfsprekendheid waarmee jij de eerste tijd na Rob zijn 
dood bij mij kwam wonen en je liefdevolle support nadien vergeet ik nooit, we hebben 
een enorm speciale band.  
En hoewel niet direct betrokken wil ik hierbij toch een aantal mensen bedanken die mij 
rond de moeilijke tijd na Robert zijn dood hebben geholpen. Zonder hen zou dit 
proefschrift er immers niet geweest zijn. Maarten en Paulien, Marein en Rene, Bulo en 
Sas, Marc, Jeannette, Joyce, Tjarda, Suzanne, Leontine, Marco, Theo, Jaap-Jan, Menno 
en  andere vrienden.  
De internisten van de maatschap interne in Amersfoort bedank ik voor de rust en de 
ruimte die zij mij gaven om mijn plekje op het werk opnieuw te vinden. Verder bedank ik 
de verpleging van de interne dagbehandeling en de polikliniek voor hun hulp hierbij.  
 
Lieve papa en mama, Jullie hebben vanaf de dag dat ik geboren werd grenzeloos 
vertrouwen in mij gehad. Geruisloos verschijnen en verdwijnen jullie in en uit mijn 
leven, wanneer ik dat nodig heb. De slapeloze nachten (met goede reden!!) zijn niet voor 
niets geweest, dank je wel. 
 
Allerliefste Robbie,  
Hoe gelukkig waren we toen ik, na onze reis door Indonesië, aan deze baan begon. Jij, 
altijd opbeurend, opgaand en luisterend naar mijn verhalen en je onmisbare humorvolle 
en wijze commentaar. Je verzorgde mij, stond na het werk klaar met de (met 
studieboeken) volgeladen rugzakken om te oefenen voor een volgende onvergetelijke 
vakantie. Jouw levenslust en kunde om van elke dag van het leven te genieten zorgde 
ervoor dat er geen minuut van de, achteraf, zo kostbare vrije tijd verloren ging.Vakanties 
gingen dankzij jou voorbij in de bergen, en niet achter de computer. Nu jij dat zelf niet 
meer kan doen, zal ik proberen deze levenswijze met jouw kracht door te zetten. Ik hou 
van je, see you!!! 
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De auteur van dit proefschrift werd op 7 juli 1969 geboren te Breda. Na het behalen van 
haar VWO diploma aan het College Blaucapel te Utrecht in 1988, ging zij een jaar op reis 
in Europa. Daarna werkte zij een jaar als verpleeghulp in een bejaarde/verzorgingstehuis 
in Utrecht, daarnaast deed ze een colloquium natuurkunde aan de Universiteit van 
Utrecht. In 1990 startte zij met de studie geneeskunde aan de Universiteit van Utrecht. In 
1993 werd de studie 8 maanden onderbroken voor een wetenschappelijke stage bij de 
afdeling Immunologie, vakgroep Infectieziekten en Immunologie faculteit 
Diergeneeskunde Universiteit Utrecht (hoofd Prof. dr. W. Van Eden) onder begeleiding 
van Dr. M. Wauben en Dr. I. Joosten en bij het instituut voor Medische Microbiologie en 
Immunologie (Prof. dr. S. Buus) Kopenhagen, Denemarken. De wachttijd voor de co-
schappen van oktober 1994 tot februari 1995 werd gebruikt voor een reis naar India, 
Nepal en Thailand. In mei 1996 vertrok zij voor het co-assistentschap Gynaecologie en 
Obstetrie naar Zimbabwe (begeleider: Drs. D.A.A. Verkuyl, United Bulawayo Hospitals, 
Bulawayo). In maart 1997 werd het artsexamen gehaald, en in mei 1997 begon zij als 
arts-onderzoeker bij het Eijkman-Winkler Instituut (hoofd: Prof. dr. J. Verhoef) onder 
begeleiding van Prof. dr. I. M. Hoepelman. In mei 1999 startte zij haar opleiding tot 
internist in het ziekenhuis Eemland te Amersfoort (opleider: Dr. A. van de Wiel). Vanaf 
september 2001 werkte zij opnieuw binnen het EWI aan het onderzoek dat wordt 
beschreven in dit proefschrift, vanaf 1 april 2002 gecombineerd met een tijdelijke functie 
bij de Stichting Artsen Laboratorium Utrecht /Trombosedienst. Vanaf 1 januari 2003 zal 
zij haar opleiding tot internist vervolgen binnen het Universitair Medisch Centrum 
Utrecht (opleider: Prof. dr. D.W. Erkelens).  
